الدليل العام للأدوية المعتمدة
إصدار 2026 · 246 دواء
معنى تصنيف الحمل بالأحرف (FDA)
- A — دراسات على البشر لم تُظهر خطراً على الجنين.
- B — لا خطر في دراسات الحيوان ولا دراسات كافية على البشر؛ آمن غالباً.
- C — خطر محتمل أو لا توجد دراسات كافية؛ يُستخدم إذا رجحت الفائدة.
- D — دليل على خطر للجنين؛ يُستخدم في الحالات الحرجة فقط.
- X — ممنوع في الحمل؛ الخطر يفوق أي فائدة.
Aldarb General Hospital Drug Formulary — Edition 2026
246 results
ACETAZOLAMIDE,Diamox®
Carbonic anhydraseinhibitor,ophthalmicagent,Antiglaucoma
Pregnancy: cautionLactation: avoid
ACETAZOLAMIDE,Diamox®
Carbonic anhydraseinhibitor,ophthalmicagent,Antiglaucoma
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection
Dosage Forms
Tablet
- 250mg tablet
Injection
- 500mginjection
Dosing & Formulations
- Dose
- Adult dose Chronic open-angle glaucoma, epilepsy: oral, 250 mg–1 g per 24 hours, in divided doses. Perioperative reduction of intraocular pressure: oral/iv, Initially 250–500 mg; thereafter 250 mg every 4 hours as Required (maximum 1 g daily). Congestive heart failure, drug-induced oedema: See product information. Paediatric dose Glaucoma: oral, 5–10 mg/kg (up to 250 mg) every 6 hours (under specialist supervision). Maximum daily Dose 1 g. Epilepsy: 4–30 mg/kg
- Dose in Organ Failure
- Crcl 10-50 ml/min: Administer no more frequently than q12hr Crcl<10 ml/min: Ineffective (avoid use) Hemodialysis: 20-50% dialyzable Peritoneal dialysis: Dose adjustment not necessary
Indications & Contraindications
- Indications
- Treatmentofglaucoma,drug-inducededemaoredemaduetocongestiveheartfailure(adjunctivetherapy);centrencephalicepilepsies; preventionorameliorationofsymptomsassociatedwithacutemountainsickness
- Contraindications
- Electrolyte disturbances; severe hepatic impairment; renal impairment; sulphonamide sensitivity.
Cautions & Side Effects
- Cautions
- Avoid prolonged use; elderly; pregnancy; breast feeding, avoid extravasation at injection site (danger of necrosis), pulmonary obstruction
- Side Effects
- Taste disturbances, nausea, vomiting, diarrhoea, paraesthesia, flushing, headache, fatigue, depression, metabolic acidosis and electrolyte disturbances, blood disorders, skin disorders
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Enters breast milk; not recommended
ACYCLOVIR,Zovirax®,Clovir®
Antiviral
Pregnancy: safeLactation: caution
ACYCLOVIR,Zovirax®,Clovir®
Antiviral
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Suspension · Cream · Ointment
Dosage Forms
Other
- 200 mg
Tablet
- 800mg tablet
Injection
- 250 mginjection
Cream
- cream 5%
Ointment
- eye ointment0.3%
Suspension
- 200mg/5ml susp
Dosing & Formulations
- Dose
- Genital HSV: I.V.: Children ≥12 years and Adults (immunocompetent): Initial episode, severe: 5 mg/kg every 8 hours for 5-7 days Oral: Adults: -Initial episode: 200 mg every 4 hours while awake (5 times/day) for 10 days; 400 mg 3 times/day for 5-10 days has also been reported -Recurrence: 200 mg every 4 hours while awake (5 times/day) for 5 days; 400 mg 3 times/day for 5 days has also been reported -Chronic suppression: 400 mg twice daily or 200 mg 3-5 times/day, for up to 12 months followed by re-evaluation; 400-1200 mg/day in 2-3 divided doses has also been reported Topical: Adults (immunocompromised): Ointment: Initial episode: 1/2 ribbon of ointment for a 4 square surface area every 3 hours (6 times/day) for 7 days Herpes labialis (cold sores): Topical: Children ≥12 years and Adults: Cream: Apply 5 times/day for 4 days Herpes zoster (shingles): -Oral: Adults (immunocompetent): 800 mg every 4 hours (5 times/day) for 7-10 days. Children <12 years I.V. (immunocompromised): 20 mg/kg/dose every 8 hours for 7 days Children ≥12 years and Adults I.V. (immunocompromised): 10 mg/kg/dose or 500 mg/m2/dose every 8 hours for 7 days HSV encephalitis: I.V.: Children 3 months to 12 years: 20 mg/kg/dose every 8 hours for 10 days; dos- ing for 14-21 days also reported Children ≥12 years and Adults: 10 mg/kg/dose every 8 hours for 10 days; 10-15 mg/kg/dose every 8 hours for 14-21 days also reported Mucocutaneous HSV: Children <12 years I.V.(immunocompromised): 10 mg/kg/dose every 8 hours for 7 days Children ≥12 years and Adults I.V. (immunocompromised): 5 mg/kg/dose every 8 hours for 7 days ; dosing for up to 14 days also reported -Topical: Ointment: Adults (nonlife-threatening, immunocompromised): 1/2 ribbon of ointment for a 4 square surface area every 3 hours (6 times/day) for 7 days Neonatal HSV: I.V.: Neonate: Birth to 3 months: 10 mg/kg/dose every 8 hours for 10 days; 15 mg/kg/dose or 20 mg/kg/dose every 8 hours for 14-21 days has also been reported Varicella-zoster (chickenpox): Begin treatment within the first 24 hours of rash onset: Oral: Children ≥2 years and ≤40 kg (immunocompetent): 20 mg/kg/dose (up to 800 mg/dose) 4 times/day for 5 days Children >40 kg and Adults (immunocompetent): 800 mg/dose 4 times a day for 5 days
- Dose in Organ Failure
- Renal impairment (IV) CrCl 25-50 mL/min/1.73 m: Give recommended dose q12hr CrCl 10-25 mL/min/1.73 m: Give recommended dose q24hr CrCl<10 mL/min/1.73 m: Give 50% of recommended dose q24hr Renal impairment (PO) Normal dosage 200 mg q4hr or 400 mg q12hr and CrCl<10 mL/min/1.73 m: Decrease to 200 mg q12hr Normal dosage 800 mg q4hr and CrCl 10-25 mL/min/1.73 m: Decrease to 800 mg q8hr Normal dosage 800 mg q4hr and CrCl<10 mL/min/1.73 m: Decrease to 800 mg q12hr
Indications & Contraindications
- Indications
- Treatment of genital herpes simplex virus (HSV), herpes labialis (cold sores), herpes zoster (shingles), HSV encephalitis, neonatal HSV, mucocutaneous HSV in immunocompromised patients, varicella-zoster (chickenpox)
Cautions & Side Effects
- Cautions
- renal failure; maintain good hydration; pregnancy and breast-feeding.
- Side Effects
- nausea and vomiting, abdominal pain, headache, fatigue, skin reactions; on intravenous infusion, severe local irritation, fever, tremor.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Drug enters breast milk; use with caution
ADALIMUMAB, Humera®
Tumour necrosis factor alpha inhibitor,
Pregnancy: safeLactation: avoid
ADALIMUMAB, Humera®
Tumour necrosis factor alpha inhibitor,
- Therapeutic group
- Malignant Disease & Immunosuppression
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 40 mg SC inj
Dosing & Formulations
- Dose
- Initial dose: 160 mg subcutaneously on Day 1 (given in one day or split over 2 consecutive days), followed ,by 80 mg subcutaneously 2 weeks later (Day 15) ,Maintenance dose (beginning 2 weeks later [Day 29]): 40 mg subcutaneously every other week
Indications & Contraindications
- Indications
- Severe plaque psoriasis,Moderate to severe active rheumatoid arthritis,Active and progressive psoriatic arthritis,Severe active Crohns disease ,Severe active ulcerative colitis ,Active moderate to severe hidradenitissuppurativa
- Contraindications
- Active tuberculosis , Malignant Tumor or Cancer ,Leukemia Chronic Heart Failure ,Lupus-Like Syndrome.
Cautions & Side Effects
- Cautions
- Active infection , chronic or recurrent infection , diabetes mellitus, uncontrolled , CHF
- Side Effects
- Abdominal or stomach fullness ,body aches or pain ,cough or hoarseness ,ear congestion ,gas with abdominal or stomach pain ,lightheadedness ,loss of voice ,lower back or side pain ,muscle aches and pains ,nasal congestion
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Should be avoided , Excreted into human milk
ADENOSINE,Adenocar®
Antiarrhythmicagent,classiv
Pregnancy: cautionLactation: see details
ADENOSINE,Adenocar®
Antiarrhythmicagent,classiv
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 3mg/ mlinjection
Dosing & Formulations
- Dose
- By rapid intravenous injection into central or large peripheral vein, 3 mg over 2 seconds with cardiac monitoring; if necessary followed by 6 mg after 1-2 minutes, and then by 12 mg after a further 1-2 minutes; increments should not be given if high level AV block develops.
Indications & Contraindications
- Indications
- Rapid reversion to sinus rhythm of paroxysmal supraventricular tachycardia, including those associated with accessory pathways (e.g. Wolff- parkinson-while syndrome); aid to diagnosis of broad or narrow complex supraventricular tachycardias.
- Contraindications
- Second or third- degree AV block and sick sinus syndrome (unless pacemaker fitted); asthma.
Cautions & Side Effects
- Cautions
- Atrial fibrillation or flutter with accessory pathway (conduction down anomalous pathway may increase); heart transplant.
- Side Effects
- Transient facial flush, chest pain, dyspnea, bronchospasm, choking sensation, nausea, light- headedness; severe bradycardia; ECG may show transient rhythm disturbances.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Potential for serious adverse reactions in nursing infants; decision to interrupt nursing after administration of adenosine or not should consider importance of drug to mother
ALBENDAZOLE,zentel®
Anthelmintics
Pregnancy: cautionLactation: caution
ALBENDAZOLE,zentel®
Anthelmintics
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 200mg tablet
- 400mgtablet
Dosing & Formulations
- Dose
- Oral: Children and adults: Neurocysticercosis: < 60 kg: 15mg/kg/day in divided doses (maximum: 800mg/day) for 8-30 days > 60 kg: 400mg twice daily for 8-30 days Note: give concurrent anticonvulsant and steroid therapy during the first wk Hydatid: < 60 kg: 15mg/kg/day in 2 divided doses (maximum: 800mg/day) > 60 kg: 400mg daily Note: administer dose for three 28-day cycles with a 14-day drug-free inter- Val and between Adults: Cysticercus cellulosae: 400mg twice daily for 8-30 days; may repeat prn Disseminated microsporidiosis: 400 mg twice daily Eschinococcus granulosus (tapeworm): 400mg twice daily for 1-6 months Intestinal microsporidiosis: 400mg twice daily for 21 days Ocular microsporidiosis: 400mg twice daily in combination with fumagilin
Indications & Contraindications
- Indications
- Treatment of parenchymal neurocysticercosis and cystic hydatid disease of the liver, lung, and peritoneum caused buy echinococcus granulosus
Cautions & Side Effects
- Cautions
- Children under 2 years; monitor liver function when used for protracted therapy.
- Side Effects
- On long-term use as for hydatid cysts, abdominal discomfort, headache, fatigue, fever, loss of hair.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Unknown, use caution
ALBUMIN (HUMAN)
Pregnancy: not in sourceLactation: not in source
ALBUMIN (HUMAN)
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 20 mg/ml Vial
Dosing & Formulations
- Dose
- In adults, an intravenous infusion of 25g should be given. If adequate response (stabilization of circulation) is not achieved within 15 to 30 minutes, an additional dose may be given. In spite of limited information about the efficacy in pediatric subjects, an intravenous infusion of 2.5 to 12.5g or 0.5 to 1g/kg body weight may be given. If adequate response (stabilization of circulation) is not achieved within 15 to 30 minutes, an additional dose may be given.
Indications & Contraindications
- Indications
- Severe hypovolaemia; plasma exchange.
- Contraindications
- Cardiac disease, severe anaemia.
Cautions & Side Effects
- Cautions
- Correct dehydration, avoid or administer very cautiously in patients with cardiac disease.
- Side Effects
- Hypersensitivity reactions.
ALENDRONATE,Fosamax®
Bisphosphonatederivative
Pregnancy: cautionLactation: caution
ALENDRONATE,Fosamax®
Bisphosphonatederivative
- Therapeutic group
- Musculoskeletal & Joint Diseases
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 70mgtablet
Dosing & Formulations
- Dose
- Treatment of postmenopausal osteoporosis, 10 mg daily or 70 mg once weekly. Treatment of osteoporosis in men, 10 mg daily. Prevention and treatment of corticosteroid-induced osteoporosis in postmenopausal women not receiving hormone replacement therapy, 10 mg daily. Counselling: Tablets should be swallowed whole with plenty of water while sitting or standing; to be taken on an empty stomach at least 30 minutes before breakfast (or another oral medicine); patient should stand or sit upright for at least 30 minutes after taking tablet.
- Dose in Organ Failure
- Mild-to-moderate renal impairment (crcl 35-60 ml/min): Dose adjustment not necessary Severe renal impairment (crcl<35 ml/min): Not recommended
Indications & Contraindications
- Indications
- Treatment of postmenopausal osteoporosis and osteoporosis in men. Prevention and treatment of corticosteroid-induced osteoporosis in postmenopausal women not receiving hormone replacement therapy.
- Contraindications
- Abnormalities of oesophagus and other factors which delay emptying (e.g. Stricture or achalasia), hypocalcaemia.
Cautions & Side Effects
- Cautions
- Upper gastro-intestinal disorders (dysphagia, symptomatic oesophageal disease, gastritis, duodenitis, or ulcers—see also under contra-indications and side effects); history (within 1 year) of ulcers, active gastro- intestinal bleeding,
- Side Effects
- Oesophageal reactions, abdominal pain and distension, dyspepsia, regurgitation, melaena, diarrhoea or constipation, flatulence, musculoskeletal pain, headache; rarely rash, pruritus, erythema, photosensitivity, uveitis, scleritis.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Unknown whether drug is excreted in milk; use with caution
ALFACALCIDOL,One-Alpha®
VitaminDAnalog
Pregnancy: riskLactation: avoid
ALFACALCIDOL,One-Alpha®
VitaminDAnalog
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule · Injection · Drops
Dosage Forms
Capsule
- Capsules-1 mcgand0
Other
- 25mcg
Drops
- 2mcg/ mldrops
Injection
- 2mcg/mlinjection
Dosing & Formulations
- Dose
- Initial dose for all indications: Adults: 1 microgram daily Children over 20 kg bodymass: 1 microgram daily Children under 20 kg bodymass: 0,05 micrograms/kg daily -Maintenance doses are generally in the range 0,25 - 2 micrograms daily. Neonatal hypocalcaemia : 0,05 - 0,1 micrograms/kg/day.
Indications & Contraindications
- Indications
- Disturbances in calcium metabolism in consequence of reduced endogene- ous production of 1.25– dihydroxy vitamin D3., Renal osteodystrophy, postop- erative or idiopathic hypoparathyroidism, pseudohypoparathyroidism, vitamin- D resistant rickets or osteomalacia, vitamin-D dependant rickets, neonatal hypocalcaemia or rickets, malabsorption of calcium, osteoporosis, malab- sorptive & nutritional rickets and osteomalcia.
- Contraindications
- Hypercalcaemia, metastatic calcification
Cautions & Side Effects
- Cautions
- Accurate dosing must be observed in infants; monitor calcium level in high doses of Vitamin D in adults and in renal impairment.
- Side Effects
- In overdose: anorexia, lassitude, nausea and vomiting, diarrhoea, weight loss.
Pregnancy & Lactation
- Pregnancy
- Not to be used in the first trimester of pregnancy
- Lactation
- Enters breast milk; not recommended
ALLOPURINOL,Zyloric®,No-Uric®
XanthineOxidaseInhibitor
Pregnancy: cautionLactation: caution
ALLOPURINOL,Zyloric®,No-Uric®
XanthineOxidaseInhibitor
- Therapeutic group
- Musculoskeletal & Joint Diseases
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 100&300mgtablet
Dosing & Formulations
- Dose
- initially, 100mg daily as a single dose, after meals gradually increased over 1-3 weeks according to the plasma or urinary uric acid concentration, to about 300mg daily. Usual maintenance dose, 200-600mg, rarely 900mg daily, divided into doses of not more than 300mg. Child, (in neoplastic conditions, enzyme disorders), 10- 20mg/kg daily.
Indications & Contraindications
- Indications
- gout prophylaxis, hyperuricaemia
- Contraindications
- not a treatment for acute gout; if patient is receiving allopurinol when attack occurs continue as normal and treat attack separately.
Cautions & Side Effects
- Cautions
- administer prophylactic colchicine or NSAID (not aspirin or salicylate) until at least 1 month after hyperuricaemia corrected; ensure adequate fluid intake (2 liters/day).
- Side Effects
- rashes, fever (withdraw therapy). If the rash is mild the drug can be re-introduced with caution and discontinued immediately if rash recur; malaise, vertigo, headache, symptomless xanthine deposits in muscle, alopecia, hepatotoxicity.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Agent is distributed into breast milk; use with caution
ALPRAZOLAM, Xanax®
Benzodiazepine anticonvulsants
Pregnancy: riskLactation: compatible
ALPRAZOLAM, Xanax®
Benzodiazepine anticonvulsants
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Powder · Solution
Dosage Forms
Other
- 0.5mg
- 1mg
- oral concentrate
Tablet
- 2mg (oral tablet
Solution
- injectable solution
- intravenous solution
Powder
- compounding powder)
Dosing & Formulations
- Dose
- One to six mg per day, given in divided doses
Indications & Contraindications
- Indications
- Used to treatanxiety disorders,panic disorders, and anxiety caused by depression
- Contraindications
- Hypersensitivity to benzodiazepines or to any components of the formulation Alprazolam tablets are contraindicated with ketoconazole and itraconazole, since these medications significantly impair the oxidative metabolism mediated by cytochrome P450 3A (CYP3A)
Cautions & Side Effects
- Cautions
- You should not use lorazepam if you have narrow-angle glaucoma or myasthenia gravis, or if you are allergic to Valium or a similar medicine , Do not use lorazepam if you are pregnant, myasthenia gravis .
- Side Effects
- Relaxed and calm , Being forgetful ,changes in patterns and rhythms of speech ,clumsiness or unsteadiness ,difficulty with coordination ,discouragement Mdrowsiness ,feeling sad or empty ,irritability ,lack of appetite
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Because of reports of effects in infants, including sedation, alprazolam is probably not the best benzodiazepine for repeated use during nursing, especially with a neonate or premature infant. A shorter-acting benzodiazepine without active metabolites is preferred. After a single dose of alprazolam, there is usually no need to wait to resume breastfeeding.
ALPROSTADIL,Prostin VR®
Prostaglandin
Pregnancy: riskLactation: see details
ALPROSTADIL,Prostin VR®
Prostaglandin
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 500mcg/mlinjection
Dosing & Formulations
- Dose
- -Initial dose: 0.05 to 0.1 mcg/ kg per minute by continuous IV infusion. -Maintenance dose: May be as low as 0.01 mcg/kg per minute.
Indications & Contraindications
- Indications
- Maintenance of patency in congenital heart defects (ductus arteriosus) in neonates prior to corrective surgery; erectile dysfunction.
- Contraindications
- In sickle cell anaemia, multiple myeloma or leukaemia;
Cautions & Side Effects
- Cautions
- History of haemorrhage, avoid in hyaline membrane disease, monitor arterial pressure
- Side Effects
- Apnoea (particularly in infants under 2 kg), flushing, bradycardia, hypotension, tachycardia, cardiac arrest, oedema, diarrhoea, fever, convulsions, disseminated intravascular coagulation, hypokalemia
Pregnancy & Lactation
- Pregnancy
- X
- Lactation
- Not indicated for use in women
ALUMINIUM HYDROXIDE+MAGNESIUMHYDROXIDE ,Maalox®, Moxal®,Rialox®
Antacid
Pregnancy: cautionLactation: caution
ALUMINIUM HYDROXIDE+MAGNESIUMHYDROXIDE ,Maalox®, Moxal®,Rialox®
Antacid
- Therapeutic group
- Gastrointestinal System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Suspension
Dosage Forms
Tablet
- 405+100 mg tablet
Suspension
- 405+100 mg/5ml suspension Moxal®
- 225mg +200mg /5ml suspension Rialox®
Dosing & Formulations
- Dose
- Oral: 5-10ml or one tablet 4-6times/day, between mealand at bedtime. Child under 12 years, not recommended.
Indications & Contraindications
- Indications
- Dyspepsia, gastritis, gastric and duodenal ulceration, reflux oesophagitis.
- Contraindications
- Hypophosphataemia and hypersensitivity to aluminum hydroxide or magnesium hydroxide.
Cautions & Side Effects
- Cautions
- Patients with gastrointestinal haemorrhage, patient with CHF, oedema, hypertension, renal failure, cirrhosis.
- Side Effects
- Constipation, chalky taste, stomach cramps, decrease bowel motility, fecal impaction.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excretion in milk unknown; use caution
AMIKACIN,Amikin®
Antibiotic,Aminoglycoside
Pregnancy: riskLactation: avoid
AMIKACIN,Amikin®
Antibiotic,Aminoglycoside
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 100&500 mg injection
Dosing & Formulations
- Dose
- Adult dose Doses listed are a guide for <48 hours' treatment. Individualise dose based on drug concentration monitoring for longer term treatment. IM/IV, 16–24 mg/kg once daily or in 2–3 doses. Use the higher dose for young adults and the lower one for the elderly. Paediatric dose Child >10 years, IM/IV 18 mg/kg once daily or 15 mg/kg daily in 2–3 doses. Child <10 years, IM/IV 22.5 mg/kg once daily or 7.5 mg/kg three times daily.
- Dose in Organ Failure
- Renal Impairment/Elderly CrCl>90 mL/min &<60 years old: q8hr CrCl 60-90 mL/min OR >60 years old: q12hr CrCl 25-60 mL/min: q24hr CrCl 10-25 mL/min: q48hr CrCl<10 mL/min: q72hr Following dialysis in ESRD
Indications & Contraindications
- Indications
- Serious infections due to organisms resistant to gentamicin and tobramycin including Pseudomonas, Proteus, Serratia, and other gram+ve bacilli, docu- mented infection of mycobacterial organisms susceptible to amikacin
- Contraindications
- Myastheniagravis.
Cautions & Side Effects
- Cautions
- pregnancy; renal impairment, infants and elderly (adjust dose and frequency); avoid prolong therapy.
- Side Effects
- ototoxic and nephrotoxic effects, neuromuscular blocking effect, allergic reactions.
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- excretion in milk unknown/not recommended
AMINOPHYLLINE
Bronchodilator
Pregnancy: cautionLactation: not in source
AMINOPHYLLINE
Bronchodilator
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 25mg/mL injection
Dosing & Formulations
- Dose
- Adult dose IV, loading dose, 5 mg/kg. Maintenance infusion rates: Otherwise healthy adults, 0.5 mg/kg/hour Patients with cor pulmonale, 0.3 mg/kg/hour Patients with congestive heart or hepatic failure, 0.1–0.2 mg/kg/hour Smokers, 0.8 mg/kg/hour. Pediatric dose IV, loading dose, 5–10 mg/kg (maximum 500 mg) over 20 minutes, followed
Indications & Contraindications
- Indications
- Reversible airways obstruction, status asthmatic, left ventricular failure, severe acute asthma.
Cautions & Side Effects
- Cautions
- Educe dose in liver disease; epilepsy, breast- feeding, pregnancy, cardiac disease, elderly patients, fever, hypertension, hyperthyroidism; peptic ulcer and hypokalemia.
- Side Effects
- Tachycardia, palpitations, nausea, gastro- intestinal disturbances, insomnia, arrhythmias, and convulsions especially/if given rapidly by intravenous injection;
Pregnancy & Lactation
- Pregnancy
- C
AMIODARONE,Cordarone®
Antiarrhythmicagent,classiii
Pregnancy: riskLactation: avoid
AMIODARONE,Cordarone®
Antiarrhythmicagent,classiii
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection
Dosage Forms
Tablet
- 200mgtablet
Injection
- 50 mg/mlinjection
Dosing & Formulations
- Dose
- By mouth, 200 mg 3 times daily for 1 week reduced to 200 mg twice daily for a further week. Maintenance, usually 200 mg daily or the minimum required to control the arrhythmias. By l.v. Infusion via central catheter, up to 5 mg/kg over 20-120 minutes with ecg and blood pressure monitoring; max. 1.2 g in 24 hours.
Indications & Contraindications
- Indications
- Treatment of arrhythmias when other antiarrhythmic drugs are contraindicated or ineffective; supraventricular and ventricular tachycardias, atrial fibrillation and flutter and ventricular fibrillation. Also for tachyarrhythmias associated with wolff-parkinson-white syndrome.
- Contraindications
- Sinus bradycardia, sino-atrial block, thyroid dysfunction, iodine sensitivity.
Cautions & Side Effects
- Cautions
- Sinus bradycardia, heart block unless pacemaker is fitted; avoid in severe conduction defects or sinus node disease, cardiomyopathy and heart failure.
- Side Effects
- Nausea, vomiting, raised serum transaminases, jaundice, bradycardia, thyroid dysfunction, corneal opacity, photosensitivity and skin discolouration; circulatory collapse can occur with rapid IV injection.
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Excreted into breast milk; not recommended
AMITRIPTYLINE,Tryptizol®
Antidepressant, Tricyclic (tertiaryamine)
Pregnancy: cautionLactation: avoid
AMITRIPTYLINE,Tryptizol®
Antidepressant, Tricyclic (tertiaryamine)
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Other
- 10
Tablet
- 25&50 mg tablet
Dosing & Formulations
- Dose
- Adults: -Depression: Oral:50-150 mg/dayassingledoseatbedtimeorindivideddoses.May graduallyincreaseupto300mg/day Migraineprophylaxis: Oral:Initial:10-25 mg atbedtime Usualdose:150mg Reporteddosingrange:10-400mg/day Painmanagement:Oral:Initial: 25 mgat bedtime,mayincreaseastoleratedto100mg/day Elderly:Depression:Oral: -Initialdose:10-25mgat bedtime,doseshould beincreasein 10-25mgincrements everyweekiftolerated –Dosingrange:25-150mg/day
Indications & Contraindications
- Indications
- Depressive illness, particularly where sedation is required; nocturnal enuresis in children; neuropathic pain); migraine prophylaxis
- Contraindications
- Recent myocardial infarction, heart block, mania; severe liver disease.
Cautions & Side Effects
- Cautions
- Sedation may affect patient's responses. Avoid abrupt cessation of therapy, epilepsy; pregnancy and breast-feeding, hepatic impairment, thyroid disease, anesthesia, diabetes.
- Side Effects
- Antimuscarinic effects- dry mouth, sedation, blurred vision (disturbance of accommodation, increased intra-ocular pressure), constipation, nausea, difficulty with micturition; cardiovascular side effects
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Distributed in breast milk; do not nurse
AMOXICILLIN,Amoxil®
Antibiotic,Penicillin
Pregnancy: safeLactation: caution
AMOXICILLIN,Amoxil®
Antibiotic,Penicillin
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule · Suspension
Dosage Forms
Other
- 250mg
Capsule
- 500 mgcapsule
Suspension
- 250mg/5mlsuspension
Dosing & Formulations
- Dose
- Adult dose Oral, 250–500 mg eight-hourly or 500–875 mg Every 12 hours. Paediatric dose 7.5–15 mg/kg every eight hours; (up to 22.5 mg/kg every Eight hours in severe infections).
- Dose in Organ Failure
- Renal impairment: patients with impaired renal function do not generally require dose reduction unless impairment is severe; do not administer extended-release product in patients with crcl<30 ml/min Gfr <30 ml/min: should not receive 875 mg (immediate release) or 775 mg (extended release) Gfr 10-30 ml/min: 250-500 mg q12hr, depending on severity of infection Gfr <10 ml/min: 250-500 mg q24hr depending on severity of infection Hemodialysis patients: 250-500 mg q24hr, depending on severity of infection; patients should receive additional dose during and at completion of dialysis; do not administer extended-release product or 875 mg immediate release
Indications & Contraindications
- Indications
- Otitismedia,sinusitis,andinfectionscausedbysusceptibleorganismsinvolvingtherespiratorytract,skin, andurinarytract;prophylaxisofbacterial endocarditisinpatientsundergoingsurgicalor dentalprocedures;aspartofa multidrugregimenfor H.pylorieradication
- Contraindications
- Penicillin hypersensitivity.
Cautions & Side Effects
- Cautions
- Renal impairment, history of allergy, skin rash, viral infections.
- Side Effects
- Diarrhoea (discontinue treatment if severe), gastrointestinal discomfort.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excreted in breast milk, use caution
AMPHOTERICINB,Fungizone®
Antifungal,Parenteral
Pregnancy: safeLactation: caution
AMPHOTERICINB,Fungizone®
Antifungal,Parenteral
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 50 mg/10 ml vial
Dosing & Formulations
- Dose
- Usual dosage ranges: Infants and Children: *Test dose: I.V.: 0.1 mg/kg/dose to a maximum of 1 mg; infuse over 30-60 minutes. *Maintenance dose: 0.25-1 mg/kg/day given once daily; infuse over 2-6 Hours. , amphotericin B can be administered on an every-other-day basis at 1 -1.5 mg/kg/dose; cumulative dose: 1.5-2 g over 6-10 weeks. *Duration of therapy: Varies with nature of infection, usual duration is 4-12 weeks or cumulative dose of 1-4 g Adults: *Test dose: 1 mg infused over 20-30 minutes. *Maintenance dose: Usual: 0.05-1.5 mg/kg/day; 1-1.5 mg/kg over 4-6 hours every other day may be given once therapy is established. Adult: Bladder irrigation: Candidal cystitis: Irrigate with 50mcg/ml solution instill periodically or continuously for 5-10days or until cultures are clear
- Dose in Organ Failure
- Renal Impairment Crcl<10 ml/min: 0.5-0.7 mg/kg IV q24-48hr Consider other antifungal agents that may be less nephrotoxic Intermittent hemodialysis: 0.5-1 mg/kg IV q24hr after dialysis session Continuous renal replacement therapy: 0.5-1 mg/kg IV q24hr
Indications & Contraindications
- Indications
- Treatment of severe systemic and central nervous system infections caused by susceptible fungi such as Candida species, Histoplasma capsulatum, Cryptococcus neoformans, Aspergillus species, Blastomyces dermatitidis, Torulopsis glabrata, and Coccidioides immitis; fungal peritonitis; irrigant for bladder fungal infections; used in fungal infection in patients with bone mar- row transplantation, amebic meningoencephalitis, ocular aspergillosis , candi- dal cystitis, chemoprophylaxis, immunocompromised patients at risk of as- pergillosis, refractory meningitis, coccidioidal arthritis.
- Contraindications
- Concurrent use of nephrotoxic drugs.
Cautions & Side Effects
- Cautions
- (when given intravenously) monitor renal and hepatic function and blood count; corticoids; pregnancy and breast-feeding.
- Side Effects
- (when given intravenously) gastrointestinal disturbances, anaphylaxis; nephrotoxicity; headache, muscle and joint pain; blood disorders.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excretion in milk is unknown; due to the potential for serious adverse reactions in breast-fed infants, a decision should be made whether to discontinue nursing orwhether to discontinue the drug, taking into account the importance of the drug to the mother
AMPICILLIN,Penbritin®,Epicocillin®
Antibiotic,Penicillin
Pregnancy: safeLactation: caution
AMPICILLIN,Penbritin®,Epicocillin®
Antibiotic,Penicillin
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 500mg &1ginjection
Dosing & Formulations
- Dose
- Adult dose IM/IV, 500 mg–1 g every 4–6 hours. Meningitis or septicaemia: 200 mg/kg/day in divided Doses every 4–6 hours. Maximum 14 g daily. Paediatric dose IM/IV, 10–25 mg/kg every 6 hours. Maximum 50 mg/kg Every 4 hours.
- Dose in Organ Failure
- Renal impairment Crcl<10 ml/min: use q12-16hr
Indications & Contraindications
- Indications
- Susceptiblebacterial infections (nonbeta-lactamase-producing organisms); susceptible bacterialinfectionscausedby streptococci,pneumococci, non-penicillinase-producingstaphylococci,Listeria,meningococci;somestrainsof H.influenzae,Salmonella,Shigella,E.coli,Enterobacter,andklebsiella
- Contraindications
- Penicillin hypersensitivity.
Cautions & Side Effects
- Cautions
- Renal impairment, history of allergy, skin rash, viral infections.
- Side Effects
- Diarrhoea (discontinue treatment if severe), gastrointestinal discomfort.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excreted in breast milk, use caution
ARTESUNATE
Antimalrial
Pregnancy: Not availableLactation: caution
ARTESUNATE
Antimalrial
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Unclassified
- Dosage form
- Injection
Dosage Forms
Injection
- 60mg injection
Dosing & Formulations
- Dose
- 2.4 mg/kg iv/im at 0, 12 hours, 24 hours, then Q day
Indications & Contraindications
- Indications
- Treatment(immediate and other) of malaria
Cautions & Side Effects
- Cautions
- The powder for injection is difficult to dissolve and care should be taken to ensure that it is completely dissolved before parenteral administration.
- Side Effects
- Fever, gastrointestinal distruburbances, pruritus; dizziness; headache; tinnitus, neutropenia; elevates liver enzyme levels; ecg abnormalities
Pregnancy & Lactation
- Pregnancy
- Not available
- Lactation
- Unknown
ASPIRIN,Acetylsalicylicacid,Jusprin®
Salicylate
Pregnancy: cautionLactation: see details
ASPIRIN,Acetylsalicylicacid,Jusprin®
Salicylate
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 81 &500 mg tablet
Dosing & Formulations
- Dose
- Secondary prevention of stroke or myocardial infarction, 300 mg daily (75, 81 or 100 mg daily for long term use with established cardiovascular disease, after coronary bypass surgery; or 150--300 mg on as soon as possible after an ischemic event). 300-900 mg every 4-6 hours when necessary, max. 4 g daily. Child and adolescent not recommended.
Indications & Contraindications
- Indications
- Mild to moderate, pain, pyrexia; antiplatelet.
- Contraindications
- Children and adolescents under 16 years and in breast-feeding (Reye's syndrome); previous or active peptic ulceration, haemophilia.
Cautions & Side Effects
- Cautions
- Gastro-intestinal ulcers, haemophilia, anticoagulant therapy, asthma, impaired renal or hepatic function, dehydration, pregnancy; elderly.
- Side Effects
- Mild and occasional, high rate of gastro- intestinal irritation with slight asymptomatic blood loss, increased bleeding time, bronchospasm and skin reactions in hypersensitive patients.
Pregnancy & Lactation
- Pregnancy
- C / D (full-dose aspirin in 3rd trimester, expert analysis)
- Lactation
- Drug enters breast milk; decision should be made regarding whether to discontinue nursing or to discontinue drug, taking into account importance of drug to mother.
ATENOLOL,Normoten®,Tenormin®
Beta1selectiveBlocker
Pregnancy: riskLactation: caution
ATENOLOL,Normoten®,Tenormin®
Beta1selectiveBlocker
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 100 mg tablet
Dosing & Formulations
- Dose
- by mouth, hypertension, 50-100 mg daily. Angina, 100 mg daily in 1 or 2 doses. Arrhythmias, 50-100 mg daily.
- Dose in Organ Failure
- Renal impairment CrCl 15-35 mL/min/1.73 m: Not to exceed 50 mg/day PO CrCl<15 mL/min/1.73 m: Not to exceed 25 mg/day PO CrCl>35 mL/min/1.73 m: Dose adjustment not necessary
Indications & Contraindications
- Indications
- hypertension, angina, arrhythmias, early intervention in acute myocardial infarction.
- Contraindications
- Asthma; uncontrolled heart failure; Prinzmetalss angina; marked bradycardia; hypotension.
Cautions & Side Effects
- Cautions
- first degree AV block; portal hypertension and chronic obstructive pulmonary disease; late pregnancy; breast feeding
- Side Effects
- Gastro intestinal disturbances; bradycardia, heart failure, hypotension, conduction disorders, bronchospasm, peripheral vasoconstriction
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Drug enters breast milk; neonates born to mothers who are receiving atenolol at parturition or breastfeeding may be at risk for hypoglycemia and bradycardia; use with caution
ATRACURIUM,Tracium®
Muscle Relaxant, Neuromuscular Blocker Agent
Pregnancy: cautionLactation: caution
ATRACURIUM,Tracium®
Muscle Relaxant, Neuromuscular Blocker Agent
- Therapeutic group
- Anaesthesia & Muscle Relaxants
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 10mg/ml injection (2.5ml ampoule)
Dosing & Formulations
- Dose
- IV (not to be used I.M.) use ideal body weight for obese patients Children 1 month to 2 years: initial 0.3-0.4mg/kg followed by maintenance doses as needed to maintain neuromuscular blockade Children >2 years to Adults: 0.4-0.5 mg/kg, then 0.08-0.1 mg/kg 20-45 min- utes after initial dose to maintain neuromuscular block, followed by repeat doses of 0.08-0.1 mg/kg At 15-25 minute intervals Adults: 0.2-0.4mg/kg Pretreatment /priming: 10% of intubating dose given 3-5 minutes before initial dose. Continuous infusion: Surgery: Initial: 9-10 mcg/kg/minute at initial signs of recovery from bolus dose; block usually maintained by rate of 5-9 mcg/kg/ minute under balanced anesthesia.
Indications & Contraindications
- Indications
- Adjunct to general anesthesia to facilitate endotracheal intubation and to relax skeletal muscles during surgery; to facilitate mechanical ventilation in ICU patients; does not relieve pain or produce sedation
Cautions & Side Effects
- Cautions
- may cause significant histamine release leading to cardiovascular effects.
- Side Effects
- Flushing, Bronchial secretions, erythema, hives, itching, wheezing
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- excretion in milk unknown; use with caution
ATROPINESULPHATE,Atropin-Care®,Apitropin®,Riatropine®
Cholinergic Antagonist,Antimuscarinic,MydriaticAgent(Ophthalmic)s
Pregnancy: cautionLactation: caution
ATROPINESULPHATE,Atropin-Care®,Apitropin®,Riatropine®
Cholinergic Antagonist,Antimuscarinic,MydriaticAgent(Ophthalmic)s
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Unclassified
- Dosage form
- Injection · Ointment
Dosage Forms
Injection
- 500mcg/ml injection
Other
- 0.1mg/ml prefilled syring
- 0.5mg/ml prefilled syring
- 0.5%
- 1% eyedrop
Ointment
- 1% eye ointment
Dosing & Formulations
- Dose
- Neonates, Infants, and Children: Doses <0.1 mg have been associated with paradoxical bradycardia. Inhibit salivation and secretions (preanesthesia): <5 kg: 0.02 mg/kg/dose 30-60 minutes preop then every 4-6 hours as needed. Use of a minimum dosage of 0.1 mg in neonates <5 kg will result in dosages >0.02 mg/kg. . >5 kg: 0.01-0.02 mg/kg/dose to a maximum 0.4 mg/dose 30-60 minutes preop; minimum dose: 0.1 mg Bradycardia: I.V., intratracheal: 0.02 mg/kg, minimum dose 0.1 mg, maximum single dose: 0.5 mg in children and 1 mg in adolescents; may repeat in 5- minute intervals to a maximum total dose of 1 mg in children or 2 mg in ado- lescents. Prehospital I.M.: Birth to <2 years: Mild-to-moderate symptoms: 0.05 mg/kg; severe symp- toms: 0.1 mg/kg 2-10 years: Mild-to-moderate symptoms: 1 mg; severe symptoms: 2 mg >10 years: Mild-to-moderate symptoms: 2 mg; severe symptoms: 4 mg Hospital/emergency department: I.M.: Birth to <2 years: Mild-to-moderate symptoms: 0.05 mg/kg I.M. or 0.02 mg/kg I.V.; severe symptoms: 0.1 mg/kg I.M. or 0.02 mg/kg I.V. 2-10 years: Mild-to-moderate symptoms: 1 mg; severe symptoms: 2 mg >10 years: Mild-to-moderate symptoms: 2 mg; severe symptoms: 4 mg Children: Organophosphate or carbamate poisoning: Children: Organophosphate or carbamate poisoning: -I.V.: 0.03-0.05 mg/kg every 10-20 minutes until atropine effect, then every 1- 4 hours for at least 24 hours Adults: Doses <0.5 mg have been associated with paradoxical bradycardia Asystole or pulseless electrical activity: I.V.: 1 mg; repeat in 3-5 minutes if asystole persists; total dose of 0.04 mg/kg. Intratracheal: Administer 2-2.5 times the recommended I.V. dose; dilute in 10 mL NS or distilled water. Inhibit salivation and secretions (preanesthesia): I.M., I.V., SubQ: 0.4-0.6 mg 30-60 minutes preop and repeat every 4-6 hours Bradycardia: I.V.: 0.5-1 mg every 5 minutes, not to exceed a total of 3 mg or 0.04 mg/kg; may give intratracheally in 10 mL NS Neuromuscular blockade reversal: I.V.: 25-30 mcg/kg 30-60 seconds before neostigmine or 7-10 mcg/kg 30-60 seconds before edrophonium Organophosphate or carbamate poisoning: -I.V.: Initial: 1-5 mg; doses should be doubled every 5 minutes until signs of muscarinic excess abate. Overly aggressive dosing may cause anticholiner- gic toxicity. -I.V. Infusion: 0.5-1 mg/hour or 10% to 20% of loading dose/hour Mydriasis, cycloplegia (preprocedure): Ophthalmic (1% solution): Instill 1-2 drops 1 hour before procedure. Uveitis: *Ophthalmic1% solution: Instill 1-2 drops 4 times/day
Indications & Contraindications
- Indications
- Injection: Preoperative medication to inhibit salivation and secretions, symp- tomatic sinus bradycardia; AV block (nodal level); ventricular asystole; anti- dote for organophosphate pesticide poisoning ophthalmic: Produce mydriasis and cycloplegia for examination of the retina and optic disc and accurate measurement of refractive errors; uveitis
- Contraindications
- glaucoma.
Cautions & Side Effects
- Cautions
- systemic effects may follow topical application especially in children; patients should be advised not to drive immediately after instillation.
- Side Effects
- local irritation, increased intra-ocular pressure, systemic
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- trace amounts enter breast milk; use with caution
AZATHIOPRINE,Imuran®
Immunosuppressantagent
Pregnancy: riskLactation: avoid
AZATHIOPRINE,Imuran®
Immunosuppressantagent
- Therapeutic group
- Malignant Disease & Immunosuppression
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 50mgtablet
Dosing & Formulations
- Dose
- Adult and paediatric doses Organ transplantation: IV/oral, initially 2–5 mg/kg daily; maintenance dose 1–3 mg/kg daily. Autoimmune disorders: Oral, 1 mg/kg daily, increasing over several weeks to a maximum daily dose of 2.5 mg/ kg; maintenance dose (adults) 50–150 mg daily.
- Dose in Organ Failure
- Dosing adjustment in renal impairment: Clcr 10-50 ml/minute: Administer 75% of normal dose daily Clcr <10 ml/minute: Administer 50% of normal dose daily -Hemodialysis: Dialyzable (~45% removed in 8 hours)
Indications & Contraindications
- Indications
- Adjunctivetherapyinpreventionofrejection ofkidney transplants;activerheumatoidarthritis
Cautions & Side Effects
- Cautions
- Monitor blood count regularly;hepatic impairment; renalimpairment; reduce dose in elderly.
- Side Effects
- Hypersensitivity reactions;dose related bone marrow depression;alopecia; increase incidenceof infections; nausea.
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Drug excreted at low levels in breast milk; use not recommended
AZITHROMYCIN,Zithromax®
Antibiotic,Macrolide
Pregnancy: safeLactation: caution
AZITHROMYCIN,Zithromax®
Antibiotic,Macrolide
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule · Suspension · Drops
Dosage Forms
Capsule
- 250mgcapsule
Suspension
- 200mg/5mlsuspension
Drops
- 15mg eye drops
Dosing & Formulations
- Dose
- Adult dose Sexually transmitted chlamydia infections: 1 g single dose. Other indications: 500 mg daily for three days or 500 mg on day one and 250 mg daily for four days. Paediatric dose Streptococcal pharyngitis and tonsillitis: 10–20 mg/kg Once daily for three days (maximum 500 mg). Chlamydial conjunctivitis and trachoma: 20 mg/kg as a Single dose or once weekly for up to three weeks.
Indications & Contraindications
- Indications
- Acute otitis media due to H. Influenzae, M. Catarrhalis, or S.Pneumoniae; pharyngitis/tonsillitis due to S. Pyogenes; mild to moderate URTI & LRTI, infections of the skin and skin structure, community-acquired pneumonia, pelvic inflammatory disease (PID), sexually-transmitted diseases (urethritis/ cervicitis), pharyngitis/tonsillitis, and genital ulcer disease (chancroid), Mycoplasma pneumoniae, and C. Psittaci , acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) due to H. Influenzae, M. Ca- tarrhalis, or S. Pneumonia, Acute bacterial sinusites
- Contraindications
- Hepatic disease; pregnancy.
Cautions & Side Effects
- Cautions
- Renal impairment; breast-feeding.
- Side Effects
- Diarrhoea, nausea and vomiting, abdominal pain, allergic reactions, cholestatic jaundice.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Unknown whether drug is excreted into breast milk; use with caution
BACLOFEN,Lioresal®, Baclofen®
SkeletalMuscleRelaxant
Pregnancy: cautionLactation: avoid
BACLOFEN,Lioresal®, Baclofen®
SkeletalMuscleRelaxant
- Therapeutic group
- Anaesthesia & Muscle Relaxants
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Syrup
Dosage Forms
Tablet
- 10 mgtablet
Syrup
- 1mg/ml syrup
Dosing & Formulations
- Dose
- By mouth, ADULT over 18 years, initially 5 mg 3 times daily, gradually increased; usual maintenance dose up to 60 mg daily in divided doses (max. 100 mg daily); CHILD under 18 years, initially 300 micrograms/kg daily in 4 divided doses, increased gradually at weekly intervals until satisfactory response; usual maintenance dose 0.75–2 mg/kg daily in divided doses; CHILD up to 8 years, max. total daily dose 40 mg/day; CHILD 8–18 years, max. total daily dose 60 mg/day.
- Dose in Organ Failure
- Renal impairment: risk of toxicity—use smaller doses (e.g. 5 mg daily by mouth) and if necessary increase dosage interval; if eGFR less than 15 ml/minute/1.73m2 manufacturer advises use by mouth only if potential benefit outweighs risk; excreted by kidney.
Indications & Contraindications
- Indications
- chronic severe spasticity resulting from disorders such as multiple sclerosis or traumatic partial section of spinal cord.
- Contraindications
- Specific contra-indications for intrathecal treatment local or systemic infection.
Cautions & Side Effects
- Cautions
- psychiatric illness, Parkinson's disease, cerebrovascular disease, elderly; respiratory impairment; epilepsy; history of peptic ulcer
- Side Effects
- gastro-intestinal disturbances, dry mouth; hypotension, respiratory or cardiovascular depression; sedation, drowsiness, confusion, dizziness.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Enters breast milk in small amounts; not recommended
BETAHISTINE,Betaserc®
Histamine H1agonist
Pregnancy: No dataLactation: not in source
BETAHISTINE,Betaserc®
Histamine H1agonist
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Other
- 8mg
Tablet
- 16mg tablet
Dosing & Formulations
- Dose
- Adults:8-16mg 3times/day;administration withmealsisrecommended
Indications & Contraindications
- Indications
- Vertigo, Mnieres disease.
- Contraindications
- Phaeochromocytoma
Cautions & Side Effects
- Cautions
- Asthma, history of pepticulcer, pregnancy and breast-feeding.
- Side Effects
- GI disturbances,headache, pruritus, rashes.
Pregnancy & Lactation
- Pregnancy
- No data
BETAMETHASONE, Riavate®,Tabeta® , Salibet®, Defosalic®
Corticosteroid
Pregnancy: cautionLactation: caution
BETAMETHASONE, Riavate®,Tabeta® , Salibet®, Defosalic®
Corticosteroid
- Therapeutic group
- Skin / Dermatological
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Cream · Ointment · Lotion
Dosage Forms
Cream
- Valerate 0.1% Skin Ointment&cream
- dipropionate 0.05% oint.&cream 0.1%Scalp Lotion
Lotion
- Betamethason 0.05+ salicylic acid 2% lotion& lotion
Dosing & Formulations
- Dose
- Topical: ≤12 years: Use is not recommended. ≥13 years: Apply once or twice daily Adults: Foam: Apply to the scalp twice daily, once in the morning and once at night Cream/ointment: Apply once or twice daily
Indications & Contraindications
- Indications
- severe inflammatory skin disorders.
- Contraindications
- untreated bacterial, fungal or viral skin infections, acne vulgaris, rosacea.
Cautions & Side Effects
- Cautions
- avoid prolonged use especially in children and infants; avoid prolonged use on the face
- Side Effects
- Dermatologic: Acneiform eruptions, dermatitis, burning, dry skin, erythema, folliculitis, hypertrichosis, miliaria, pruritus, skin atrophy, striae
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- is not known whether topical corticosteroid use could result in sufficient systemic absorption to produce detectable quantities in human milk; use with caution.
BISACODYL, Laxocodyl,Dulcolax®
Laxative,Stimulant
Pregnancy: cautionLactation: caution
BISACODYL, Laxocodyl,Dulcolax®
Laxative,Stimulant
- Therapeutic group
- Gastrointestinal System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Suppository
Dosage Forms
Suppository
- 10mgsuppository
Tablet
- 5mgtablet
Dosing & Formulations
- Dose
- Adults:Rectalsuppository:10mg asasingledose Children:Rectalsuppository:<2years:5mgasasingledose,>2years:10mg
Indications & Contraindications
- Indications
- constipation, bowel evacuation before radiological procedures, endoscopy and surgery.
- Contraindications
- Abdominal pain, appendicitis, intestinal obstruction
Cautions & Side Effects
- Side Effects
- Excessive bowel activity (griping, diarrhoea, nausea, vomiting); perianal irritation; bloating; flatulence; abdominal cramping.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Has not been detected in excreted milk; use with caution
Bisoprolol ,concor®
Beta1selectiveblocker
Pregnancy: cautionLactation: caution
Bisoprolol ,concor®
Beta1selectiveblocker
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 5 mg tab
Dosing & Formulations
- Dose
- Hypertension and angina, usually 10 mg once daily (5mg may be adequate in some patients); max. 20 mg daily. Adjunct in stable moderate to severe heart failure, initially 1.25 mg once daily in the morning for 1 week, then, if well tolerated, increased to 2.5 mg once daily for 1 week, then 3.75 mg once daily for 1 week, then 5 mg once daily for 4 weeks, then 7.5mg once daily for 4 weeks, then 10 mg once daily; max. 10 mg daily.
Indications & Contraindications
- Indications
- Hypertension, angina and as an adjunct in heart failure.
Cautions & Side Effects
- Side Effects
- Dizziness,dyssomnia,bradyarrhythmia,upper respiratory infection,diarrhea,rhinitis,arthralgia,cough,dyspnea,nausea,pharyngitis,sinusitis,vomiting
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excretion in milk unknown; use caution
BRIMONIDINE, Alphagan®
Antiglaucoma, Alpha agoinst
Pregnancy: safeLactation: caution
BRIMONIDINE, Alphagan®
Antiglaucoma, Alpha agoinst
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Drops
Dosage Forms
Drops
- 0.15% eye drops
Dosing & Formulations
- Dose
- 1 gtt in affected eye(s) TID, approximately 8 hours apart.
Indications & Contraindications
- Indications
- ocular hypertension, open-angle glaucoma.
- Contraindications
- Concomitant MAOI therapy.
Cautions & Side Effects
- Cautions
- severe cardiovascular disease; cerebral or coronary insufficiency, Raynauds syndrome, postural hypotension, depression, hepatic or renal impairment; pregnancy, breast-feeding.
- Side Effects
- ocular reactions including conjunctival hyperaemia, stinging, pruritus, allergy, and conjunctival folliculosis, visual disturbances, blepharitis.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- It is not known whether this drug is excreted in milk. A decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
BROMHEXIN HCL, Ezolvin®
Mucolytic
Pregnancy: safeLactation: avoid
BROMHEXIN HCL, Ezolvin®
Mucolytic
- Therapeutic group
- Respiratory System
- Storage
- Unclassified
- Dosage form
- Tablet · Syrup
Dosage Forms
Syrup
- 4mg/5ml syp
Tablet
- 8mg tab
Dosing & Formulations
- Dose
- By mouth, 8-16mg 3-4 times daily. Child up to 1 year, 2mg twice daily. 1-5 years, 4mg twice daily.6-10 years, 4mg 4 times daily.
Indications & Contraindications
- Indications
- Bromhexine is a mucolytic used in the treatment of respiratory disorders associated with productive cough.
Cautions & Side Effects
- Cautions
- Gastric ulceration, asthmatic patients; reduced Clearance of bromhexine or its metabolites in patients with severe hepatic or renal impairment.
- Side Effects
- Headache, dizziness, sweating, and skin rashes. Inhalation of bromhexine has occasionally produced cough or bronchospasm in susceptible subjects.
Pregnancy & Lactation
- Pregnancy
- A
- Lactation
- Passes into breast milk. Avoid breastfeeding while using this
BROMOCRIPTINE,Parlodel®
Anti-Parkinson'sAgent,dopamineagonist
Pregnancy: safeLactation: see details
BROMOCRIPTINE,Parlodel®
Anti-Parkinson'sAgent,dopamineagonist
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 2.5mgtablet
Dosing & Formulations
- Dose
- Prevention of lactation,orally 2.5 mg on day 1 and then 2.5mg twice daily for 14 days.Suppression of lactation, 2.5 mgdaily for 2-3 days and then 2.5 mgtwice daily for 14 days. Hypogonadism,galactorrhoea, infertility,initial dose of 1-1.25 mg atbed time to minimize the hypotensiveeffect, increase gradually to 7.5mg daily in divided doses.
Indications & Contraindications
- Indications
- Amenorrheawithorwithoutgalactorrhea;infertilityorhypogonadism;prolactin-secretingadenomas;acromegaly;Parkinson'sdisease
- Contraindications
- Sensitivity tobromocriptine; toxaemia of pregnancyand hypertension in postpartumwomen or in puerperium.
Cautions & Side Effects
- Cautions
- Peptic ulcer; mental disorders;cardiovascular disease.
- Side Effects
- Nausea, vomiting,constipation; dyskinesia, fatigue;hypotension.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Should not be used during lactation
BUDESONIDE, Symbicort®, RhinocortAqua®, Pulmicort®
Corticosteroids inhalant
Pregnancy: safeLactation: see details
BUDESONIDE, Symbicort®, RhinocortAqua®, Pulmicort®
Corticosteroids inhalant
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Suspension · Nebulizer solution · Powder · Spray
Dosage Forms
Spray
- 64mcg /dosenasalspray (rhinocortaqua®)
Suspension
- 0.5mg/mlnebulisersuspension
Other
- 200mcg/dose oral turbohaler (Pulmicort®)
Powder
- 160/4.5mcg/doseinhalationpowder (Budesonide/Formoterol:Symbicort®)
Dosing & Formulations
- Dose
- Nasalspray Children≥6yearsandadults:256 mcg/dayadministeredasasingle64 mcgsprayineachnostriltwicedaily Rhinitis:Initial: 256 mcg/dayadministeredas two64 mcgspraysineach Nostril oncedailyorasingle64 mcgsprayineachnostriltwicedaily. Inhalation Adults, initially or in severe asthma, or when reducing or discontinuing oral corticosteroids, 1-2mg twice daily. Child 3 months - 12 years, 0.5 - 1mg twice daily. Maintenance, usually half above doses. Croup, 2mg as a single dose (or as two 1mg doses separated by 30 minutes).
Indications & Contraindications
- Indications
- A corticosteroid used in prophylaxis of asthma especially if not fully controlled by bronchodilators or cromoglycate.
Cautions & Side Effects
- Cautions
- Pulmonary tuberculosis and viral infections in the airways; pregnancy.
- Side Effects
- Mild irritation in the throat, coughing and hoarseness; candidal infections of the oropharynx; bronchoconstriction in hyperreactive patients.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Drug enters breast milk; use only if benefits greatly outweigh risks
BUPIVACAINE, Marcaine® ,Bucaine®
Localanesthetic
Pregnancy: cautionLactation: avoid
BUPIVACAINE, Marcaine® ,Bucaine®
Localanesthetic
- Therapeutic group
- Anaesthesia & Muscle Relaxants
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Other
- 0.5%
Injection
- local anesthesia and heavy for spinal injection
Dosing & Formulations
- Dose
- Children>12yearsandadults: Localanesthesia:Infiltration:0.25% infiltratedlocally;maximum:175 mg Caudalblock(preservativefree):15-30mlof0.25%or0.5% Epiduralblock(otherthancaudalblock;preservativefree):Administerin3-5 Mlincrements,allowingsufficienttimetodetecttoxicmanifestationsofinad- vertenti.V.ori.T.administration: 10-20mlof0.25%or0.5% -Surgicalprocedures requiringahighdegreeofmusclerelaxationandpro- Longedeffectsonly:10-20 ml of0.75% -Peripheralnerveblock:5mlof0.25or0.5%; maximum:400mg/day -Sympathetic nerveblock:20-50 mlof 0.25% -Retrobulbaranesthesia:2-4ml of0.75% Adults:Spinalanesthesia:Preservativefreesolutionof0.75%bupivacainein 8.25%dextrose: -Lowerextremity andperinealprocedures:1ml -Lowerabdominalprocedures:1.6ml -Normalvaginaldelivery:0.8mlcesareansection:1-1.4ml
Indications & Contraindications
- Indications
- Localanesthetic(injectable)forperipheralnerveblock, infiltration.
- Contraindications
- Intravenous regional anaesthesia (Biers block).
Cautions & Side Effects
- Side Effects
- Seizure,hypotension,bradycardia,palpitations,heartblock,ventricularar-rhythmias.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excretion in milk unknown/not recommended
CABERGOLIN E
Dopaminergic antiparkinsonism agents Prolactin inhibitors
Pregnancy: safeLactation: see details
CABERGOLIN E
Dopaminergic antiparkinsonism agents Prolactin inhibitors
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 0.5 mg
Dosing & Formulations
- Dose
- Initial dose: 0.25 mg orally twice a week -Increase dose in increments of 0.25 mg twice a week no more frequently than every 4 weeks according to patient's prolactin level Maximum dose: 1 mg twice a week
Indications & Contraindications
- Indications
- Used to treat a hormone imbalance in which there is too much prolactin in the blood (also called hyperprolactinemia).
- Contraindications
- Severe Uncontrolled High Blood Pressure ,heart valve disease ,Blockage or Closing Off of Blood Vessels ,Lung Fibrosis ,Liver Problems ,Retroperitoneal Fibrosis ,Severely Increased Blood Pressure and Edema During Pregnancy ,A Mother who is Producing Milk and Breastfeeding ,Excess Fibrous Tissue around Covering of Heart
Cautions & Side Effects
- Cautions
- Safety and efficacy have not been established in patients younger than 18 years.
- Side Effects
- Difficulty having a bowel movement (stool) mdizziness ,excess air or gas in the stomach or intestines ,full feeling ,headache ,lack or loss of strength ,passing gas
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Cabergoline is usually not used during breastfeeding because it suppresses lactation
CAFFEINE CITRATE,
Respiratory stimulants
Pregnancy: cautionLactation: caution
CAFFEINE CITRATE,
Respiratory stimulants
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 20mg/ml inj
Dosing & Formulations
- Dose
- orally or by intravenous injection,initially 20 mg/kg, then 5mg/kg once daily starting 24 hoursafter initial dose (some neonatesmay require 10 mg/kg).
Indications & Contraindications
- Indications
- neonatal apnoea; adjunct to extubation in preterm infants
Cautions & Side Effects
- Cautions
- necrotizing enterocolitismay occur, infants with cardiovasculardisorders, hepatic or renal impairmentand seizure disorders,
- Side Effects
- physical signs ofwithdrawal including irritability,lethargy; headache, tachycardia,raised serum glucose concentration.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- enters breast milk; use with caution
CALAMINELOTION
Antipruritic,Topicalskinproduct
Pregnancy: safeLactation: caution
CALAMINELOTION
Antipruritic,Topicalskinproduct
- Therapeutic group
- Skin / Dermatological
- Storage
- Unclassified
- Dosage form
- Lotion
Dosage Forms
Lotion
- Lotion
Indications & Contraindications
- Indications
- Itchingoftheskin
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Unknown, caution advised
CALCITONIN,Miacalcic®
Drugaffectingbonemetabolism,Hormone
Pregnancy: cautionLactation: avoid
CALCITONIN,Miacalcic®
Drugaffectingbonemetabolism,Hormone
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 100internationalunit injection
Dosing & Formulations
- Dose
- Hypercalcaemia, by subcutaneous or intramuscular injection, 5-10 units/kg daily in 1-2 divided doses, adjust according to clinical and biochemical response. Pagets disease of bone, intramuscular or subcutaneous injection, a dose range of 50 units 3 times weekly to 100 units daily are used as single or divided doses. Postmenopausal osteoporosis, intramuscular Or subcutaneous injection, Supplement of dietary calcium and vitamin D is recommended.
Indications & Contraindications
- Indications
- Hypercalcaemia; Pagets disease; osteoporosis.
- Contraindications
- Hypersensitivity to synthetic calcitonin.
Cautions & Side Effects
- Cautions
- Administration may lead to hypocalcaemic tetany; monitor for possible allergic reactions to calcitonin since it is an exogenous protein; resistance to salmon calcitonin may develop due to antibody formation.
- Side Effects
- Gastrointestinal disturbances; skin rash; nasal spray may cause local irritation and ulceration, rhinitis sinusitis, epistaxis.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excretion in milk unknown/not recommended
CALCITRIOL (1, 25-Dihydroxycholecalciferol) Rocaltrol
Pregnancy: not in sourceLactation: not in source
CALCITRIOL (1, 25-Dihydroxycholecalciferol) Rocaltrol
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule
Dosage Forms
Other
- 250 nanograms
Capsule
- 500 nanograms Capsule
Dosing & Formulations
- Dose
- By mouth, renal osteodystrophy, initially 250 nanograms daily, or on alternate days (in patients with normal or only slightly reduced plasma-calcium concentration), increased if necessary in steps of 250 nanograms at intervals of 2–4 weeks; usual dose 0.5–1 microgram daily.
Indications & Contraindications
- Indications
- Vitamin D deficiency. Management of postmenopausal osteoporosis.
- Contraindications
- Hypercalcaemia; metastatic calcification.
Cautions & Side Effects
- Cautions
- Monitor plasma calcium, phosphate, and creatinine during dosage titration.
- Side Effects
- Symptoms of overdosage include anorexia, lassitude, nausea and vomiting, diarrhoea, constipation, weight loss, polyuria, sweating, headache, thirst, vertigo, and raised concentrations of calcium and phosphate in plasma and urine.
CALCIUMCARBONATE,Seacal®,Adcal®,Caltrate®,
Calciumsalt,electrolytesupplement,Oral
Pregnancy: safeLactation: compatible
CALCIUMCARBONATE,Seacal®,Adcal®,Caltrate®,
Calciumsalt,electrolytesupplement,Oral
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 500 mg tablet
Dosing & Formulations
- Dose
- Hypocalcemia (dose depends on clinical condition and serum calcium level): Dose expressed in mg of elemental calcium Children: 45-65 mg/kg/day in 4 divided doses Adults: 1-2 g or more/day in 3-4 divided doses Antacid: Children 2-5 years (24-47 lb): Elemental calcium 161 mg as needed; maxi- mum 483 mg per 24 hours Children 6-11 years (48-95 lb): Elemental calcium 322 mg as needed; maxi- mum: 966 mg per 24 hours Adults: Dosage based on acid-neutralizing capacity of specific product; gen- Erally, 1-2 tablets or 5-10 ml every 2 hours; maximum: 7000 mg calcium carbonate per 24 hours; specific product labeling should be consulted Dietary supplementation: Adults: 500 mg to 2 g divided 2-4 times/day Osteoporosis: Adults >51 years: 1200 mg/day
Indications & Contraindications
- Indications
- As an antacid; calcium deficiency or hyperphosphatemia (eg, osteoporosis, osteomalacia, mild/moderate renal insufficiency, hypoparathyroidism, post- menopausal osteoporosis, rickets
- Contraindications
- Hypercalcaemia; hypercalciuria.
Cautions & Side Effects
- Cautions
- Renal impairment.
- Side Effects
- Mild gastro-intestinal disturbances; bradycardia, arrhythmias.
Pregnancy & Lactation
- Pregnancy
- Available evidence suggests safe use during pregnancy and breast-feeding.
- Lactation
- Safe; crosses the placenta; appears in breast milk
CALCIUMCHLORIDE
Calcium Salt, ElectrolyteSupplement(Parenteral)
Pregnancy: cautionLactation: caution
CALCIUMCHLORIDE
Calcium Salt, ElectrolyteSupplement(Parenteral)
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 10%injection
Dosing & Formulations
- Dose
- Acute, symptomatic ionized hypocalcemia, hyperkalemia, or Mg toxicity: Neonates: 20 mg/kg; may repeat as necessary Infants and Children: 20 mg/kg; may repeat as necessary Adults: 500-1000 mg, may repeat as necessary Hypocalcemia secondary to citrated blood transfusion: I.V.: Neonates, Infants, and Children: Give 32 mg (0.45 meq elemental calcium) For each 100 mlcitrated blood infused. Adults: 200-500 mg per 500 ml of citrated blood (infused into another vein) Hypocalcemic tetany: I.V.: Neonates: 40-60 mg/kg/dose repeated every 6-8 hours Infants and Children: 10 mg/kg over 5-10 minutes; may repeat after 6-8 hours Or follow with an infusion with a maximum dose of 200 mg/kg/day; alterna- tively, higher doses of 35-50 mg/kg/dose repeated every 6-8 hours have been used Adults: 1000 mg over 10-30 minutes; may repeat after 6 hours
Indications & Contraindications
- Indications
- Acute symptomatic hypocalcemia; cardiac disturbances of hyperkalemia or hypocalcemia; emergent treatment of hypocalcemic tetany; severe hyper- magnesemia
Cautions & Side Effects
- Side Effects
- Arrhythmia, bradycardia, cardiac arrest, hypotension, syncope, vasodilation, hypercalcemia, tingling sensation, renal calculi
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- As a component of human milk calcium enters milk. Use caution.
CAPTOPRIL, Capoten®
Angiotensin-convertingenzyme(ace)inhibitor
Pregnancy: cautionLactation: avoid
CAPTOPRIL, Capoten®
Angiotensin-convertingenzyme(ace)inhibitor
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 25mgtablet
Dosing & Formulations
- Dose
- Alone mild to moderate hypertension, initially 12.5 mg twice daily. Maintenance dose, 25 mg twice daily; can be increased at 2-4 week intervals until a satisfactory response is obtained to a max. Of 50 mg twice daily. A thiazide diuretic may be added; its dose is increased at 1-2 week intervals until optimum response is obtained or until max. Dose is reached. Severe hypertension, starting dose is 12.5 mg twice daily increased to a max. Of 50 mg three times daily. A dose of 150 mg daily should not normally be exceeded. Other antihypertensive can be used but their doses are individual. Heart failure, a starting dose of 6.25 or 12.5 mg. Usual maintenance dose is 25 mg two or three times daily. Usual max. Dose is 150 mg daily. Diabetic nephropathy, 75-100 mg daily in divided doses. Child, initially 0.3 mg/kg (0.15 mg/kg if a diuretic is given) 3 times daily; may be increased to a max. Dose of 6 mg/kg body weight in divided doses. This dose should not be exceeded.
Indications & Contraindications
- Indications
- Mild to moderate hypertension as an adjunct to thiazide therapy; severe hypertension resistant to other treatment; adjunct treatment in severe congestive heart failure.
- Contraindications
- Captoprilhypersensitivity, and in renovascular disease; pregnancy.
Cautions & Side Effects
- Side Effects
- Dry cough, hypersensitivity, pancreatitis, rhinitis, and sore throat, profound hypotension.
Pregnancy & Lactation
- Pregnancy
- C (1st trimester) / D (2nd and 3rd trimesters)
- Lactation
- Enters breast milk/not recommended
CARBAMAZEPINE,Tegretol®
Anticonvulsant
Pregnancy: riskLactation: avoid
CARBAMAZEPINE,Tegretol®
Anticonvulsant
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Syrup
Dosage Forms
Tablet
- 200 mgtablet
Syrup
- 100mg/mlsyrup
Dosing & Formulations
- Dose
- 100 mg once or twice daily at start and then gradually increased until the best effect is obtained. Usual maintenance dose is 200 mg 3-4 times daily; max. 1.6 g daily in some patients.
Indications & Contraindications
- Indications
- Trigeminal neuralgia, epilepsy. Has no effect on other types of headaches.
- Contraindications
- AV conductionabnormality; bone marrow depression.
Cautions & Side Effects
- Cautions
- Hepatic or renal impairment;blood disorders; pregnancyand breast feeding.
- Side Effects
- Nausea and vomiting,dizziness, drowsiness, ataxia, blooddisorders, skin rashes.
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Enters breast milk; not recommended
CARBIDOPA+LEVODOPA,Sinemet®
Anti-Parkinson's Agent,DopamineAgonist
Pregnancy: cautionLactation: not in source
CARBIDOPA+LEVODOPA,Sinemet®
Anti-Parkinson's Agent,DopamineAgonist
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 25mg/100mg tablet
- 10mg/100 mg tablet
Dosing & Formulations
- Dose
- Parkinsonsdisease: Immediatereleasetablet: -Initial:Carbidopa25mg/Levodopa 100mg3times/day times/daymayberequired *Maximum:8 tabletsofanystrength/dayor200 mgofcarbidopaand2000 Mgoflevodopa Restless legsyndrome: Carbidopa25mg/levodopa100mggiven30-60 Minutesbeforebedtimemayrepeatdose once Elderly:Initial:Carbidopa25 mg/levodopa 100mgtwicedaily,increaseasnecessary
- Dose in Organ Failure
- Renal impairment: Safety and efficacy not established; use with caution Hepatic impairment: Safety and efficacy not established; use with caution
Indications & Contraindications
- Indications
- TreatmentofParkinson's disease(exceptdrug-inducedParkinsonism)
- Contraindications
- closed angleglaucoma.
Cautions & Side Effects
- Cautions
- peptic ulcer, cardiovasculardiseases, diabetes mellitus,open angle glaucoma, avoid abruptwithdrawal.
- Side Effects
- anorexia, nausea andvomiting, insomnia, agitation, posturalhypotension reddish discolorationof urine and other body fluids,psychotic disorders.
Pregnancy & Lactation
- Pregnancy
- C
CARBIMAZOLE,Neo-Mercazole®
Antithyroidagent
Pregnancy: Not availableLactation: see details
CARBIMAZOLE,Neo-Mercazole®
Antithyroidagent
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 5mg tablet
Dosing & Formulations
- Dose
- 15 to 40 mg daily; a larger dose may be required occasionally. This dose is continued until the patient becomes euthyroid, usually after 4 to 8 weeks and the dose is then gradually reduced to a maintenance dose of 5 to 15 mg. Duration of therapy is given for 12 to 18 months. Children to be treated by specialist with initial dose of carbimazole of 250 mcg/kg three times daily, and to be adjusted according to response.
Indications & Contraindications
- Indications
- Hyperthyroidism, thyrotoxicosis.
Cautions & Side Effects
- Cautions
- Pregnancy, breast-feeding; tracheal obstruction; large goiter; liver disorders.
- Side Effects
- Nausea, mild gastro-intestinal disturbances, headache, rashes and pruritus, arthralgia.
Pregnancy & Lactation
- Pregnancy
- Not available
- Lactation
- The lowest effective dose of the drug should be used as the amount in milk may be sufficient to affect neonatal thyroid function. Carbimazole appears in breast milk but this does not preclude breast-feeding: as long as neonatal development is closely monitored and the lowest effective dose is used.
CARVEDILOL,Dilatrend®
Betablockerwithalpha-blockingactivity
Pregnancy: cautionLactation: avoid
CARVEDILOL,Dilatrend®
Betablockerwithalpha-blockingactivity
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Other
- 25mg
Tablet
- 6.25 mgtablet
Dosing & Formulations
- Dose
- Hypertension, initially 12.5 mg once daily increased after 2 days to 25 mg once daily. Max. Daily dose is 50 mg. Elderly may require much lower dosage, usually 12.5mg once daily. Angina, initially 12.5 mg twice daily increased after 2 days up to 25 mg twice daily. Heart failure, initially 3.125 mg twice daily increased at intervals of 2 weeks to 6.25 mg twice daily then 25 mg twice daily. Max. 50 mg twice daily in patients over 85 kg body weight.
- Dose in Organ Failure
- Renal impairment: No dosage adjustments necessary Hepatic impairment: Contraindicated in severe liver impairment
Indications & Contraindications
- Indications
- Hypertension; angina; adjunct to diuretics, digoxin or ACE-inhibitors in symptomatic chronic heart failure.
- Contraindications
- Severe chronic heart failure, constrictive respiratory tract diseases; allergic rhinitis
Cautions & Side Effects
- Cautions
- Unstable angina; reduced performance of the heart; recent heart attack; impaired renal function
- Side Effects
- Postural hypotension, dizziness, headache, GI disturbances, bradycardia; occasionally diminished peripheral circulation; peripheral oedema, and painful extremities; dry mouth, dry eyes
Pregnancy & Lactation
- Pregnancy
- C (manufacturer); D (2nd and 3rd trimesters, expert analysis)
- Lactation
- Unknown whether drug is excreted in milk; not recommended
CASTOROIL
Stimulant laxatives
Pregnancy: riskLactation: compatible
CASTOROIL
Stimulant laxatives
- Therapeutic group
- Gastrointestinal System
- Storage
- Unclassified
- Dosage form
- Unclassified
Dosage Forms
Other
- Liquid
Dosing & Formulations
- Dose
- 5-20 ml when required. Child up to 1 year, 1-5 ml; 1-12 years, 5-15 ml in milk or fruit juice before breakfast or on an empty stomach.
Indications & Contraindications
- Indications
- constipation, bowel evacuation before radiological procedures, endoscopy, surgery. Acts within 2-8 hours
- Contraindications
- intestinal obstruction.
Cautions & Side Effects
- Cautions
- pregnancy, menstruation, undiagnosed abdominal pain.
- Side Effects
- nausea, vomiting, abdominal colic, severe purgative.
Pregnancy & Lactation
- Pregnancy
- X
- Lactation
- Safe
CEFOTAXIME,Claforan®,Foxime®
Antibiotic,Thirdgenerationcephalosporin
Pregnancy: safeLactation: caution
CEFOTAXIME,Claforan®,Foxime®
Antibiotic,Thirdgenerationcephalosporin
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 1ginjection
Dosing & Formulations
- Dose
- Adult dose Moderately severe infections: IM/IV, 1 g every 8–12 hours. Severe infections: IV, 2 g every 8–12 hours. Maximum daily dose 12 g. Paediatric dose IM/IV, 100–150 mg/kg daily in 2–4 divided doses. Meningitis: 50 mg/kg every 6 hours.
Indications & Contraindications
- Indications
- Susceptible infection in respiratory tract, skin and skin structure, bone and joint, urinary tract, gynecologic as well as septicemia, and documented or suspected meningitis. Active against most gram –ve bacilli (not Pseudomo- nas) and gram +ve cocci (not enterococcus).
- Contraindications
- Cephalosporins hypersensitivity
Cautions & Side Effects
- Cautions
- Renal impairment, penicillin sensitivity.
- Side Effects
- Rash,pruritus,Diarrhea,nausea,vomiting, colitis,Painatinjectionsite
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Drug enters breast milk; use with caution
CEFTRIAXONE,Rocephine®, Enoxirt®
Antibiotic,Thirdgenerationcephalosporin
Pregnancy: safeLactation: caution
CEFTRIAXONE,Rocephine®, Enoxirt®
Antibiotic,Thirdgenerationcephalosporin
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 1ginjection
Dosing & Formulations
- Dose
- Adult dose IM/IV, 1–2 g once daily (or in 2 divided doses). Maximum 4 g daily. Prophylaxis for Neisseria meningitidis contacts: IM, 250 mg as a single dose. Specific indications: see approved Product Information. Paediatric dose IM/IV, 50 mg/kg once daily; maximum 2 g daily. Meningitis: IM/IV, 100 mg/kg daily or in 2 divided doses. Maximum 4 g daily. Prophylaxis for Haemophilus influenzae type B meningitis Contacts: IM, 50 mg/kg daily (up to 1 g) for two days. Prophylaxis for Neisseria meningitidis contacts: IM, 125 mg as a single dose.
Indications & Contraindications
- Indications
- LRTI, acute bacterial otitis media, skin and skin structure infections, bone and joint infections, intra-abdominal and urinary tract infections, pelvic inflam- matory disease (PID), uncomplicated gonorrhea, bacterial septicemia, and meningitis; used in surgical prophylaxis
- Contraindications
- Cephalosporins hypersensitivity
Cautions & Side Effects
- Cautions
- Renal impairment, penicillin sensitivity.
- Side Effects
- Indurationfollowing I.M.injection,Eosinophilia,thrombocytosis,Hepatic:Elevatedtransaminases
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Drug enters breast milk in low concentrations; use with caution
CEFUROXIME,Zinacef®,Zinoxinor®
Antibiotic,Secondgenerationcephalosporin
Pregnancy: safeLactation: caution
CEFUROXIME,Zinacef®,Zinoxinor®
Antibiotic,Secondgenerationcephalosporin
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Suspension
Dosage Forms
Tablet
- 250 mgtablet
Injection
- 750 mginjection
Suspension
- 250mg /5ml susp
Other
- 50mg inection for ophtha
Dosing & Formulations
- Dose
- Adult dose 250–500 mg twice daily. Gonococcal infection: 1 g single dose.
- Dose in Organ Failure
- Renal impairment Crcl>30 ml/min: No adjustment necessary Crcl 10-30 ml/min: Administer dose q24hr Crcl<10 ml/min: Administer dose q48hr
Indications & Contraindications
- Indications
- Infectionscausedbystaphylococci, group b streptococci,H.influenzae(aandb),E.coli,Enterobacter,Salmonella,&Klebsiella; susceptible infections of the LRSI,OM, UTI,skin&softtissue,boneandjoint,sepsis& gonorrhea
- Contraindications
- Cephalosporins hypersensitivity
Cautions & Side Effects
- Cautions
- Renal impairment, penicillin sensitivity.
- Side Effects
- Eosinophilia,decreasedhemoglobinandhematocrit,Thrombophlebitis,Hepatic:Increasedtransaminases,increasedalkalinephosphatase
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Drug excreted in breast milk; use with caution
CELECOXIB,Celebrex®
Nsaids
Pregnancy: cautionLactation: caution
CELECOXIB,Celebrex®
Nsaids
- Therapeutic group
- Musculoskeletal & Joint Diseases
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule
Dosage Forms
Capsule
- 200 mg cap
Dosing & Formulations
- Dose
- Osteoarthritis, 200 mg daily in 1–2 divided doses, increased if necessary to max. 200 mg twice daily; CHILD not recommended. Rheumatoid arthritis, 100 mg twice daily, increased if necessary to 200 mg twice daily; CHILD not recommended. Ankylosing spondylitis, 200 mg daily in 1–2 divided doses, increased if necessary to max. 400 mg daily in 1–2 divided doses; CHILD not recommended. Celebrex 200 mg Capsules
Indications & Contraindications
- Indications
- Pain and inflammation in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
- Contraindications
- Sulfonamide sensitivity; inflammatory bowel disease
Cautions & Side Effects
- Cautions
- Monitor blood pressure before and during treatment.
- Side Effects
- Headache,Hypertension,Fever,Dyspepsia,Upper respiratory tract infection, Arthralgia,Cough,Vomiting,Diarrhea,Gastroesophageal reflux,Sinusitis, Abdominal pain,Nausea,Back pain,Insomnia,Pharyngitis,Flatulence,Rash, Dizziness,Peripheral edema.
Pregnancy & Lactation
- Pregnancy
- C; D at ≥30 weeks' gestation (may cause premature closure of ductus arteriosus)
- Lactation
- Drug enters breast milk; use caution
CEPHALEXIN,Keflex®
Antibiotic,Firstgenerationcephalosporin
Pregnancy: safeLactation: caution
CEPHALEXIN,Keflex®
Antibiotic,Firstgenerationcephalosporin
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule · Suspension
Dosage Forms
Capsule
- 250mgcapsule
Suspension
- 125mg/5mlsuspension
Dosing & Formulations
- Dose
- Adult dose 250 mg–1,000 mg every 6, 8 or 12 hours. Maximum daily dose 4 g. Prophylaxis for urinary tract infection: 250 mg at night. Paediatric dose Moderate infections: 25–50 mg/kg daily in four Divided doses. Severe infections: 50–100 mg/kg daily in four Divided doses. Maximum daily dose 4 g. Prophylaxis for urinary tract infection: 12.5 mg/kg (maximum 250 mg) at night.
- Dose in Organ Failure
- Renal Impairment CrCl<10 mL/min: 250-500 mg PO q12-24hr CrCl 10-50 mL/min: 500 mg PO q8-12hr Hepatic Impairment Not studied
Indications & Contraindications
- Indications
- Susceptiblebacterialinfections,includingRTI,OM,Skin&skinstructureinfection, bone infection, &genitourinary tract infection including acuteprostatitis,alternativetherapyforacutebacterialendocardititisprophylaxis
- Contraindications
- Cephalosporins hypersensitivity
Cautions & Side Effects
- Cautions
- Renal impairment, penicillin sensitivity.
- Side Effects
- Diarrhoea, pseudomembranous colitis (on higher doses or prolonged use associated with diarrhoea) abdominal pain, nausea and vomiting, headache, allergic reactions.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Drug excreted in breast milk; use with caution
Cephradine, velosef®
Antibiotic,firstgenerationcephalosporin
Pregnancy: safeLactation: not in source
Cephradine, velosef®
Antibiotic,firstgenerationcephalosporin
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Unclassified
- Dosage form
- Injection
Dosage Forms
Other
- 500 mg
Injection
- 1ginjection
Dosing & Formulations
- Dose
- Usual dosage range: Children>9 months: usual dose: 25-100mg/kg/day in divided doses every 6 or 12 hours (maximum 4g/day) Adults: 250-500mg every 6-12 hours Indication-specific dosing: Children>9 months: otitis media: 75-100mg/kg/day in divided doses every 6 Or 12 hours (maximum dose is 4g/day)
Indications & Contraindications
- Indications
- Treatment of infections when caused by susceptible strains in respiratory, genitourinary, gastrointestinal, skin and soft tissue, bone and joint infections; treatment of susceptible gram-positive bacilli & cocci (never enterococcus); some gram-negative bacilli including e. Coli, proteus, and klebsiella may be susceptible.
- Contraindications
- Cephalosporins hypersensitivity
Cautions & Side Effects
- Cautions
- Renal impairment, penicillin sensitivity.
- Side Effects
- Diarrhoea, pseudomembranous colitis (on higher doses or prolonged use associated with diarrhoea) abdominal pain, nausea and vomiting, headache, allergic reactions.
Pregnancy & Lactation
- Pregnancy
- B
CETIRIZINE,Zyrtec®
Non-sedatingantihistamine
Pregnancy: safeLactation: avoid
CETIRIZINE,Zyrtec®
Non-sedatingantihistamine
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 10mgtablet
Dosing & Formulations
- Dose
- Adult and child over 6 years, 10mg daily or 5mg twice daily. Child 2-6 years, hay fever, 5mg daily or 2.5mg twice daily.
Indications & Contraindications
- Indications
- Long-acting non-sedating antihistamine with some mast-cell stabilising activity used in symptomatic relief of allergy such as hay fever, urticaria.
- Contraindications
- Pregnancy and breast feeding.
Cautions & Side Effects
- Cautions
- Prostatic hypertrophy, urinary retention, glaucoma and hepatic disease.
- Side Effects
- Palpitations and arrhythmias; hypotension; hypersensitivity reactions; depression.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excreted in breast milk; use not recommended
CHLORALHYDRATE,Chloral®
Sedative-hypnotic,Nonbenzodiazepine
Pregnancy: cautionLactation: see details
CHLORALHYDRATE,Chloral®
Sedative-hypnotic,Nonbenzodiazepine
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Syrup
Dosage Forms
Syrup
- 40mg/mlsyrup
Dosing & Formulations
- Dose
- Children: Sedationor anxiety:Oral:5-15mg/kg/dose every8hours(maximum:500 Mg/dose) Priortoeeg:Oral:20-25mg/kg/dose,30-60minutespriortoeeg; mayrepeatin30minutes tomaximumof100 mg/kg or2gtotal Hypnotic:Oral:20-40 mg/kg/doseuptoamaximumof50mg/kg/24 hoursor 1g/doseor2g/24hours Conscious sedation:Oral:50-75 mg/kg/dose30-60 minutespriortoprocedure; mayrepeat30minutesafterinitialdoseif needed,toatotalmaximumdoseof120 mg/kg or1gtotal Adults:Oral:Sedation,anxiety:250mg3times/day Hypnotic:500-1000mg atbedtimeor30minutespriortoprocedure,nottoexceed2g/24hours Renal impairment: Contraindicated in moderate-severe renal impairment Hepatic Impairment: Contraindicated in moderate-severe hepatic impairment
Indications & Contraindications
- Indications
- Insomnia, sedation in the elderly.
- Contraindications
- Severe cardiac disease, gastritis, hepatic and renal disease; pregnancy; breast-feeding; porphyria.
Cautions & Side Effects
- Cautions
- Doses are taken well-diluted with water to minimize gastro-intestinal disturbances. Contact with skin and mucous membranes should be avoided.
- Side Effects
- Gastric irritation (nausea and vomiting reported), abdominal distention and flatulence; also ataxia, confusion, rashes, headache, lightheadednes
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Small amount secreted into breast milk
CHLORAMPHENICOL,Riachol®
Antibiotic,Miscellaneous
Pregnancy: cautionLactation: not in source
CHLORAMPHENICOL,Riachol®
Antibiotic,Miscellaneous
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Drops · Ointment
Dosage Forms
Drops
- 0.5%eyedrops
Ointment
- 1%eyeointment
Other
- 5%eardrop
Dosing & Formulations
- Dose
- Ophthalmic: Children and Adults: Instill 1-2 drops 4-6 times/day; increase interval between applications after 72 hours to 2-3 times/day for not more than 7 days.
Indications & Contraindications
- Indications
- Serious infections due to organisms resistant to other less toxic antibiotics or when its penetrability into the site of infection is clinically superior to other antibiotics to which the organism is sensitive; useful in infections caused by Bacteroides, H. Influenzae, Neisseria meningitidis, Salmonella, & Rickettsia; active against many vancomycin-resistant enterococci
- Contraindications
- Pregnancy, breast-feeding, porphyria.
Cautions & Side Effects
- Side Effects
- Blood disorders, peripheral neuritis, optic neuritis, nausea, vomiting, diarrhoea, stomatitis.
Pregnancy & Lactation
- Pregnancy
- C
CHLORHEXIDINE Gluconate,Chlorasept®
Antibiotic: Oral Rinse, Topical
Pregnancy: safeLactation: caution
CHLORHEXIDINE Gluconate,Chlorasept®
Antibiotic: Oral Rinse, Topical
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- Mouthwash 0.2%
Dosing & Formulations
- Dose
- Oral rinse: Swish 15 mL undiluted oral rinse around in mouth for 30 sec- onds, then expectorate. Cleanser: Surgical scrub: Scrub 3 minutes and rinse thoroughly, wash for an additional 3 minutes Hand wash: W ash for 15 seconds and rinse Hand rinse: Rub 15 seconds and rinse
Indications & Contraindications
- Indications
- Skin cleanser for surgical scrub, cleanser for skin wounds, preoperative skin preparation, germicidal hand rinse, and as antibacterial dental rinse.
Cautions & Side Effects
- Side Effects
- Oral: >10%: Increase of tartar on teeth, changes in taste. Topical: Skin erythema and roughness, dryness, allergic reactions
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- excretion in milk unknown; use with caution
CHLOROQUINE,Avloclor®
Antimalrial
Pregnancy: cautionLactation: avoid
CHLOROQUINE,Avloclor®
Antimalrial
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Syrup
Dosage Forms
Tablet
- 250mg tablet(150mg base)
Syrup
- 75mg (base)/5ml syrup
Injection
- 40mg (base)/ml injection
Dosing & Formulations
- Dose
- Suppressionorprophylaxisofmalaria: Oral:Children:Administer5mgbase/kg/weekonthesame dayeachweek(nottoexceed300mgbase/dose):begin1-2weekspriortoexposure;con- tinuefor4-6weeksafterleavingendemicarea.Ifsuppressivetherapyisnot begunpriortoexposure,double theinitialloadingdose to10mgbase/kgand administerin2divideddoses6hoursapart, followedbytheusualdosageregimen Acuteattack:Oral: Children:10mg/kg(base)onday1,followedby5mg/kg6 hourslaterand 5mg/kg(base)on days2 andday3 Adults:1g(600mg)onday1followedby500mg6hours later,followedby 500mg on days2 and3 Extraintestinalamebiasis: Children:Oral: 10mg/kgoncedailyfor 2-3weeks(upto300mgbase/day)Adults: Oral:1g/day(600mgbase)for2daysfollowedby500mg/day(300mgbase) foratleast 2-3weeks
Indications & Contraindications
- Indications
- Suppression or chemoprophylaxis of malaria; treatment of uncomplicated or mild to moderate malaria; extraintestinal amebiasis
- Contraindications
- Epilepsy, hypersensitivity,psoriasis.
Cautions & Side Effects
- Cautions
- Renal and hepatic impairment;pregnancy; gastrointestinaldisorders; neurological disorders.
- Side Effects
- Gastrointestinal disturbances, headache, visual disturbances, skin reaction.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Enters breast milk/not recommended
CHLORPHENIRAMINEMaleate, Histan®,Histop®,Pirafene®
Antihistamine
Pregnancy: cautionLactation: avoid
CHLORPHENIRAMINEMaleate, Histan®,Histop®,Pirafene®
Antihistamine
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Syrup
Dosage Forms
Tablet
- 4mgtablet
Syrup
- 2mg/mlsyrup
Dosing & Formulations
- Dose
- By mouth, 4mg 3-4 times daily. Max. Dose, 24mg daily. Child under 1 year, not recommended. 1-2 years, 1mg twice daily. 2-5 years, 1mg 4-6 times daily with a max. Dose of 6mg daily. 6-12 years, 2mg 4-6 times daily with a max. Dose of 12mg daily.
Indications & Contraindications
- Indications
- Symptomatic relief of allergic conditions including urticaria and angioedema, rhinitis, and conjunctivitis, and in pruritic skin disorders. Intravenously as an adjunct in the emergency treatment of anaphylactic shock.
Cautions & Side Effects
- Cautions
- Epilepsy, prostatic hypertrophy, glaucoma and hepatic disease.
- Side Effects
- Drowsiness; impaired ability to drive or operate machinery; headache; psychomotor impairment, anti-muscarinic effects such as urinary retention, dry mouth, blurred vision, and gastro-intestinal disturbances.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excretion in milk unknown/not recommended
CHLORPHENIRAMINEMALEATE+PSEUDOEPHEDRINE, Allergetin®, Flumid®
Antihistaminewithdecongestant
Pregnancy: cautionLactation: avoid
CHLORPHENIRAMINEMALEATE+PSEUDOEPHEDRINE, Allergetin®, Flumid®
Antihistaminewithdecongestant
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Syrup
Dosage Forms
Syrup
- 2mg+30mg/5mlsyrup
Dosing & Formulations
- Dose
- Children:2-6years:15mg every4-6hours -6-12years:30mg every4-6hours Children≥12yearsandadults: 60mg every4-6hours
Indications & Contraindications
- Indications
- Reliefofnasalcongestionassociatedwith thecommoncold,hayfever,andotherallergies,sinusitis, Eustachian tubeblockage,andvasomotorandallergicrhinitis
Cautions & Side Effects
- Side Effects
- Hypertension, palpitation, dizziness, psychiatric disturbances.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Enters breastmilk/contraindicated
CHLORPROMAZINE HCL, Largactil®
Phenothiazine antiemetic
Phenothiazine antipsychotics
Pregnancy: NOT CLASSIFIEDLactation: see details
CHLORPROMAZINE HCL, Largactil®
Phenothiazine antiemetic Phenothiazine antipsychotics
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Unclassified
- Dosage form
- Tablet
Dosage Forms
Other
- 25mg
- IM
Tablet
- 100mg tablet
Dosing & Formulations
- Dose
- Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled
Indications & Contraindications
- Indications
- used to treat psychotic disorders such as schizophrenia or manic-depression, and severe behavioral problems in children ages 1 through 12 , used to treat nausea and vomiting, anxiety before surgery, chronic hiccups, acute intermittent porphyria, and symptoms of tetanus
- Contraindications
- Do not use in patients with known hypersensitivity to phenothiazines. Do not use in comatose states or in the presence of large amounts of central nervous system depressants (alcohol, barbiturates, narcotics, etc.)
Cautions & Side Effects
- Cautions
- Leukopenia, Neutropenia and Agranulocytosis
- Side Effects
- Extrapyramidal reactions (e.g., Parkinson-like symptoms, dystonia, akathisia, tardive dyskinesia), drowsiness, dizziness, skin reactions or rash, dry mouth, orthostatic hypotension, amenorrhea, galactorrhea, weight gain
Pregnancy & Lactation
- Pregnancy
- NOT CLASSIFIED
- Lactation
- Chlorpromazine is detectable in the milk of some mothers during therapy, but levels appear not to correlate well with the maternal dose or serum level. Some breastfed infants become drowsy during maternal chlorpromazine therapy.
CHORIONICGONADOTROPIN,Pregnyl®
Ovulationstimulator
Pregnancy: riskLactation: caution
CHORIONICGONADOTROPIN,Pregnyl®
Ovulationstimulator
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Unclassified
- Dosage form
- Injection
Dosage Forms
Injection
- 1500&5000internationalunit(I.M.injection)
Dosing & Formulations
- Dose
- Children: Various regimens: Prepubertal cryptorchidism: -4000 units 3 times/week for 3 weeks or -5000 units every second day for 4 injections or -500 units 3 times/week for 4-6 weeks or -15 injections of 500-1000 units given over 6 weeks Hypogonadotropic hypogonadism:Males: -500-1000 units 3 times/week for 3 weeks, followed by the same dose twice weekly for 3 weeks or 4000 units 3 times/week for 6-9 months, then reduce dosage to 2000 units 3 times/week for additional 3 months Adults: Induction of ovulation: Females: 5000-10,000 units one day following Last dose of menotropins Spermatogenesis induction associated with hypogonadotropic hypo- Gonadism: Males: regimens vary (1000-2000 units 2-3 times a week).
Indications & Contraindications
- Indications
- Induces ovulation and pregnancy in anovulatory, infertile females; treatment of hypogonadotropic hypogonadism, prepubertal cryptorchidism; spermato- genesis induction with follitropin alfa or follitropin beta
- Contraindications
- Androgen-dependent tumours.
Cautions & Side Effects
- Cautions
- Cardiac or renal dysfunction, asthma, epilepsy, migraine.
- Side Effects
- Headache, irritability, precocious puberty, gynaecomastia, injection site pain, multiple pregnancy.
Pregnancy & Lactation
- Pregnancy
- X
- Lactation
- Not known if distributed in breast milk; use caution
CIPROFLOXACIN,Ciprobay®,Ciprolon®,Ciprocin®,Opticin®
Antibiotic,Quinolones
Pregnancy: cautionLactation: avoid
CIPROFLOXACIN,Ciprobay®,Ciprolon®,Ciprocin®,Opticin®
Antibiotic,Quinolones
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Drops
Dosage Forms
Injection
- 200mgvial
Tablet
- 500mgtablet
Other
- 0.3%eyedrop
Drops
- 0.5mg/0.25ml ear drops
Dosing & Formulations
- Dose
- Adult dose Uncomplicated urinary tract infection: 250 mg 12-hourly. Complicated urinary tract infection: 500 mg 12-hourly. Respiratory, skin, gastrointestinal and more complicated Infections: 500–750 mg 12-hourly (see approved Product Information for specific indications). IV, 200–400 mg 12-hourly infused over 30–60 minutes. Paediatric dose 5–10 mg/kg 12-hourly. Cystic fibrosis: 15 mg/kg (max 750 mg) 12-hourly.
- Dose in Organ Failure
- Renal impairment: Caution. Dosage adjustment Necessary. Clcr 30–50 ml/min 250–500 mg 12 hourly. Clcr 5–29 ml/min 250–500 mg every 18 hours. Hepatic impairment: Caution. Monitor clinically.
Indications & Contraindications
- Indications
- Children: Complicated UTI and pyelonephritis due to E. Coli. Children and Adults: Ophthalmologically, for superficial ocular infections (corneal ulcers, conjunctivitis) due to susceptible strains Adults: Treatment of the following infections when caused by susceptible Bacteria: UTI; acute uncomplicated cystitis in females; chronic bacterial prostatitis; LRTI ; acute sinusitis; skin and skin structure infections; bone & joint infections; complicated intra-abdominal infections (+ metronidazole); infectious diarrhea; typhoid fever due to Salmonella typhi; uncomplicated cervical and urethra gonorrhea (due to N. Gonorrhoeae); nosocomial pneu- monia; empirical therapy for febrile neutropenic patients (+ piperacillin)
Cautions & Side Effects
- Cautions
- Renal impairment; patients with history of seizure or epilepsy, G6PD deficiency, pregnancy and breast-feeding.
- Side Effects
- Nausea and vomiting, gastrointestinal disturbances; headache, dizziness, sleep disturbances; hyperglycaemia; tremor; tendonitis
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug enters breast milk; usenot recommended
CITALOPRAM, Cipram ®
Selective serotonin reuptake inhibitor
Pregnancy: cautionLactation: caution
CITALOPRAM, Cipram ®
Selective serotonin reuptake inhibitor
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 20 mg tablet
Dosing & Formulations
- Dose
- Adult dose 20–40 mg daily. Maximum recommended daily dose40 mg.
Indications & Contraindications
- Indications
- Depressive illness, panic disorder
- Contraindications
- QT-interval Prolongation (avoid concomitant administration of Drugs that prolong QT interval)
Cautions & Side Effects
- Cautions
- Susceptibility to QT-interval Prolongation
- Side Effects
- Hepatitis, palpitation, Tachycardia, oedema, bradycardia, postural Hypotension, haemorrhage, QT-interval prolongation, Coughing, yawning, confusion, impaired concentration, Aggression, malaise, amnesia, migraine, paraesthesia, Abnormal dreams, euphoria, mydriasis, taste Disturbance, increased salivation, rhinitis, tinnitus, Polyuria, micturition disorders, hypokalaemia, pruritus; Paradoxical increased anxiety during initial Treatment of panic disorder (reduce dose)
Pregnancy & Lactation
- Pregnancy
- C. Use when clinically indicated if it is the drug of choice. Increased risk of reversible withdrawal symptoms in newborns.
- Lactation
- Breastfeeding: Use with caution. Small amounts areExcreted in breast milk. Monitor the infant for adverseEffects (e.g. Sedation, restlessness, irritability, poor feeding).
CLARITHROMYCIN,Klacid®
Antibiotic,Macrolide
Pregnancy: cautionLactation: caution
CLARITHROMYCIN,Klacid®
Antibiotic,Macrolide
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Suspension
Dosage Forms
Tablet
- 250mg tablet
Suspension
- 125mg/5ml susp
Dosing & Formulations
- Dose
- Adult dose 250–500 mg twice daily. Paediatric dose 7.5 mg/kg (maximum 500 mg) twice daily. Mycobacterium infections: 7.5–15 mg/kg twice daily.
- Dose in Organ Failure
- Renal impairment (crcl<30 ml/min): Reduce normal dose by 50% In combination with atazanavir: crcl 30-60 ml/min decrese, dose by 50%; crcl<30 ml/min, decrease dose by 75%
Indications & Contraindications
- Indications
- Pharyngitis/ tonsillitis due to susceptible S. Pyogenes, Acute maxillary sinusi- tis & acute exacerbation of chronic bronchitis due to susceptible H.Influen- zae, M. Catarrhalis, or S. Pneumonia, Pneumonia due to susceptible H. Influ- enzae, Mycoplasma pneumoniae, S.pneumoniae, or Chlamydia pneumoniae, Uncomplicated skin/skin structure infections due to susceptible S. Aureus, S. Pyogenes, Disseminated mycobacterial infections due to M. Avium or M. Intracellulare, Prevention of disseminated mycobacterial infections due to M. Avium complex (MAC) disease, Duodenal ulcer disease due to H. Pylori in regimens with other drugs, Alternate antibiotic for prophylaxis of bacterial endocarditis
- Contraindications
- Hepatic disease; pregnancy.
Cautions & Side Effects
- Cautions
- Renal impairment; breast-feeding.
- Side Effects
- Diarrhea, vomiting, abnormaltaste,bunincreased
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug is excreted in breast milk; use with caution
CLINDAMYCIN ,Dalacin®, Derma-T®
Antibiotic,Miscellaneous
Pregnancy: safeLactation: avoid
CLINDAMYCIN ,Dalacin®, Derma-T®
Antibiotic,Miscellaneous
- Therapeutic group
- Skin / Dermatological
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection · Solution
Dosage Forms
Injection
- 300 mg/2mlinjection
Solution
- 1% topicalsolution
Dosing & Formulations
- Dose
- Adult dose Oral, 150–450 mg every 6 hours. IV, 600–2,700 mg daily given in 2–4 doses, usually 450–900 mg every 8 hours. Maximum IV 4.8 g daily. Paediatric dose Oral, 5–7.5 mg/kg every 6–8 hours. IM/IV, 10 mg/kg every 6–8 hours.
Indications & Contraindications
- Indications
- Against aerobic and anaerobic streptococci (except enterococci), most staphylococci, Bacteroides sp and Actinomyces; bacterial vaginosis; prophy- laxis in the prevention of bacterial endocarditis in high-risk patients undergo- ing surgical or dental procedures in patients allergic to penicillin; may be useful in PCP; used topically in treatment of severe acne; vaginally for Gard- nerella vaginalis
- Contraindications
- Diarrhoeal states; avoid injections containing benzyl alcohol in neonates.
Cautions & Side Effects
- Cautions
- bacterial overgrowth may occur; risk of Clostridium difficile induced diarrhoea and pseudomembranous colitis, concomitant use with erythromycin is not recommended,
- Side Effects
- diarrhoea (discontinue treatment), abdominal discomfort, oesophagitis, oesophageal ulcers, taste disturbances, nausea,vomiting
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excreted in breast milk; manufacturer suggests discontinue drug or do not nurse
CLOBETASOL PROPIONATE, Clobederm®
Corticosteroids, topical
Pregnancy: cautionLactation: caution
CLOBETASOL PROPIONATE, Clobederm®
Corticosteroids, topical
- Therapeutic group
- Skin / Dermatological
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Cream
Dosage Forms
Other
- 0.05% oint
Cream
- cream
Dosing & Formulations
- Dose
- Apply to affected area q12hr for up to 2 weeks; not to exceed 50 g or 50 mL/week
Indications & Contraindications
- Indications
- short term therapy of severe resistant inflammatory skin disorders.
- Contraindications
- untreated bacterial, fungal or viral skin infections, acne vulgaris, rosacea.
Cautions & Side Effects
- Cautions
- avoid prolonged use especially in children and infants; avoid prolonged use on the face.
- Side Effects
- Skin atrophy,Striae,Burning,Cracking/fissuring of the skin,ErythemaFolliculitis, Irritation,Numbness,Pruritus,Stinging,Hypopigmentation,Intracranial hypertension reported in children with use of topical formulation,Adrenal suppression, Cushing syndrome, hyperglycemia,Acneform lesions,Secondary infection,Pigmentation changes
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excretion in milk unknown; use with caution
CLOMIPHENECITRATE, Clomid®
Ovulationstimulator
Pregnancy: riskLactation: caution
CLOMIPHENECITRATE, Clomid®
Ovulationstimulator
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Unclassified
- Dosage form
- Tablet
Dosage Forms
Tablet
- 50mgtablet
Dosing & Formulations
- Dose
- Male(infertility):25mg/dayfor 25dayswith5days rest,or100mg every Monday,Wednesday,Friday Female(ovulatory failure):50mg/dayfor5days (firstcourse);start theregimenonoraboutthefifthday of cycle.
Indications & Contraindications
- Indications
- Anovulatory infertility.
- Contraindications
- Hepatic disease, ovarian cysts, abnormal uterine bleeding, endometrial carcinoma, pregnancy.
Cautions & Side Effects
- Cautions
- Use smallest dose possible in women with polycystic disease; patients should be warned of the possibility of multiple pregnancy; visual disturbances mandates discontinuation of therapy.
- Side Effects
- Visual disturbances, hot flushes, gastrointestinal disturbances, liver impairment, ovarian enlargement and cyst formation, breast tenderness.
Pregnancy & Lactation
- Pregnancy
- X
- Lactation
- It is not known whether clomiphene is excreted in human milk. Use with cautionin nursing women. In some patients, clomiphene may reduce lactation.
CLOTRIMAZOLE,Otozol®Canesten®
Antifungal,Topical
Pregnancy: safeLactation: caution
CLOTRIMAZOLE,Otozol®Canesten®
Antifungal,Topical
- Therapeutic group
- Skin / Dermatological
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Cream
Dosage Forms
Other
- 10mg/mleardrop
Cream
- 1%cream
Dosing & Formulations
- Dose
- Children >3 years and Adults: Topical (cream): Apply twice daily; if no improvement occurs after 4 weeks of therapy, re-evaluate diagnosis Children >12 years and Adults: Vaginal Cream: 1%: Insert 1 applicatorful vaginal cream daily (at bedtime) for 7 consecutive days Ear drop: Instill 1-2 drops in the ear three or four times daily, continue for 2 Weeks after signd of infection disappears.
Indications & Contraindications
- Indications
- Susceptible fungalinfections,includingoropharyngealcandidiasis,dermato-phytoses, superficial mycoses, & cutaneous candidiasis, as well as vul- vovaginalcandidiasis
Cautions & Side Effects
- Side Effects
- Mildburning,occasionallocal irritation,stingingontheskin orvaginalarea.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excretion in milk unknown; use with caution
CLOXACILLIN,Prostaphlin®
Antibiotic,Penicillin,B-Lactam
Pregnancy: safeLactation: not in source
CLOXACILLIN,Prostaphlin®
Antibiotic,Penicillin,B-Lactam
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule · Injection · Suspension
Dosage Forms
Capsule
- 250&500capsule
Injection
- 250 mginjection
Suspension
- 125 mg/5mlsuspension
Dosing & Formulations
- Dose
- Children>1month(<20kg):50-100mg/kg/dayin divided doses every 6hours;uptoMaximumof4g/day Children(>20kg)andAdults:250-500mgevery 6 hours
Indications & Contraindications
- Indications
- Susceptiblebacterial infections,notablypenicillinase-producingstaphylococcicausingrespiratorytract,skinandskinstructure,boneandjoint,UTI
- Contraindications
- Hypersensitivity to penicillins
Cautions & Side Effects
- Cautions
- renal impairment necessitates dose reduction; history of sensitivity.
- Side Effects
- Nausea,diarrhea,abdominalpain
Pregnancy & Lactation
- Pregnancy
- B
CO-AMOXICLAV,(AMOXICILLIN&CLAVULANATEPOTASSIUM),Augmentin®
Antibiotic,Penicillin
Pregnancy: safeLactation: caution
CO-AMOXICLAV,(AMOXICILLIN&CLAVULANATEPOTASSIUM),Augmentin®
Antibiotic,Penicillin
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Unclassified
- Dosage form
- Tablet · Injection · Suspension
Dosage Forms
Other
- 375 mg
- 625mg
Tablet
- 1g Tablet
Injection
- 600mginjection
Suspension
- 156mg5mlsuspension
Dosing & Formulations
- Dose
- Doses are based on amoxycillin component. Adult dose Oral, 250–500 mg eight-hourly or 500–875 mg Every 12 hours. Paediatric dose 7.5–15 mg/kg every eight hours; (up to 22.5 mg/kg every Eight hours in severe infections).
- Dose in Organ Failure
- Renal impairment Crcl<30 ml/min: do not use 875/125 mg tablet or extended-release tablets Crcl 10-30 ml/min: 250-500/125 mg po q12hr Crcl<10 ml/min: 250-500/125 mg po q24hr Hemodialysis: 250-500/125 mg po q24hr; administer additional dose both during and at end of dialysis Hepatic impairment Dose with caution; monitor hepatic function regularly
Indications & Contraindications
- Indications
- Otitismedia,sinusitis,&infectionscaused by susceptibleorganismsinvolvingthelrt,skinandskinstructure,and urinarytract;spectrumsameas amoxicillin withadditional coverageofbeta-lactamaseproducingb.catarrhalis,H.influenzae,N.gonorrhoeae,ands.aureus(notmrsa). Dental: orofacialinfections whenbeta-lactamase-producingstaphylococciandbeta-lactamase-producingbacteroidesarepresent
- Contraindications
- Penicillin hypersensitivity.
Cautions & Side Effects
- Cautions
- Renal impairment, Hepatic impairment, history of allergy, skin rash, viral infections.
- Side Effects
- Diarrhea,Diaperrash,Mycosis,Nausea,Rash,Vomiting,Loosestool,Candidiasis, Vaginitis .
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Drug excreted in breast milk; use caution
COLCHICINE, Colmeditin®
Anti-inflammatory,UricosuricAgent
Pregnancy: cautionLactation: caution
COLCHICINE, Colmeditin®
Anti-inflammatory,UricosuricAgent
- Therapeutic group
- Musculoskeletal & Joint Diseases
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 500mcgtablet
Dosing & Formulations
- Dose
- Acute gout, 500 micrograms 2–4 times daily until symptoms relieved, max. 6 mg per course; course not to be repeated within 3 days Prevention of gout attacks during initial treatment with allopurinol or uricosuric drugs, 500 micrograms twice daily. Prophylaxis of familial Mediterranean fever [unlicensed], 0.5–2 mg once daily.
Indications & Contraindications
- Indications
- acute gout; short-term prophylaxis during initial therapy with allopurinol and uricosuric drugs; prophylaxis of familial Mediterranean fever (recurrent polyserositis)
- Contraindications
- blood disorders, pregnancy (teratogenicity)
Cautions & Side Effects
- Cautions
- elderly; gastro-intestinal disease; cardiac disease
- Side Effects
- nausea, vomiting, and abdominal pain; excessive doses may cause profuse diarrhoea, gastro- intestinal haemorrhage, rash, renal and hepatic damage dry mouth, nausea, gastro-intestinal disturbance, altered liver enzymes, hypotension, drowsiness, fatigue, dizziness.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug enters breast milk; use with caution
CROMOLYN(SodiumCromoglycate), Intal®
Antiallergic
Pregnancy: safeLactation: caution
CROMOLYN(SodiumCromoglycate), Intal®
Antiallergic
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosing & Formulations
- Dose
- Inhalation: -For chronic control of asthma, taper frequency to the lowest effective dose (i.e., 4 times/day to 3 times/day to twice daily): Note: Not effective for imme- diate relief of symptoms in acute asthmatic attacks; must be used at regular intervals for 2-4 weeks to be effective. -Nebulization solution: Children >2 years and Adults: Initial: 20 mg 4 times/ day; usual dose: 20 mg 3-4 times/day Metered spray: Children 5-12 years: Initial: 2 inhalations 4 times/day; usual dose: 1-2 inhalations 3-4 times/day Children ≥12 years and Adults: Initial: 2 inhalations 4 times/day; usual dose: 2 -4 inhalations 3-4 times/day Prevention of allergen- or exercise-induced bronchospasm: Administer 10-15 minutes prior to exercise or allergen exposure but no longer than 1 hour be- fore Ophthalmic: Children>4 years and Adults:1-2 drops in each eye 4-6 times/d
Indications & Contraindications
- Indications
- Inhalation: May be used as an adjunct in the prophylaxis of allergic disorders, including asthma; prevention of exercise-induced bronchospasm Ophthalmic: Treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis
Cautions & Side Effects
- Side Effects
- Increase in sneezing, burning, stinging, or irritation inside of nose, headache
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Unknown if excreted in breast milk, use caution
CYANOCOBALAMIN,Depovit®
Vitamin,watersoluble
Pregnancy: safeLactation: compatible
CYANOCOBALAMIN,Depovit®
Vitamin,watersoluble
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 1000mcg/mlinjection
Dosing & Formulations
- Dose
- Pernicious anemia: Children: 30-50 mcg/day for 2 or more weeks (to a total dose of 1000-5000 mcg), then follow with 100 mcg/month as maintenance dosage. Adults: 100 mcg/day for 6-7 days; if improvement, administer same dose on Alternate days for 7 doses; then every 3-4 days for 2-3 weeks; once hema- tologic values have returned to normal, maintenance dosage: 100 mcg/month Vitamin B 12 deficiency: Children: Neurologic signs: 100 mcg/day for 10-15 days (total dose of 1-1.5 mg), then once or twice weekly for several months; may taper to 60 mcg every month -Hematologic signs: 10-50 mcg/day for 5-10 days, followed by 100-250 mcg/ Dose every 2-4 weeks Adults: Initial: 30 mcg/day for 5-10 days; maintenance: 100-200 mcg/month Schilling test: Adults: I.M.: 1000 mcg
Indications & Contraindications
- Indications
- Treatment of pernicious anemia; vitamin B 12 deficiency; increased B 12 requirements due to pregnancy, thyrotoxicosis, hemorrhage, malignancy, liver or kidney disease
Cautions & Side Effects
- Side Effects
- Headache,anxiety,dizziness,pain,nervousness, hypoesthesia,itching,sorethroat, nausea andvomiting,dyspepsia,diarrhea,dyspnea,rhinitis
Pregnancy & Lactation
- Pregnancy
- A / C (dose exceeding RDA recommendation)
- Lactation
- Drug distributed in milk; safe to use
CYCLOPENTOLATE,Cyclogyl®
AnticholinergicAgent,Ophthalmic
Pregnancy: cautionLactation: caution
CYCLOPENTOLATE,Cyclogyl®
AnticholinergicAgent,Ophthalmic
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 1%eye drop
Dosing & Formulations
- Dose
- Children:Instill1 dropof 0.5%,1%, or2% ineyefollowedby1drop of 0.5% Or1% in5 minutes,if necessary Adults:Instill1dropof1%followedby anotherdropin5minutes;2%solutioninheavily pigmentediris
Indications & Contraindications
- Indications
- Diagnosticproceduresrequiringmydriasisandcycloplegia
Cautions & Side Effects
- Cautions
- Darkly pigmented iris is more resistant to pupillary dilatation and caution should be exercised to avoid overdosage; mydriasis can precipitate acute angle-closure glaucoma (usually in those aged over 60 years and hypermetropic (long-sighted), who are predisposed to the condition because of a shallow anterior chamber)
- Side Effects
- Increaseintraocularpressure,lossofvisualaccommodation,allergic reaction
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excretion in milk unknown; use with caution
DAPSON,Dapson®
Antileprotic
Pregnancy: cautionLactation: avoid
DAPSON,Dapson®
Antileprotic
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 100 mg tablet
Dosing & Formulations
- Dose
- Leprosy: Children: 1-2mg/kg/24 hours up to a maximum of 100mg/day Adults: 50-100mg/day for 3-10 years Dermatitis herpetiformis: Adults: Start at 50mg/day, increase to 300mg/day, Or higher to achieve full control.
Indications & Contraindications
- Indications
- Treatment of leprosy and dermatitis herpetiformis
Cautions & Side Effects
- Cautions
- Cardiac and pulmonarydisease, anaemia; G6PD deficiency;pregnancy and breast-feeding.
- Side Effects
- Dose related haemolyticanaemia, methaemoglobinaemia,skin reactions, gastrointestinaldisturbances, neuropathy; dapsonesyndrome characterized by rashwith fever and eosinophilia
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Enters breast milk; not recommended
DEFEROXAMINE,Desferal®
Antidote
Pregnancy: cautionLactation: caution
DEFEROXAMINE,Desferal®
Antidote
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 500mg injection
Dosing & Formulations
- Dose
- Acute iron toxicity: Children ≥3 years: -I.M.: 90 mg/kg/dose every 8 hours (maximum: 6 g/24 hours) -I.V.: 15 mg/kg/hour (*maximum: 6 g/24 hours) Adults: I.M., I.V.: Initial: 1000 mg, may be followed by 500 mg every 4 hours for up to 2 doses; subsequent doses of 500 mg have been administered every 4-12 hours *Maximum recommended dose: 6 g/day (per manufacturer) Chronic iron overload: Children ≥3 years: -I.V.: 15 mg/kg/hour (maximum: 12 g/24 hours) -subq: 20-40 mg/kg/day over 8-12 hours (maximum: 1000-2000 mg/day) Adults: -I.M., I.V.: 500-1000 mg/day I.M.; in addition, 2000 mg should be given I.V. With each unit of blood transfused (administer separately from blood) maximum: 1 g/day in absence of transfusions; 6 g/day if patient received transfusions -subq: 1-2 g every day or 20-40 mg/kg/day over 8-24 hours
Indications & Contraindications
- Indications
- Acute iron intoxication or when clinical signs of significant iron toxicity exist; Chronic iron overload secondary to multiple transfusions
Cautions & Side Effects
- Cautions
- Elderly (increased risk of side-effects); history of liver cirrhosis
- Side Effects
- Fatal gastro-intestinal haemorrhage; gastro-intestinal disturbances; gastro-intestinal ulceration; headache; proteinuria; pruritus; rash; elevated transaminases; earache; disturbances of hearing and vision
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Unknown if excreted in breast milk, use caution
DENOSUMAB, Prolia®
Miscellaneous bone resorption inhibitors
Pregnancy: riskLactation: caution
DENOSUMAB, Prolia®
Miscellaneous bone resorption inhibitors
- Therapeutic group
- Musculoskeletal & Joint Diseases
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 60 mg/ml
Dosing & Formulations
- Dose
- 60 mg subcutaneously once every 6 months
Indications & Contraindications
- Indications
- Used to treat osteoporosis in postmenopausal women also used to increase bone mass in women and men with a high risk of bone fracture caused by receiving treatments for certain types of cancer.
- Contraindications
- Hypocalcemia , Pregnancy , Hypersensitivity
Cautions & Side Effects
- Cautions
- Hypersensitivity , Hypocalcemia And Mineral Metabolism , Osteonecrosis Of The Jaw
- Side Effects
- Back pain,blistering, crusting, irritation, itching, or reddening of the skin ,bloody or cloudy urine ,cracked, dry, or scaly skin ,difficult, burning, or painful urination ,frequent urge to urinate ,muscle or bone pain ,pain in the arms or legs ,rash ,skin rash, encrusted, scaly, and oozing ,swelling
Pregnancy & Lactation
- Pregnancy
- X
- Lactation
- Excreted into human milk Unknown use with caution
DESMOPRESSIN,Minirin®
Antihemophilicagent,hemostaticagent
Pregnancy: safeLactation: caution
DESMOPRESSIN,Minirin®
Antihemophilicagent,hemostaticagent
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Solution
Dosage Forms
Solution
- 0.1mg/ml nasalsolution
Other
- 20 mcg
- 60mcg
Tablet
- 120mcg tablet
Dosing & Formulations
- Dose
- Treatment of hypothalamic (cranial) diabetes insipidus, intranasally, adult 10-40 micrograms daily in 1-2 divided doses. Child 5-20 micrograms daily. By injection, adult 1-4 micrograms daily. Child 400 nanograms daily. Orally, adult and child, 300 micrograms daily in divided doses; maintenance, 300-600 micrograms. Diagnosis of diabetes insipidus, intranasally, adult and child 20 micrograms. By injection, adult and child 2 micrograms. Restrict fluid intake 1 hour before and 8 hours after administration.
Indications & Contraindications
- Indications
- Diagnosis and treatment of hypothalamic diabetes insipidus; boosting Factor VIII in haemophilia.
- Contraindications
- Cardiac insufficiency and disorders treated with diuretics.
Cautions & Side Effects
- Cautions
- Migraine, epilepsy, heart failure, asthma; pregnancy; avoid fluid overload.
- Side Effects
- Fluid retention when fluid intake is not restricted, gastric pain, headache, convulsions due to hyponatraemia, nausea and vomiting.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Distributed into breast milk; use caution
DEXAMETHASONE,Oradexon®, Decadron®
Anti-inflammatoryagent,Corticosteroid
Pregnancy: cautionLactation: avoid
DEXAMETHASONE,Oradexon®, Decadron®
Anti-inflammatoryagent,Corticosteroid
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Ointment
Dosage Forms
Tablet
- 500mcgtablet
Injection
- 4mg/mlinjection
Ointment
- 0.05%eyeointment
Dosing & Formulations
- Dose
- By mouth, usual range 0.5–10 mg daily; CHILD 10–100 mcg/kg daily; By intramuscular injection or slow intravenous injection or infusion (as dexamethasone phosphate), initially 0.5–24 mg; CHILD 200–400 mcg/kg daily. Cerebral oedema associated with malignancy (as dexamethasone phosphate), by intravenous injection, 10 mg initially, then 4 mg by intramuscular injection every 6 hours as required for 2–4 days then gradually reduced and stopped over 5–7 days. Adjunctive treatment of bacterial meningitis, (starting before or with first dose of antibacterial treatment, as dexamethasone phosphate), by intravenous injection, 10 mg every 6 hours for 4 days; CHILD 150 mcg/kg every 6 hours for 4 days. Dexamethasone 1 mg dexamethasone phosphate 1.2 mg dexamethasone sodium phosphate 1.3 mg
Indications & Contraindications
- Indications
- Suppression of inflammatory and allergic disorders; shock; diagnosis of Cushing's syndrome; congenital adrenal hyperplasia; cerebral oedema; inflammation associated with malignancy; croup; nausea and vomiting with chemotherapy; rheumatic disease; eye.
- Contraindications
- Systemic infection; avoid live virus vaccines in those receiving immunosuppressive doses (serum antibody response diminished).
Cautions & Side Effects
- Cautions
- Pregnancy and breast-feeding. Adrenal suppression and infection, children and adolescents (growth retardation possibly irreversible), elderly (use with supervision particularly on long-term treatment)
- Side Effects
- Gastro-intestinal effects include dyspepsia, peptic ulceration (with perforation), abdominal distension, acute pancreatitis, oesophageal ulceration and candidiasis
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug excreted in breast milk; not recommended
DEXTROMETHORPHAN, Dextrocuf® ,Kafosed®
Antitussive
Pregnancy: cautionLactation: caution
DEXTROMETHORPHAN, Dextrocuf® ,Kafosed®
Antitussive
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Syrup
Dosage Forms
Syrup
- 15mg/5mlsyrup
Dosing & Formulations
- Dose
- Children:2-6years(syrup): 2.5-7.5mgevery4-8hours -6-12years: 5-10mgevery 4 hoursor 15 mgevery 6-8hours Children>12yearsandadults:10-20mgevery4 hrsor30 mgevery6-8hrs
Indications & Contraindications
- Indications
- Symptomaticreliefofcoughscausedbyminorviralurtiorinhaledirritants;
Cautions & Side Effects
- Side Effects
- Drowsiness,dizziness
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known if excreted in breast milk; use caution
DEXTROSE 50%
Intravenousnutritionaltherapy
Pregnancy: safeLactation: not in source
DEXTROSE 50%
Intravenousnutritionaltherapy
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- D5W+0.9Ns
- D5W+1/2NS
- D5W+1/4NS
- D10W+NS
- D10W+ NS
Dosing & Formulations
- Dose
- Accordingtopatient'sneed
Indications & Contraindications
- Indications
- Fluidreplacement
Cautions & Side Effects
- Side Effects
- Hyperosmolarity ,Edema ,Venous thrombosis ,Tachypnea ,Fever ,Hypermolar syndrome ,Hypervolemia ,Phlebitis, Diarrhea
Pregnancy & Lactation
- Pregnancy
- A/B/C/D
DIAZEPAM,Valium®
Anxiolytic-sedative–hypnotic,Benzodiazepine
Pregnancy: riskLactation: avoid
DIAZEPAM,Valium®
Anxiolytic-sedative–hypnotic,Benzodiazepine
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection
Dosage Forms
Tablet
- 5mgtablet
Injection
- 10mg/mlinjection
Other
- rectal supp 5
Dosing & Formulations
- Dose
- By mouth, anxiety, 2 mg 3 times daily increased in severe anxiety to 15-30 mg daily in divided doses. Elderly patients, half adult dose. Child in night terrors and somnambulism 1-5 mg daily at bedtime. Insomnia associated with anxiety - 5-15 mg at bedtime. By IM or slow IV injection, (at a rate of not more than 5mg/minute), for severe anxiety, control of acute panic attacks, and acute alcohol withdrawal, 10 mg repeated if necessary after 4 hours.
Indications & Contraindications
- Indications
- Anxiety, insomnia, adjunctive treatment of acute alcohol withdrawal; epilepsy; febrile convulsions; muscle spasm; peri-operative use.
- Contraindications
- Respiratory depression; marked neuromuscular respiratory weakness including unstable myasthenia gravis; acute pulmonary insufficiency; sleep apnoea syndrome; severe hepatic impairment
Cautions & Side Effects
- Cautions
- May alter reaction time and patient's ability to drive or operate machinery. Respiratory disease, muscle weakness and myasthenia gravis, history of drug or alcohol abuse
- Side Effects
- Drowsiness and lightheadedness the next day; confusion and ataxia (especially in the elderly); amnesia; dependence; paradoxical increase in aggression; muscle weakness
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Enters breast milk; not recommended
DICLOFENACSODIUM,Voltaren®,Rumafen®,Ocugesic®,Diclogesic®
NSAIDs,Analgesic,Antipyretic&Anti-inflammatory
Pregnancy: cautionLactation: avoid
DICLOFENACSODIUM,Voltaren®,Rumafen®,Ocugesic®,Diclogesic®
NSAIDs,Analgesic,Antipyretic&Anti-inflammatory
- Therapeutic group
- Musculoskeletal & Joint Diseases
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Gel · Suppository
Dosage Forms
Tablet
- 50 mgtablet
Injection
- 75 mginjection
Suppository
- 12.5mgchildrensuppository
- 50 mg adult suppository0.1%eyedropOcugesic®
Gel
- 1% gel
Dosing & Formulations
- Dose
- By mouth, 75–150mg daily in 2–3 divided doses By deep intramuscular injection into the gluteal muscle, acute exacerbations of pain and postoperative pain, 75mg once daily (twice daily in severe cases) for max. of 2 days Ureteric colic, 75mg then a further 75mg after 30 minutes if necessary. By intravenous infusion (in hospital setting), 75mg repeated if necessary after 4–6 hours for max. 2 days. Prevention of postoperative pain, initially after surgery 25–50mg over 15–60 minutes then 5mg/hour for max. 2 days. By rectum in suppositories, 75–150mg daily in divided doses. Max. total daily dose by any route 150mg. child 1–12 years, juvenile arthritis, by mouth or by rectum, 1–3mg/kg daily in divided doses (25mg e/c tablets, 12.5mg and 25mg suppositories only) child 6–12 years, postoperative pain, by rectum, 1– 2mg/kg daily in divided doses (12.5mg and 25mg suppositories only) for max. 4 days.
Indications & Contraindications
- Indications
- Pain and inflammation in rheumatic disease (including Still's disease) and other musculoskeletal disorders; acute gout; post-operative pain.
- Contraindications
- porphyria; Intravenous use. Additional contra-indications include concomitant NSAID or anticoagulant use (including low-dose heparin), history of haemorrhagic diathesis, history of asthma, moderate or severe renal impairment, hypovolaemia, dehydration.
Cautions & Side Effects
- Cautions
- breastfeeding.
- Side Effects
- diarrhea, constipation, gas or bloating, headache, dizziness, ringing in the ears, unexplained weight gain, excessive tiredness, lack of energy, upset stomach, loss of appetite, itching, pain in the upper right part of the stomach
Pregnancy & Lactation
- Pregnancy
- C (oral) / D (3rd trimester)
- Lactation
- Excreted in breast milk; not recommended
DIGOXIN,Lanoxin®
Antiarrhythmic agent,classiv, cardiac glycoside
Pregnancy: cautionLactation: caution
DIGOXIN,Lanoxin®
Antiarrhythmic agent,classiv, cardiac glycoside
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Syrup
Dosage Forms
Other
- 0
- 125&0
- 0
Tablet
- 25mg Tablet
Syrup
- 50mcg/Mlsyrup
Injection
- 5mg/2ml Injection
Dosing & Formulations
- Dose
- It has to be adjusted individually for each patient and the indicated doses are intended only as an initial guide. By mouth, rapid digitalization, 1 – 1.5 mg in divided doses over 24 hours. Less urgent digitalization, 125-250 mcg twice daily for up to 1 week. Maintenance, 0.125 - 0.25 mg once daily according to renal function status. By iv infusion, for very rapid control, digitalizing dose of 0.75 – 1.25 mg in 50 ml over 2 or more hours, followed by normal maintenance therapy. Im route not recommended, except when other methods of administration are not available.
Indications & Contraindications
- Indications
- Heart failure, supraventricular arrhythmias (particularly atrial fibrillation).
- Contraindications
- Heart block, supraventricular arrhythmias caused by wolff-parkinson-white syndrome, ventricular tachycardia or fibrillation.
Cautions & Side Effects
- Cautions
- Recent myocardial infarction, hypothyroidism; reduce dose in elderly and in renal failure; avoid hypokalaemia or hypomagnesaemia
- Side Effects
- Usually associated with excessive dosage, include: anorexia, nausea, vomiting, diarrhea and abdominal pain; visual disturbances, headache, fatigue, drowsiness, confusion, dizziness
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug enters breast milk; use with caution
DINOPROSTONE,ProstinE2®
Uterinestimulant,Prostaglandin
Pregnancy: cautionLactation: caution
DINOPROSTONE,ProstinE2®
Uterinestimulant,Prostaglandin
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Refrigerator (2–8°C)
- Dosage form
- Tablet · Injection
Dosage Forms
Injection
- 10 mg injection
Tablet
- 3mg tablet
Dosing & Formulations
- Dose
- By IV route, diluted with normal saline or concentration 5% dextrose to produce a solution of 1.5 mcg/ml and infused at a 0.25 meg/minute for 30 minutes and then maintained or increased. Cases of fatal death in utero may require higher doses; initial doses of 0.5 mcg/minute may be used with step increments at intervals of not less than one hour. Therapeutic abortion, missed abortion, and hydatidiform mole, as a solution containing 5 mcg/ml, 2.5 mcg/minute for at least 30 minutes then increased if necessary to 5mcg/minute; should be maintained for at least 4 hours before increasing further. By vagina, induction of labour, in vaginal tablets, inserted high into the posterior fornix, 3mg, followed after 6-8 hours by 3mg if labor is not established; max 6mg of vaginal tablets.
Indications & Contraindications
- Indications
- Induction and augmentationof labour at term; medicalinduction of therapeutic abortion.
- Contraindications
- Cardiac, pulmonary,renal, hepatic disease; foetaldistress; untreated pelvic infection
Cautions & Side Effects
- Cautions
- Asthma, glaucoma, cardiac,hepatic or renal impairment;hypertension; epilepsy; closelymonitor uterine contractility whenoxytocin is used in sequence.
- Side Effects
- Nausea, diarrhoea;dizziness; bronchospasm, fever, backache.
Pregnancy & Lactation
- Pregnancy
- C(Supp.),X(Injection)
- Lactation
- Excretion in milk unknown
DIPHENHYDRAMINE+AMM.CL, Exylin®
Expectorant
Pregnancy: cautionLactation: avoid
DIPHENHYDRAMINE+AMM.CL, Exylin®
Expectorant
- Therapeutic group
- Respiratory System
- Storage
- Unclassified
- Dosage form
- Syrup
Dosage Forms
Syrup
- 13.5+131.5mg/mlsyrup
Other
- 7mg for pedia
Dosing & Formulations
- Dose
- 5-15ml threetimeaday
Indications & Contraindications
- Indications
- Cough,bronchialcongestion
Cautions & Side Effects
- Cautions
- May cause drowsiness, Pregnancy.
- Side Effects
- Sedation and drowsiness.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug enters breast milk; contraindicated
DOMPERIDONE, Motilium®
Dopamine Antagonist, Prokinetic Gastrointestinal Agent
Pregnancy: cautionLactation: caution
DOMPERIDONE, Motilium®
Dopamine Antagonist, Prokinetic Gastrointestinal Agent
- Therapeutic group
- Gastrointestinal System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Syrup
Dosage Forms
Tablet
- 10mg tablet
Syrup
- 5mg/5ml syrup
Dosing & Formulations
- Dose
- Adult dose Oral, 10–20 mg every 6–8 hours. Maximum 80 mg daily. Lactation stimulation, 10 mg three times daily; taper dose over 7–10 days before stopping. Paediatric dose Oral, 0.2–0.4 mg/kg 4–8 hourly. Maximum 40 mg daily.
Indications & Contraindications
- Indications
- Acute nausea and vomiting especially when associated with cytotoxic therapy, apomorphine and other dopaminergic drugs, emergency hormonal contraception; dyspepsia, gastro-oesophageal reflux.
- Contraindications
- Routine prophylaxis in post-operative vomiting; prolactinoma, hepatic impairment; where increased gastro-intestinal motility harmful; pregnancy.
Cautions & Side Effects
- Cautions
- Children; renal impairment; breast-feeding; chronic use.
- Side Effects
- Increased prolactin concentrations; reduced libido; rash; acute dystonic reactions.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- No Data
DORZOLAMIDE,Xola®
Ophthalmicagent,Antiglaucoma
Pregnancy: cautionLactation: avoid
DORZOLAMIDE,Xola®
Ophthalmicagent,Antiglaucoma
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 2%eye drop
Dosing & Formulations
- Dose
- Adults:Glaucoma:Instill1dropintheaffectedeye(s)3times/day
Indications & Contraindications
- Indications
- Lowers intraocular pressure to treat glaucoma in patients with ocular hyper- tension or open-angle glaucoma
- Contraindications
- Hyperchloraemic acidosis; pregnancy and breast-feeding.
Cautions & Side Effects
- Cautions
- Feeding. Cautions: hepatic impairment; systemic absorption follows topical administration; chronic corneal defects.
- Side Effects
- Local ocular irritation, eyelid inflammation and crusting, corneal oedema, bitter taste, epistaxis, paraesthesia.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known whether distributed into breast milk; Do not nurse
DOXYCYCLINE,Vibramycin®
Antibiotic,Tetracycline
Pregnancy: riskLactation: avoid
DOXYCYCLINE,Vibramycin®
Antibiotic,Tetracycline
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule
Dosage Forms
Capsule
- 100mgcapsule
Dosing & Formulations
- Dose
- Orally, for general use, 100 mg twice daily for 1 day and then 100 mg once daily. In severe infections, 100 mg twice daily.
Indications & Contraindications
- Indications
- Principally in the treatment of infections caused by susceptible Rickettsia, Chlamydia, and Mycoplasma; alternative to mefloquine for malaria prophy- laxis; treatment for syphilis, uncomplicated Neisseria gonorrhoeae, Listeria, Actinomyces israelii, and Clostridium infections in penicillin-allergic patients; used for community-acquired pneumonia and other common infections due to susceptible organisms; anthrax due to Bacillus anthracis, including inhala- tional anthrax (postexposure); treatment of infections caused by uncommon susceptible gram-negative and gram-positive organisms
- Contraindications
- Breast-feeding; children under 12 years.
Cautions & Side Effects
- Cautions
- Hepatic impairment.; renal impairment; alcohol dependence.
- Side Effects
- Nausea and vomiting, gastrointestinal disturbances, allergic skin reactions; headache and visual disturbances may indicate intracranial hypertension; teeth discoloration, anorexia; tinnitus, dry mouth; anxiety; flushing; fungal superinfection.
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Enters breast milk; Not recommended
DYDROGESTERONE,Duphaston®
Humanprogesterone
Pregnancy: Not recommendedLactation: not in source
DYDROGESTERONE,Duphaston®
Humanprogesterone
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 10mgtablet
Dosing & Formulations
- Dose
- Endometriosis, 10 mg 2-3 times daily from day 5 to day 25th of cycle or continuously. Failure of nidation, irregular cycles, 10 mg twice daily from 11th to 25th day for at least 6 cycles. Habitual abortion, 10 mg twice daily from day 11th to 25th day of cycle until conception, then continuously until 20th week of pregnancy and gradually reduced. Dysfunctional uterine bleeding, 10 mg twice daily for 5-7 days to arrest bleeding; 10 mg twice daily from 11th to 25th day of cycle to prevent bleeding. Dysmenorrhoea, 10 mg twice daily from 5th to 25th day of cycle. Amenorrhoea, 10 mg twice daily from 11th to 25th day of cycle following estrogen therapy from 1st to 25th day of cycle. Premenstrual syndrome, 10 mg twice daily from 12th to 26th day of cycle. Hormone replacement therapy, with continuous estrogen therapy, 10 mg daily on days 15-28 of each 28-day estrogen HRT cycle increased to 10 mg twice daily if withdrawal bleed is early or endometrial biopsy shows inadequate progestational response.
Indications & Contraindications
- Indications
- Endometriosis, habitual abortion, failure of nidation, menstrual disorders, amenorrhoea, dysfunctional uterine bleeding.
- Contraindications
- History of liver tumours; severe liver impairment; genital or breast cancer; severe arterial disease; undiagnosed vaginal bleeding & porphyria; history of idiopathic jaundice, severe pruritis, pemphinoid gestations.
Cautions & Side Effects
- Cautions
- Conditions that may worsen with fluid retention e.g. Epilepsy, hypertension, migraine, asthma, cardiac or renal dysfunction, and in those susceptible to thromboembolism.
- Side Effects
- Menstrual disturbances; premenstrual like syndrome (including bloating, fluid retention, breast tenderness); weight gain, nausea, headache, dizziness, insomnia, drowsiness, depression, skin reactions.
Pregnancy & Lactation
- Pregnancy
- Not recommended
ERYTHROMYCIN,Erythrocin®
Antibiotic,Macrolide
Pregnancy: safeLactation: caution
ERYTHROMYCIN,Erythrocin®
Antibiotic,Macrolide
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Suspension
Dosage Forms
Tablet
- 250mgtablet
Suspension
- 200mg/5mlsuspension
Injection
- 1 gvial
Dosing & Formulations
- Dose
- Adult dose Oral, 175–500 mg 6–8 hourly; maximum dose 4 g daily. IV (erythromycin lactobionate), 3.75–5 mg/kg 6-hourly. Specific indications: see approved Product Information. Paediatric dose Oral/IV, 7.5 mg/kg 6-hourly. Maximum 12.5 mg/kg 6-hourly or 15 mg/kg 8-hourly. Specific indications: see approved Product Information. IM injection is not recommended: it is extremely painful. Rapid IV injections should be avoided since they can Result in pain, thrombophlebitis and ototoxicity.
Indications & Contraindications
- Indications
- Systemic: Susceptible bacterial infections including S. Pyogenes, some S. Pneumoniae, some S. Aureus, M.Pneumoniae, Legionella pneumophila, diphtheria, pertussis, chancroid, Chlamydia, erythrasma, N. Gonorrhoeae, E. Histolytica, syphilis and nongonococcal urethritis, and Campylobacter gastro- enteritis; used in conjunction with neomycin for decontaminating the bowel Ophthalmic: Treatment of superficial eye infections involving the conjunctiva or cornea; neonatal ophthalmia Topical:Treatmentofacne vulgaris
- Contraindications
- Hepatic disease; pregnancy.
Cautions & Side Effects
- Cautions
- Renal impairment; breast-feeding.
- Side Effects
- Diarrhoea, nausea and vomiting, abdominal pain, allergic reactions, cholestatic jaundice.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Drug enters breast milk; use with caution
ESCITALOPRAM, Cipralex®
Selective serotonin reuptake inhibitor
Pregnancy: cautionLactation: caution
ESCITALOPRAM, Cipralex®
Selective serotonin reuptake inhibitor
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 10 mg tablet
Dosing & Formulations
- Dose
- ADULT over 18 years, Depressive illness, generalized Anxiety disorder, and obsessive-compulsive disorder, 10mg once daily increased if necessary to max. 20mg Daily; ELDERLY over 65 years, initially half adult dose;Max. 10mg daily;
Indications & Contraindications
- Indications
- Depressive illness, generalised Anxiety disorder, and obsessive-compulsive disorder
- Contraindications
- QT-interval Prolongation (avoid concomitant administration of Drugs that prolong QT interval)
Cautions & Side Effects
- Cautions
- Susceptibility to QT-interval Prolongation
- Side Effects
- Hepatitis, palpitation, Tachycardia, oedema, bradycardia, postural Hypotension, haemorrhage, QT-interval prolongation, Coughing, yawning, confusion, impaired concentration, Aggression, malaise, amnesia, migraine, paraesthesia, Abnormal dreams, euphoria, mydriasis, taste Disturbance, increased salivation, rhinitis, tinnitus, Polyuria, micturition disorders, hypokalaemia, pruritus; Paradoxical increased anxiety during initial Treatment of panic disorder (reduce dose)
Pregnancy & Lactation
- Pregnancy
- C. Use when clinically indicated if it is the drug of choice. Increased risk of reversible withdrawal symptoms in newborns.
- Lactation
- Breastfeeding: Use with caution. Small amounts areExcreted in breast milk. Monitor the infant for adverseEffects (e.g. Sedation, restlessness, irritability, poor feeding).
ESOMEPRAZOLE, Nexium®
ProtonPumpInhibitor
Pregnancy: safeLactation: caution
ESOMEPRAZOLE, Nexium®
ProtonPumpInhibitor
- Therapeutic group
- Gastrointestinal System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 20mgtablet
Dosing & Formulations
- Dose
- Adult dose: 20–80 mg daily. Paediatric dose >12 years: 20–40 mg daily.
Indications & Contraindications
- Indications
- Gastroesophageal reflux disease (GERD), duodenal ulcer associated with Helicobacter pylori in combination with amoxicillin and clarithromycin or metronidazole, gastric ulcers associated with continuous NSAID therapy.
Cautions & Side Effects
- Cautions
- Used with caution in patients with liver disease, in pregnancy, breast- feeding and it may mask the symptoms of gastric cancer.
- Side Effects
- Flatulence; abdominal pain, dyspepsia, nausea; vomiting, diarrhoea, dry mouth; constipation; Headache
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Unknown whether esomeprazole is distributed into breast milk or not.
ETANERCEPT, Enpril®
Antirheumatics, TNF alfa inhibitors
Pregnancy: safeLactation: see details
ETANERCEPT, Enpril®
Antirheumatics, TNF alfa inhibitors
- Therapeutic group
- Malignant Disease & Immunosuppression
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 25 mg inj
Dosing & Formulations
- Dose
- 50 mg subcutaneously once a week
Indications & Contraindications
- Indications
- Treat rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis, and to prevent joint damage caused by these conditions
- Contraindications
- Active tuberculosis,infection caused by the bacteria listeria monocytogenes,chronic hepatitis b ,candidiasis yeast infection
Cautions & Side Effects
- Cautions
- Tb (tuberculosis) has been seen in patients started on this medicine, lymphoma and other cancers have happened in people who take this medicine or drugs like it
- Side Effects
- Chills,cough ,fever ,sneezing ,sore throat
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Etanercept is minimally excreted into breastmilk and poorly absorbed by the infant, which would be expected because of its high molecular weight of approximately 150,000
ETHAMBUTOL,Odetol®
Antitubercular
Pregnancy: cautionLactation: caution
ETHAMBUTOL,Odetol®
Antitubercular
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 400 mg tablet
Dosing & Formulations
- Dose
- Adult dose 15–25 mg/kg daily or 30 mg/kg three times a week or 50 mg/kg twice weekly. Maximum daily dose 2.5 g. Paediatric dose >6 years: same as adult dose.
Indications & Contraindications
- Indications
- Treatment of tuberculosis and other mycobacterial diseases in conjunction with other antituberculosis agents
- Contraindications
- Optic neuritis, poor vision.
Cautions & Side Effects
- Cautions
- Renal impairment, avoid in young and elderly, monitor for visual disturbances.
- Side Effects
- Decreased visual acuity (reversible), optic neuritis, peripheral neuritis, gastrointestinal disturbances, confusion, hallucination
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Enters breast milk; use with caution
ETHINYL ESTRADIOL
Estrogens
Pregnancy: Not indicated during pregnancyLactation: see details
ETHINYL ESTRADIOL
Estrogens
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 10mcg tab
Dosing & Formulations
- Dose
- Post menopausal symptoms:10 to 50 micrograms daily, usually on a cyclical basis (e.g., 3 weeks on and 1 week off). For women without a uterus, who did not have endometriosis diagnosed, it is not recommended to add a progestogen. In women with an intact uterus (or in endometriosis when endometrial foci may be present despite hysterectomy), where a progestogen is necessary, it should be added for at least 12-14 days every month/28 day cycle to reduce the risk to the endometrium. Palliative treatment of prostatic cancer: 150 micrograms to 1.5 mg daily. Larger dose Ethinylestradiol Tablets are available. Hormone replacement therapy for failure of ovarian development : 10 to 50 micrograms daily, usually on a cyclical basis. Initial estrogen therapy should be followed by combined estrogen/progestogen therapy. Disorders of menstruation:20 to 50 micrograms daily from day 5 to day 25 of each cycle. A progestogen is given daily in addition, either throughout the cycle or from days 15 to 25 of the cycle.
Indications & Contraindications
- Indications
- Post menopausal symptoms, Palliative treatment of prostatic cancer, Hormone replacement therapy for failure of ovarian development , Disorders of menstruation
- Contraindications
- Active arterial thromboembolic disease, history of breast cancer; history of recurrent venous thromboembolism
Cautions & Side Effects
- Cautions
- Interrupt treatment periodically to assess need for continued treatment.
- Side Effects
- Local irritation; Abdominal bloating; abdominal Cramps; altered blood lipids
Pregnancy & Lactation
- Pregnancy
- Not indicated during pregnancy.
- Lactation
- Not indicated during lactation
FENTANYL,Sublimaze®
Analgesic–narcotic
Pregnancy: cautionLactation: avoid
FENTANYL,Sublimaze®
Analgesic–narcotic
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 100 mcginjection
Dosing & Formulations
- Dose
- Surgery: Children≥2years:Adjuncttoanesthesia(inductionand maintenance):Slow I.V: 2-3mcg/kg/doseevery1-2hoursas needed Adults: Premedication:I.M.,slow I.V.:50-100 mcg/dose30-60minutespriortosurgery Adjunct toregionalanesthesia:slow I.V.:25-100mcg/doseover1-2minutes. Adjunct togeneralanesthesia:slow I.V.: Lowdose: 0.5-2mcg/kg/dosedependingontheindication Moderatedose:Initial:2-20mcg/kg/dose;Maintenance(bolusorinfusion):1 -2mcg/kg/hour.Discontinuingfentanyl infusion30-60minutespriortotheendof surgerywillusuallyallowadequateventilationuponemergencefromanesthesia.Forfast-trackingand earlyextubationfollowingmajorsurgery, totalfentanyldosesarelimitedto10-15mcg/kg. Adult dose Patch: Dosage should be based on individual response and previous 24-hour opioid requirements. 25 micrograms per hour patch is approximately equivalent to 90 mg per 24 hours of oral morphine.
Indications & Contraindications
- Indications
- Adjunct analgesic in anaesthesia; severe pain in cancer cases.
- Contraindications
- Avoid in acute respiratory depression, acute alcoholism and where risk of paralytic ileus; also avoid in raised intracranial pressure or head injury
Cautions & Side Effects
- Cautions
- Elderly and debilitated patients; respiratory depression; concomitant administration with opioid premedications and other CNS - depressant drugs: pregnancy; lactating mothers.
- Side Effects
- Sedation,reliefofpain,preoperativemedication,adjunctto generalorregionalanesthesia
Pregnancy & Lactation
- Pregnancy
- C / D (prolonged use or high doses at term)
- Lactation
- Drug enters breast milk; use not recommended
FERROUSSULPHATE,Fer-in-sol®,Feromin®, FEFOL®
Bloodmodifier,ironsalt
Pregnancy: safeLactation: see details
FERROUSSULPHATE,Fer-in-sol®,Feromin®, FEFOL®
Bloodmodifier,ironsalt
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Unclassified
- Dosage form
- Tablet · Drops
Dosage Forms
Drops
- 25mg/mloral drops
Tablet
- 190 mgtablet=60 mgelementaliron
Other
- Ferrous sulphate150mg+folic 0.5mg
Dosing & Formulations
- Dose
- Children (dose expressed in terms of elemental iron): Severe iron-deficiency anemia: 4-6 mg Fe/kg/day in 3 divided doses Mild to moderate iron deficiency anemia: 3 mg Fe/kg/day in 1-2 divided Doses Prophylaxis: 1-2 mg Fe/kg/day up to a maximum of 15 mg/day Adults (dose expressed in terms of ferrous sulfate): Iron deficiency: 300 mg twice daily up to 300 mg 4 times/day or 250 mg (extended release) 1-2 times/day Prophylaxis: 300 mg/day
Indications & Contraindications
- Indications
- Preventionandtreatmentofiron-deficiencyanemias
Cautions & Side Effects
- Side Effects
- Temporary discoloration of teeth or dentures (can be minimized by thorough brushing).
Pregnancy & Lactation
- Pregnancy
- A
- Lactation
- Drug is excreted in breast milk
FINASTERIDE,Proscar®
5Alpha-reductaseinhibitor
Pregnancy: riskLactation: not in source
FINASTERIDE,Proscar®
5Alpha-reductaseinhibitor
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 5mg tablet
Dosing & Formulations
- Dose
- 5 mg daily for 6 months, reassess treatment then after. Longer therapy period may be needed.
Cautions & Side Effects
- Cautions
- Obstructive uropathy, prostate cancer; finasteride may cause feminisation of male foetus, it is recommended to use condom if sexual partner is pregnant (finasteride is excreted in semen).
- Side Effects
- Impotence, decreased libido, ejaculation disorders, testicular pain, breast tenderness and enlargement, Allergic reactions.
Pregnancy & Lactation
- Pregnancy
- X
FLAVOXATE, Flavuxate®
Urinary antispasmodics
Pregnancy: safeLactation: caution
FLAVOXATE, Flavuxate®
Urinary antispasmodics
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 100 mg tablet
Indications & Contraindications
- Indications
- used to treat bladder symptoms such as painful urination, frequent or urgent urination, increased night-time urination, bladder pain, and incontinence
- Contraindications
- closed angle glaucoma ,Narrowing of Opening Between Stomach and Small Intestine ,Paralysis of the Intestines ,Stomach or Intestine Blockage ,Bleeding of the Stomach or Intestines ,Urinary Tract Blockage
Cautions & Side Effects
- Cautions
- Carcinogenesis, Mutagenesis, Impairment of Fertility
- Side Effects
- Drowsiness ,dryness of mouth and throat
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- There are no data on the excretion of flavoxate into human milk
FLUCONAZOLE,Diflucan®
Antifungal,Oral&Parenteral
Pregnancy: cautionLactation: caution
FLUCONAZOLE,Diflucan®
Antifungal,Oral&Parenteral
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule · Injection · Suspension
Dosage Forms
Capsule
- 50mgcapsule
Injection
- 100mg injection
Suspension
- 50mg/5mlsuspension
Dosing & Formulations
- Dose
- Adult dose Generally 50–400 mg daily. Vulvovaginal candidiasis: 150 mg single dose. Onchomycosis: 150–300 mg weekly for 3–12 months. Other indications: See approved Product Information. Paediatric dose Superficial and oral candidiasis: Oral, 6 mg/kg (maximum 200 mg) on day one, then 3 mg/kg Once daily. Systemic infections: IV/oral, 12 mg/kg (maximum
- Dose in Organ Failure
- Hepatic impairment: Not studied Renal impairment Percent of recommended dose: -crcl>50 ml/min: 100% of dose -crcl ≤50 ml/min: 50% dose -Regular dialysis: 100% dose after each dialysis; on nondialysis days, reduce dose according to creatinine clearance
Indications & Contraindications
- Indications
- Treatment of oral or vaginal candidiasis unresponsive to nystatin or clotrima- zole; nonlife-threatening Candida infections (eg, cystitis, esophagitis); treat- ment of hepatosplenic candidiasis; treatment of other Candida infections in persons unable to tolerate amphotericin B; treatment of cryptococcal infec- tions; secondary prophylaxis for cryptococcal meningitis in persons with AIDS; antifungal prophylaxis in allogeneic bone marrow transplant recipients
Cautions & Side Effects
- Cautions
- Renal impairment, pregnancy and breast-feeding; monitorhepatic function.
- Side Effects
- Gastrointestinal disturbances; headache, dizziness; hepatic disorders; rash, anaphylaxis, blood disorders.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Enters breast milk; use caution
FLUMAZENIL,Anexate®
Antidote
Pregnancy: cautionLactation: caution
FLUMAZENIL,Anexate®
Antidote
- Therapeutic group
- Antidotes & Toxicology
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 0.5 mg intravenousinjecection
Dosing & Formulations
- Dose
- Reversal of sedative effects of benzodiazepines in Anaesthesia and clinical procedures BY INTRAVENOUS INJECTION Adult: 200 micrograms, dose to be administered over 15 seconds, then 100 micrograms every 1 minute if Required; usual dose 300–600 micrograms; maximum 1 mg per course Reversal of sedative effects of benzodiazepines in Intensive care BY INTRAVENOUS INJECTION Adult: 300 micrograms, dose to be administered over 15 seconds, then 100 micrograms every 1 minute if Required; maximum 2 mg per course Reversal of sedative effects of benzodiazepines in Intensive care (if drowsiness recurs after injection) INITIALLY BY INTRAVENOUS INFUSION Adult: 100–400 micrograms/hour, adjusted according To response, alternatively (by intravenous
- Dose in Organ Failure
- Renal impairment: Not studied Hepatic impairment: Initial dose adjustment not necessary; reduce dose or frequency of subsequent doses
Indications & Contraindications
- Indications
- Reversal of sedative effects of benzodiazepines in anaesthetic, intensive care and diagnostic procedures.
- Contraindications
- Life threatening conditions controlled by benzodiazepines
Cautions & Side Effects
- Cautions
- Repeated dose may be needed because of short duration; avoid rapid injection in high-risk patients; hepatic impairment; head injury
- Side Effects
- Nausea, vomiting and flushing; with rapid recovery, agitation, anxiety and fear
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excretion in milk unknown; use with caution
FLUOROMETHOLONE, Optilone®
Steroid medicine
Pregnancy: cautionLactation: caution
FLUOROMETHOLONE, Optilone®
Steroid medicine
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 1mg oint
Dosing & Formulations
- Dose
- A small amount (approximately 1.5 inch ribbon) of ointment should be applied to the conjunctival sac 1 to 3 times per day
Indications & Contraindications
- Indications
- Used to treat eye swelling caused by infections, injury, surgery, or other conditions.
- Contraindications
- Tuberculosis of the Eye, herpes zoster ophthalmicus ,herpes simplex dendritic keratitis , Increased Pressure in the Eye ,Wide-Angle Glaucoma
Cautions & Side Effects
- Cautions
- Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local corticosteroid applications
- Side Effects
- Enlarged pupils , burning, dry, or itching eyes ,decreased vision ,delayed wound healing ,discharge from eye ,headache
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excreted into human milk: Unknown
FLUOXETINE, Prozac®
Selective serotonin reuptake inhibitor
Pregnancy: cautionLactation: avoid
FLUOXETINE, Prozac®
Selective serotonin reuptake inhibitor
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 20 mg tablet
Dosing & Formulations
- Dose
- 20–80 mg daily.
Indications & Contraindications
- Indications
- Major depression, Obsessive-compulsive disorder,
- Contraindications
- Ssris should not be used if thepatient enters a manic phase.
Cautions & Side Effects
- Cautions
- Used with caution in patients with epilepsy (avoid if poorly controlled, discontinue if convulsions develop), cardiac disease, diabetes mellitus, susceptibility to angle-closure glaucoma, a history of mania or bleeding disorders
- Side Effects
- Diarrhoea, dysphagia,vasodilatation, hypotension, flushing, palpitation, Pharyngitis, dyspnoea, chills, taste disturbance,sleep disturbances, malaise, euphoria,confusion, yawning, impaired concentration, changesin blood sugar, alopecia, urinary frequency;haemorrhage, pulmonary inflammation and fibrosis,hepatitis, toxic epidermal necrolysis, priapism, and Neuroleptic malignant syndrome-like event alsoreported
Pregnancy & Lactation
- Pregnancy
- C. Use with caution when clinically indicatedif it is the drug of choice. There is increased risk ofreversible withdrawal symptoms in newborns.
- Lactation
- Use not recommended. 10% of thedose is excreted in breast milk and may accumulate dueto its long half-life. Consider other ssris first.
FLUTICASONE,Flixotide®
Corticosteroids
Pregnancy: cautionLactation: caution
FLUTICASONE,Flixotide®
Corticosteroids
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Inhaler
Dosage Forms
Other
- 50mcg
- 125mcg
Inhaler
- 250mcg/puff oral inhaler
Dosing & Formulations
- Dose
- 1 inhalation po qday; not to exceed 1 inhalation every 24 hr Starting dose is based on asthma severity; the usual recommended starting dose is 100 mcg/day May increase to 200 mcg/day after 2 weeks if patient does not respond to 100 mcg/day
- Dose in Organ Failure
- Renal impairment (all severities): No dosage adjustment required Mild hepatic impairment: No dosage adjustment required Moderate-to-severe impairment: Caution advised; monitor patients for corticosteroid-related adverse effects
Indications & Contraindications
- Indications
- Prophylaxis of asthma.
- Contraindications
- Known sensitivity or allergy; children below 4 years.
Cautions & Side Effects
- Cautions
- Active or quiscent tuberculosis; Diabetes.
- Side Effects
- Yeast infection of the mouth (oral thrush); Throat irritation; Hoarse voice; Unexpected narrowing of the airways (paradoxical bronchospasm)
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Unknown if distributed in human breast milk
FLUTICASONE+SALMETROL,Seretide®,
Corticosteroid,Inhalant,Beta2-Adrenergic Agonist, Long-Acting
Pregnancy: cautionLactation: caution
FLUTICASONE+SALMETROL,Seretide®,
Corticosteroid,Inhalant,Beta2-Adrenergic Agonist, Long-Acting
- Therapeutic group
- Respiratory System
- Storage
- Unclassified
- Dosage form
- Unclassified
Dosage Forms
Other
- 50mcg +25mcg(Seretide50Evohaler)
- 125mcg+25mcg(Seretide125
- Evohaler)
- 50mcg +100mcg (Seretide®ACCUHALER/DISKUS)
Dosing & Formulations
- Dose
- Seretide 50 Evohaler: Recommendeddoses: Children 4 years and older: Two inhalationsof25ugsalmeteroland 50ug fluticasonepropionatetwicedaily. Adult and adolescents12 years and older: Two inhalationsof25ugsalmeteroland 50ug fluticasonepropionatetwicedaily. Or. Two inhalationsof25ugsalmeteroland 125ug fluticasonepropionatetwicedaily. Or. Two inhalationsof25ugsalmeteroland 250ug fluticasonepropionatetwicedaily. . Seretide®ACCUHALER/DISKUS Adult and adolescents12 years and older: Oneinhalationtwicedaily.
Indications & Contraindications
- Indications
- Maintenancetreatmentofasthma; maintenancetreatmentofcopd
Cautions & Side Effects
- Side Effects
- Headache,Upperrespiratorytract infection,pharyngitis
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Unknown whether agent is excreted in breast milk; salmeterol plasma levels
Folicacid,folitab®
Vitamin,watersoluble
Pregnancy: safeLactation: compatible
Folicacid,folitab®
Vitamin,watersoluble
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Other
- 1mg
Tablet
- 5mg tablet
Dosing & Formulations
- Dose
- Infants: 0.1 mg/day Children <4 years: up to 0.3 mg/day children >4 years and adults: 0.4 mg/day pregnant and lactating women: 0.8 mg/day
Indications & Contraindications
- Indications
- Treatment and prophylaxis of folic acid deficiency anaemia.
Cautions & Side Effects
- Cautions
- Should not be given alone in pernicious anaemia or other vitamin b12 deficiencies.
- Side Effects
- Slightflushing,generalmalaise,pruritus,rash, bronchospasm,allergic reaction
Pregnancy & Lactation
- Pregnancy
- A
- Lactation
- Drug enters breast milk; safe for nursing
Furosemide,lasix®,salurin®
Diuretic,loop
Pregnancy: cautionLactation: caution
Furosemide,lasix®,salurin®
Diuretic,loop
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Syrup
Dosage Forms
Tablet
- 40 mgtablet
Syrup
- 1mg/mlsyrup
Injection
- 20 mg/2ml&250mg/ 25mlinjection
Dosing & Formulations
- Dose
- Adult dose Oral, 20–40 mg once or twice daily. May be gradually increased up to 400 mg daily. For patients with severe renal impairment, doses up to 1,000 mg daily may be required. IV, 20–40 mg every 1–2 hours. Paediatric dose Oral, 1–2 mg/kg once or twice daily; maximum dose 6 mg/kg. IM/IV, 0.5–1 mg/kg every 6–12 hours. Maximum dose 6 mg/kg.
- Dose in Organ Failure
- Acute renal failure: 1-3 g/day may be necessary to attain desired response; avoid use in oliguric states Hepatic impairment: monitor, especially with high dosages
Indications & Contraindications
- Indications
- Managementofedemaassociated withcongestiveheartfailureandhepaticorrenaldisease; aloneorincombinationwithantihypertensivesintreatmentofhypertension
- Contraindications
- Hypokalaemia, liver failure, prostatism.
Cautions & Side Effects
- Cautions
- Hypotension; prosthetic enlargement; pregnancy; electrolyte imbalance, diabetes and gout
- Side Effects
- Hypokalemia, hyponatraemia, hypomagnesimia, hyperuricemia, hyperglycemia, hypotension.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug excreted into breast milk; use with caution; may inhibit lactation
FUSIDICACID,Fucithalmic®Fucidin®Fucidin H®, Fucicort®
Topical Antibiotic
Pregnancy: No adequate or well controlledLactation: not in source
FUSIDICACID,Fucithalmic®Fucidin®Fucidin H®, Fucicort®
Topical Antibiotic
- Therapeutic group
- Skin / Dermatological
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Cream · Ointment
Dosage Forms
Other
- 1 % eye drop
Cream
- 2 % 15 gm cream & ointment
- Fucidic acid 2%+betamethasone 0.1% cream
- Fucidic acid 2%+ Hydrocortisone 1% cream
Dosing & Formulations
- Dose
- Ophthalmic: Children >2 years and Adults: Instill 1 drop in each eye every 12 hours for 7 days Topical: Children and Adults: Apply to affected area 3-4 times/day until favor- Able results are achieved. If a gauze dressing is used, frequency of applica- Tion may be reduced to 1-2 times/day.
Indications & Contraindications
- Indications
- Ophthalmic infections, specifically staphylococcal infections.
Cautions & Side Effects
- Side Effects
- Pruritus, rash, ocular, blurred vision.
Pregnancy & Lactation
- Pregnancy
- No adequate or well controlled studies in pregnant women.
GABAPENTIN,Neurontin®
Anticonvulsant, GABA analogs
Pregnancy: cautionLactation: caution
GABAPENTIN,Neurontin®
Anticonvulsant, GABA analogs
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Other
- 150mg
Tablet
- 300mg tablet
Dosing & Formulations
- Dose
- Partial Seizures Initial: 300 mg PO q8hr May increase up to 600 mg PO q8hr; up to 2400 mg/day administered and tolerated in clinical studies; up to 3600 mg administered for short duration and tolerated Pedia: 3-12 years (initial dose): 10-15 mg/kg/day PO divided q8hr initially; titrate up in approximately 3 days to effective maintenance dose 3-4 years (maintenance dose): 40 mg/kg/day PO divided q8hr 5-12 years (maintenance dose): 25-35 mg/kg/day PO divided q8hr >12 years (initial dose): 300 mg PO q8hr; may increa Postherpetic Neuralgia Day 1: 300 mg PO qDay Day 2: 300 mg PO q12hr Day 3: 300 mg PO q8hr Maintenance: Subsequently titrate as needed up to 600 mg PO q8hr; doses >1800 mg/day have demonstrated no additional benefit
- Dose in Organ Failure
- Renal impairment CrCl>60 mL/min: 300-1200 mg PO TID CrCl 30-60 mL/min: 200-700 mg q12hr CrCl 15-29 mL/min: 200-700 mg qDay CrCl<15 mL/min: 100-300 mg qDay Hemodialysis (CrCl<15 mL/min): Administer supplemental dose (range 125-350 mg) posthemodialysis, after each 4 hr dialysis interval; further dose reduction should be in proportion to CrCl (eg, CrCl of 7.5 mL/min should receive one-half daily posthemodialysis dose)
Indications & Contraindications
- Indications
- monotherapy and adjunctivetreatment of partial seizureswith or without secondarygeneralisation, peripheral neuropathicpain, trigeminal neuralgia.
Cautions & Side Effects
- Cautions
- avoid abrupt withdrawal,elderly; renal impairment,diabetes mellitus, false positivereadings with some urinary proteintests, pregnancy, breast-feeding.
- Side Effects
- diarrhoea, dry mouth,dyspepsia, nausea, vomiting, constipation,abdominal pain, flatulence,appetite changes
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Enters breast milk; use with caution
GENTAMICIN ,Garamycin®
Antibiotic,Aminoglycoside
Pregnancy: cautionLactation: caution
GENTAMICIN ,Garamycin®
Antibiotic,Aminoglycoside
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection · Drops · Ointment
Dosage Forms
Injection
- 20&80mg injection
Drops
- 0.3%eyedrops
Ointment
- 0.3%eyeointment
Other
- Fortifiedgentamycin14 mg/ml eye drop
Dosing & Formulations
- Dose
- Adult dose IM/IV, 3–5 mg/kg daily; up to 8 mg/kg daily in severe or Life-threatening infections. Paediatric dose IM/IV, 3–7.5 mg/kg daily in 2–3 doses.
- Dose in Organ Failure
- Crcl>90 ml/min and <60 years: q8hr Crcl 60-90 ml/min or ≥60 years: q12hr Crcl 25-60 ml/min: q24hrcrcl 10-25 ml/min: q48hr Crcl<10 ml/min: q72hr Following dialysis in ESRD
Indications & Contraindications
- Indications
- Treatment of susceptible bacterial infections, normally gram-negative organ- isms including Pseudomonas, Proteus, Serratia, and gram-positive Staphylo- coccus; treatment of bone infections, RTI, skin and soft tissue infections, as well as abdominal and urinary tract infections, endocarditis, and septicemia; used topically to treat superficial infections of the skin or ophthalmic infec- tions caused by susceptible bacteria; prevention of bacterial endocarditis prior to dental or surgical procedures
- Contraindications
- Myasthenia gravis.
Cautions & Side Effects
- Cautions
- Pregnancy; renal impairment, infants and elderly (adjust dose and frequency); avoid prolong therapy.
- Side Effects
- Ototoxic and nephrotoxic effects, neuromuscular blocking effect, allergic reactions.
Pregnancy & Lactation
- Pregnancy
- C (ophthalmic, topical); C / D (injection, varies per manufacturer)
- Lactation
- Enters breast milk; w use ith caution
GLIBENCLAMIDE(GlyBURIDE),Daonil®
Antidiabeticagent,Sulfonylurea
Pregnancy: cautionLactation: avoid
GLIBENCLAMIDE(GlyBURIDE),Daonil®
Antidiabeticagent,Sulfonylurea
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 5mg tablet
Dosing & Formulations
- Dose
- Adults: -Initial: 2.5-5 mg/day, administered with breakfast or the first main meal of the day. In patients who are more sensitive to hypoglycemic drugs, start at 1.25 mg/day. Increase in increments of no more than 2.5 mg/day at weekly intervals based on the patient's blood glucose response -Maintenance: 1.25-20 mg/day given as single or divided doses; maximum: 20 mg/day Elderly: Initial: 1.25-2.5 mg/day, increase by 1.25-2.5 mg/day every 1-3 Weeks
- Dose in Organ Failure
- Renal impairment: If crcl<50 ml/min; caution advised Hepatic impairment: Use conservative initial and maintenance doses; avoid use in severe liver disease
Indications & Contraindications
- Indications
- Management of type2 diabetesmellitus(noninsulindependent,NIDDM)
- Contraindications
- Severe hepatic and renal impairment and in porphyria
Cautions & Side Effects
- Side Effects
- Gastro-intestinal disturbances such as nausea, vomiting, diarrhoea and constipation.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known if crosses into breast milk; avoid use in nursing women
GLICLAZIDE,Diamicron®
Antidiabetic Agent,Sulfonylurea
Pregnancy: cautionLactation: avoid
GLICLAZIDE,Diamicron®
Antidiabetic Agent,Sulfonylurea
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 80mgtablet
- 30mg MR tablet
Dosing & Formulations
- Dose
- Oral: Adults: Immediate release tablet: Initial: 80-160 mg/day; typical dose range 80-320 mg/day; dosage of >160 mg should be divided into 2 equal parts for twice- daily administration; maximum dose: 320 mg/day; should be taken with meals
Indications & Contraindications
- Indications
- Management of type2 diabetesmellitus(noninsulindependent,NIDDM)
- Contraindications
- Severe hepatic and renal impairment and in porphyria
Cautions & Side Effects
- Cautions
- Encourage weight gain and should be prescribed only if poor control and symptoms persist despite adequate attempts at dieting;
- Side Effects
- Gastro-intestinal disturbances such as nausea, vomiting, diarrhoea and constipation
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- The use of sulfonylureas in breast- feeding: should be avoided because there is a theoretical possibility of hypoglycaemia in the infant.
GLUCAGON,GlucaGen®
Antidote,diagnostic agent
Pregnancy: safeLactation: caution
GLUCAGON,GlucaGen®
Antidote,diagnostic agent
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 1mg injection
Dosing & Formulations
- Dose
- By SC, IM, or IV injection, adults and children over 8 years or body-weight over 25 kg, 1 mg; CHILDREN less than 8 years or body-weight below 25 kg, 500 mcg. If no response within 10 minutes intravenous glucose must be given.
Indications & Contraindications
- Indications
- Acute hypoglycemia.
- Contraindications
- Phaeochromocytoma.
Cautions & Side Effects
- Cautions
- Ineffective in chronic hypoglycemia, starvation and adrenal insufficiency; insulinoma; glucagonoma, breast feeding.
- Side Effects
- Nausea, vomiting, rarely hypersensitivity reactions, abdominal pain, hypokalaemia, hypotension.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excretion in milk unknown; use with caution
GLYCERINE
Stimulant laxatives
Pregnancy: cautionLactation: caution
GLYCERINE
Stimulant laxatives
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Suppository
Dosage Forms
Suppository
- 900 mgsuppository
Other
- liquid60 ml
Dosing & Formulations
- Dose
- Children<6years:1infantsuppository1-2times/day asneededor2-5mL asanenema Children>6 years and Adults:1adult suppository1-2times/dayasneededor 5-15Mlasanenema
Indications & Contraindications
- Indications
- Relieving occasional constipation, promotes peristalsis and evacuation of the lower bowel.
- Contraindications
- Known hypersensitivity to glycerin anuria, severe dehydration.
Cautions & Side Effects
- Cautions
- Use cautiously in hypovolemia, confused mental state, congestive heart failure, elderly
- Side Effects
- Anal irritation; burning sensation; diarrhea; gas; nausea; stomach cramps.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known whether excreted in breast milk; no risks shown to nursing infants
Glycerol ear drop
Pregnancy: not in sourceLactation: not in source
Glycerol ear drop
- Therapeutic group
- Unclassified
- Storage
- Unclassified
- Dosage form
- Unclassified
Dosing & Formulations
- Dose
- 2-3 drops 4-6 times daily for 2 days to soften hard wax and prepare the patient for syringing. If the wax is not very hard sufficient amount is applied on the same day of syringing.
Indications & Contraindications
- Indications
- ear wax removal.
HALOPERIDOL,Haldol®
Antipsychoticagent,Butyrophenone
Pregnancy: cautionLactation: avoid
HALOPERIDOL,Haldol®
Antipsychoticagent,Butyrophenone
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Drops
Dosage Forms
Other
- 1.5
- 5
Tablet
- 10 mgtablet/5
Injection
- 50 mginjection/ 2mg drops
Dosing & Formulations
- Dose
- Adult dose Chronic psychoses: Oral, 1–15 mg daily in divided doses. Acute psychoses: IM/IV, initially 2–10 mg every hour as needed. Maximum daily dose 100 mg. Paediatric dose >5 years, initially 0.25–0.5 mg once daily, increasing weekly according to indication. Tourettes syndrome, severe aggression: 0.075 mg/kg daily. Maximum 5 mg. Psychotic disorders: 0.15 mg/kg daily. Maximum 5 mg.
Indications & Contraindications
- Indications
- Schizophrenia and related psychoses, particularly mania; tranquillization and emergency control in behavioral disturbances; short-term adjunctive treatment of severe anxiety; motor tics, hiccups.
- Contraindications
- Comatose states, CNS depression, and phaeochromocytoma, pregnancy (unless essential); breast-feeding during treatment.
Cautions & Side Effects
- Cautions
- Hyrotoxic patients, basal ganglia disease; subarachnoid haemorrhage and metabolic disturbances such as hypokalaemia, hypocalcaemia, or hypomagnesaemia hepatic impairment, renal impairment, cardiovascular disease
- Side Effects
- Extra pyramidal symptoms consisting dystonia &akathesia particularly in thyrotoxic patients. Rarely weight loss, hypoglycaemia, inappropriate antidiuretic hormone secretion.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug enters breast milk; not recommended
HYDRALAZINE,Apresoline®
Vasodilator
Pregnancy: cautionLactation: caution
HYDRALAZINE,Apresoline®
Vasodilator
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection
Dosage Forms
Tablet
- 25mgtablet
Injection
- 20mginjection
Dosing & Formulations
- Dose
- By mouth, 25 mg twice daily increased to max. Of 50 mg twice daily. By slow IV injection, 5-20 mg over 20 minutes; may be repeated after 20-30 minutes. By IV infusion, 20 mg repeated if necessary.
Indications & Contraindications
- Indications
- Moderate to severe hypertension, in addition to a beta-adrenoceptor blocker or diuretics; hypertensive crisis.
- Contraindications
- Porphyria, severe tachycardia, high output heart failure and corpulmonale, systemic lupus erythematosus
Cautions & Side Effects
- Cautions
- Reduce initial dose in renal impairment; excessive reduction in blood pressure can occur with even low IV doses.
- Side Effects
- Tachycardia, palpitation, flushing, hypotension, fluid retention, GI disturbances; headache, dizziness
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excreted in breast milk; use caution
HYDROCHLOROTHIAZIDE,Monozide®
Diuretic,thiazide
Pregnancy: safeLactation: caution
HYDROCHLOROTHIAZIDE,Monozide®
Diuretic,thiazide
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 25 mgtablet
Dosing & Formulations
- Dose
- Oedema, initially 25-100 mg, in a single or 2 divided doses, orally given in the morning. Maintenance, 25-50 mg on alternate days. Max. Recommended daily dose, 100 mg. Hypertension, 25 mg daily in single or divided doses. Dose should not exceed 50 mg a day.
Indications & Contraindications
- Indications
- Oedema, hypertension.
- Contraindications
- Renal and hepatic impairment, hyperuricaemia, severe hypokalaemia
Cautions & Side Effects
- Cautions
- Monitor electrolyte serum level; impaired hepatic and renal function; pregnancy and breast-feeding
- Side Effects
- Orthostatichypotension,hypotension,hypokalemia,anorexia,epigastricdistress
Pregnancy & Lactation
- Pregnancy
- B(manufacturer); d(expertanalysis)
- Lactation
- Drug excreted in breast milk; use with caution
HYDROCORTISONE,Solu-Cortef®, Cortef®, LocoidLipo Cr®,Alfacort cream®
Corticosteroid
Pregnancy: cautionLactation: caution
HYDROCORTISONE,Solu-Cortef®, Cortef®, LocoidLipo Cr®,Alfacort cream®
Corticosteroid
- Therapeutic group
- Skin / Dermatological
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Cream
Dosage Forms
Tablet
- 10mgtablet
Injection
- 100 mg injection
Cream
- 1%cream
- hydrocortison 0.1%lipo cream
Dosing & Formulations
- Dose
- Acute adrenal insufficiency: I.M., I.V.: Infants and young Children: Succinate: 1-2 mg/kg/dose bolus, then 25-150 mg/day in divided doses every 6-8 hours Older Children: Succinate: 1-2 mg/kg bolus then 150-250 mg/day in divided doses every 6-8 hours Adults: Succinate: 100 mg I.V. bolus, then 300 mg/day in divided doses every 8 hours or as a continuous infusion for 48 hours; once patient is stable change to oral, 50 mg every 8 hours for 6 doses, then taper to 30-50 mg/day in divided doses Chronic adrenal corticoid insufficiency: Adults: Oral: 20-30 mg/day Anti-inflammatory or immunosuppressive: Infants and Children: -Oral: 2.5-10 mg/kg/day or 75-300 mg/m2 /day every 6-8 hours -I.M., I.V.: Succinate: 1-5 mg/kg/day or 30-150 mg/m2 /day divided every 12- 24 hours Adolescents and Adults: Oral, I.M., I.V.: Succinate: 15-240 mg every 12 hours Dermatosis: Children >2 years and Adults: Topical: Apply to affected area 2-4 times/day
Indications & Contraindications
- Indications
- adrenocortical insufficiency; suppression of inflammatory and allergic disorders; anaphylactic shock; and angioedema; inflammatory bowel disease and hemorrhoids; rheumatic disease; eye; skin.
- Contraindications
- In serious bacterial, viral, or fungal infection. Hydrocortisone weakens the body's immune response.
Cautions & Side Effects
- Cautions
- kidney disease; liver disease; hypertension; sodium and water retention, potassium loss; heart disease; ulcerative colitis
- Side Effects
- upset stomach, vomiting, headache, dizziness, insomnia, restlessness, irregular or absent menstrual periods, skin rash, swollen face, lower legs, or ankles, vision problems, cold or infection that lasts a long time, muscle weakness, Melena.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug enters breast milk; use with caution
HYDROXYCHLOROQUINE,Plaquinil®
Aminoquinoline(Antimalarial), disease modifying antirheumaticdrugs (DMARDs).
Pregnancy: cautionLactation: see details
HYDROXYCHLOROQUINE,Plaquinil®
Aminoquinoline(Antimalarial), disease modifying antirheumaticdrugs (DMARDs).
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 200mg tablet
Dosing & Formulations
- Dose
- administered on expert advice, initially 400mg daily in divided doses. Maintenance, 200-400mg daily; max. 6.5mg/kg daily (but not exceeding 400mg daily). Child, up to 6.5mg/kg daily (dosage form not suitable for children under 3 years of age).
Indications & Contraindications
- Indications
- rheumatoid arthritis,discoid and systemic lupus erythematosus,malaria.
- Contraindications
- psoriatic arthritis; concurrent use of hepatotoxic drugs.
Cautions & Side Effects
- Cautions
- hepatic impairment, renal impairment, regular ophthalmological examinations are recommended; pregnancy, breast-feeding; neurological disorders; psoriasis; porphyria.
- Side Effects
- gastro-intestinal disturbances, headache, and skin reactions; ECG changes, convulsions and visual changes; blood disorders, mental changes, myopathy; Stevens- Johnson Syndrome.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug is concentrated in breast milk
HYDROXYPROGESTERONE,Proluton-Depot®
Progestin
Pregnancy: No dataLactation: see details
HYDROXYPROGESTERONE,Proluton-Depot®
Progestin
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 250 mg injection
Dosing & Formulations
- Dose
- Habitual Abortion as soon as pregnancy has been confirmed by diagnosis, 250-500 mg Proluton Depot are injected IM at weekly intervals during the initial months or in individual cases, for even longer Threatened Abortion The therapy is initiated with an IM I infection of 500 mg Proluton Depot 2-3 times weekly until the bleeding ceases, bed rest befog urgently recommended. The treatment must then be continued for several weeks with 250 mg Proluton Depot IM twice weekly until the patient remains free from complaints and bleeding despite mobilization Infertility Due to Corpus Luteum Insufficiency IM injection of 250 mg Proluton Depot about 3 days after the rise in basal body temperature. Primary and Secondary Amenorrhea Commencement of Treatment On the 1st day of treatment 2 amps Progynon Depot 10 mg IM, 14 days later, 1 amp Progynon Depot 10 mg together with 250 mg Proluton Depot IM. W ithdrawal Bleeding starts about the 28th day of treatment. Continuation of Treatment (over at least 2-3 cycles): On the 6th day of the artificial cycle, 1 amp Progynon Depot 10 mg lm and on the 16th day, another Ampoule Progynon Depot 10 mg together with 250 mg Proluton Depot IM (1st day of bleeding =1st day of the cycle). An attempt can then be made to stop the estrogen-treatment, and to induce a Cyclical bleeding by an IM injection of 250 mg Proluton Depot between the 18th and the 20th day of the cycle.
Indications & Contraindications
- Indications
- Habitual & imminent abortion, infertilitity duo to corpus luteum insufficiency,
- Contraindications
- Currentthrombosis or thromboembolic disordersor history of these conditions,known or suspected breastcancer.
Cautions & Side Effects
- Cautions
- Thromboembolic disorder,sensitivity reactions, allergicreactions
- Side Effects
- Diarrhea; mild bruising,itching, or pain at the injectionsite; nausea
Pregnancy & Lactation
- Pregnancy
- No data
- Lactation
- Excreted into breast milk,risk/benefit ratio should be weighed.
HYDROXYUREA, Hydrea®
Antimetabolites
Pregnancy: riskLactation: caution
HYDROXYUREA, Hydrea®
Antimetabolites
- Therapeutic group
- Malignant Disease & Immunosuppression
- Storage
- Unclassified
- Dosage form
- Tablet
Dosage Forms
Tablet
- 500 mg tablet
Dosing & Formulations
- Dose
- 15 mg/kg/day orally
Indications & Contraindications
- Indications
- Used to treat chronic myeloid leukemia, ovarian cancer, and certain types of skin cancer.
- Contraindications
- Acute or severe bronchial asthma ,hepatic impairment ,hypercarbia ,hypersensitivity ,hypersensitivity to codeine ,paralytic ileus
Cautions & Side Effects
- Cautions
- This drug may cause severe myelosuppression. Blood counts should be monitored at baseline and throughout treatment. Treatment should be interrupted and the dose should be reduced as necessary. Malignancies: this drug is carcinogenic. Patients should use sun protection and be monitored for malignancies.
- Side Effects
- Cough or hoarseness ,fever or chills, lower back or side pain ,painful or difficult urination
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Not known if distributed in breast milk; use caution
HYOSCINE–N-BUTYLBROMIDE, Buscopan®
Anticholinergic Agent
Pregnancy: cautionLactation: caution
HYOSCINE–N-BUTYLBROMIDE, Buscopan®
Anticholinergic Agent
- Therapeutic group
- Gastrointestinal System
- Storage
- Unclassified
- Dosage form
- Tablet · Injection · Syrup · Suppository
Dosage Forms
Tablet
- 10 mg tablet
Suppository
- 10 mg suppository
Injection
- 20mg injection
Syrup
- 5mg/5ml syp
Dosing & Formulations
- Dose
- By mouth, adult dose is 20 mg 4 times daily; child 6-12 years, 10 mg 3 times daily. Irritable bowel syndrome, 10 mg 3 times daily; increased if necessary up to 20 mg 4 times daily. By IM or IV injection, acute spasm and spasm in diagnostic procedures, 20 mg repeated after 30 minutes if necessary.
Indications & Contraindications
- Indications
- Symptomatic relief of gastro-intestinal or genito-urinary tract disorders characterized by smooth muscle spasm, bowel colic and excessive respiratory secretions.
- Contraindications
- Hypersensitivity to scopolamine or any component of the formulation of narrow angle glaucoma, GI or GU obstruction, acute hemorrhage, paralytic ileus, thyrotoxicosis, tachycardia secondary to cardiac insufficiency, myasthenia gravis
Cautions & Side Effects
- Cautions
- Use with caution with hepatic or renal impairment pregnancy, use with caution in patient with GI obstruction, use with caution in Down syndrome, in children and elderly.
- Side Effects
- Unticholinergic side effects including dry mouth, dryness of skin, tachycardia, and urinary retention, constipation, dilatation of the pupil with loss of accommodation, photophobia.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug distributed into breast milk; use caution
IBUPROFEN,Brufen®
NSAIDs,Analgesic,Antipyretic &Anti-inflammatory
Pregnancy: cautionLactation: avoid
IBUPROFEN,Brufen®
NSAIDs,Analgesic,Antipyretic &Anti-inflammatory
- Therapeutic group
- Musculoskeletal & Joint Diseases
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Syrup
Dosage Forms
Tablet
- 400mg tablet
Syrup
- syrup (100mg/5ml)
Dosing & Formulations
- Dose
- Adults: 1.2 to 1.8 g daily divided in 3-4 doses preferably after food. Max. 2.4 g daily. Maintenance: 0.6 -1.2g daily. Juvenile rheumatoid arthritis – Child over 5kg body weight 30 – 40mg/kg daily in3-4 divided doses. Fever and pain: Child over 5kg body weight 20-30mg/kg daily in3-4 divided doses. OR 3 – 6 months (over 5 kg): 50mg 3 times daily. 6 months to 1 year: 50mg 3-4 times daily; 1-3 years: 100mg 3 times daily; 4-6 years: 150mg 3 times daily; 7-9 years: 200mg 3 times daily; 10-12 years: 300mg 3 times daily.
Indications & Contraindications
- Indications
- pain and inflammation in rheumatic disease (including juvenile arthritis) and other musculoskeletal disorders; mild to moderate pain including dysmenorrhoea; post-operative analgesia; migraine; fever and pain in children; post immunization pyrexia.
- Contraindications
- Known hypersensitivity to aspirin and other Non steroidal anti inflammatory drugs
Cautions & Side Effects
- Cautions
- Elderly; allergic disorders; renal, hepatic or cardiac impairment.
- Side Effects
- Headache, edema, nervousness,itching,rash, fluid retention, dyspepsia,vomiting,abdominalpain/cramps/distress,pepticulcer,GIbleed,GIperforation, heartburn,nausea,indigestion,tinnitus
Pregnancy & Lactation
- Pregnancy
- C / D (3rd trimester)
- Lactation
- Drug excreted into breast milk; use not recommended
IMIPENEM+CILASTATIN,Tienam®
Antibiotic,Carbapenem
Pregnancy: cautionLactation: caution
IMIPENEM+CILASTATIN,Tienam®
Antibiotic,Carbapenem
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection · Infusion
Dosage Forms
Injection
- 500 mg/vialIVinfusion
Dosing & Formulations
- Dose
- Dosage is based on the Imipenem content Neonates: Non-CNS infections: I.V.: <1 week: 25mg/kg every 12 hours 1-4 weeks: 25mg/kg every 8 hours 4 weeks to 3 months: 25mg/kg every 6 hours Children >3 months: Non-CNS infections: IV.,: 15-25 mg/kg every 6 hours (Maximum dosage: susceptible infections: 2g/day; moderately susceptible organisms: 4g/day) Children: Cystic fibrosis: IV., Doses up to 90mg/kg have been used Adults: Mild infections: IM., : 500mg every 12 hours IV., Fully susceptible organisms: 250mg every 6hours *Moderately-susceptible organisms: 500mg every 6 hours Moderate infections: IM.: 750mg every 12 hours IV.: Fully susceptible organisms: 500mg every 6-8 hours(1.5-2g/day) *Moderately-susceptible organisms: 500mg every 6 hours or 1 g every 8 Hours (2-3 g/day) Severe infections: IV., Note: IM administration is not intended for severe or life-threatening infections (eg., septicemia, endocarditis, shock) *Fully susceptible organisms: 500mg every 6 hours *Moderately-susceptible organisms: 1 g every 6-8 hours (3-4g/day) *Urinary tract infection, uncomplicated: IV.: 250mg every 6 hours *Urinary tract infection, complicated: IV.: 500mg every 6 hours
- Dose in Organ Failure
- Renal impairment Crcl ≥71 ml/min/1.73 m: 250 mg IV q6hr Crcl 41-70 ml/min/1.73m: 250 mg IV q8hr Crcl 21-40 ml/min/1.73 m: 125-250 mg IV q12hr Crcl ≤20 ml/min/1.73 m: 125-250 mg IV q12hr Crcl<5 ml/min/1.73 m: Use IV only if hemodialysis is instituted within 48 hours Hemodialysis: Give supplemental dose after each dialysis, then q12hr
Indications & Contraindications
- Indications
- Treatment of respiratorytract, urinarytract,intra-abdominal,gynecologic,boneandjoint,skin structure,andpolymicrobicinfectionsaswellasbacterialsepticemiaandendocarditis.Antibacterialactivityincludesresistant gram-negative bacilli (Pseudomonas aeruginosa and Enterobacter sp), gram-positivebacteria (methicillin-sensitive Staphylococcus aureusandstrepto- coccussp)andanaerobes.
- Contraindications
- Hypersensitivity to beta-lactam compounds; breast-feeding
Cautions & Side Effects
- Cautions
- Renal impairment; CNS disorders; pregnancy.
- Side Effects
- Nausea, vomiting, diarrhoea, tooth and tongue discoloration, hearing loss; allergic reactions; CNS disturbances.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug distributed in breast milk; use with caution
IMIPRAMINE,Tofranil®
Antidepressant,Tricyclic (tertiaryamine)
Pregnancy: riskLactation: avoid
IMIPRAMINE,Tofranil®
Antidepressant,Tricyclic (tertiaryamine)
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 10 &25 mg tablet
Dosing & Formulations
- Dose
- Initially 75 mg daily in divided doses or as a single dose at bedtime increased gradually to 200 mg (up to 225 mg in hospitalized patients); up to 150 mg may be given as a single dose at bedtime; Maintenance dose, 75-100 mg daily Elderly patients, 10-25 mg 1-3 times daily. Nocturnal enuresis, child 6-7 years, 25 mg; 8-11 years, 25-50 mg; Over 11 years, 50-75 mg at bedtime; Max. Period of treatment (including gradual withdrawal) should not exceed 3 months.
Indications & Contraindications
- Indications
- Depressive illness, nocturnal enuresis in children.
- Contraindications
- Recent myocardial infarction, heart block, mania; severe liver disease.
Cautions & Side Effects
- Cautions
- Sedation may affect patient's responses. Avoid abrupt cessation of therapy, epilepsy; pregnancy and breast-feeding, hepatic impairment, thyroid disease, anesthesia, diabetes.
- Side Effects
- Antimuscarinic effects- dry mouth, sedation, blurred vision (disturbance of accommodation, increased intra-ocular pressure), constipation, nausea, difficulty with micturition; cardiovascular side effects
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Distributed in breast milk; do not nurse
INDAPAMIDE,Natrilix®
Diuretic,thiazide–related
Pregnancy: safeLactation: avoid
INDAPAMIDE,Natrilix®
Diuretic,thiazide–related
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 1.5mgSRtablet
Dosing & Formulations
- Dose
- Adultsoral: Edema:2.5-5mg/day Hypertension:1.25mginthemorning,may increaseto5mg/day
Indications & Contraindications
- Indications
- Managementofmildtomoderatehypertension;treatmentofedemaincongestiveheartfailureandnephroticsyndrome
- Contraindications
- Severe hepatic or renal impairment.
Cautions & Side Effects
- Cautions
- Avoid diuretics, liable to cause hypokalaemia; monitor plasma potassium and urate levels in the elderly, gout and in patients on digoxin, hyperparathyroidism, porphyria.
- Side Effects
- Nausea, headache, dizziness, muscle cramps, rashes, slight weight loss; postural hypotension, hypokalemia.
Pregnancy & Lactation
- Pregnancy
- B(manufacturer); D(expertanalysis)
- Lactation
- Not known if excreted into breast milk, avoid
INDOMETHACIN,Indocid®
NSAIDs,Analgesic,Antipyretic&Anti-inflammatory
Pregnancy: cautionLactation: avoid
INDOMETHACIN,Indocid®
NSAIDs,Analgesic,Antipyretic&Anti-inflammatory
- Therapeutic group
- Musculoskeletal & Joint Diseases
- Storage
- Unclassified
- Dosage form
- Capsule · Injection · Suppository
Dosage Forms
Capsule
- 25 mgcapsule
Suppository
- 100 mgsuppositories
Injection
- 1mg injection
Dosing & Formulations
- Dose
- by mouth, 50-200mg daily in divided doses with food. By rectum in suppositories, 100mg at night, repeated in the morning if required. If rectal and oral treatments are to be combined, max. total daily dose 150-200mg.
Indications & Contraindications
- Indications
- pain and moderate to severe inflammation in rheumatic disease and other acute musculoskeletal disorders; acute gout; dysmenorrhoea; closure of ductusarteriosus.
- Contraindications
- peptic ulceration, salicylate hypersensitivity.
Cautions & Side Effects
- Cautions
- may impair the ability to drive or operate machinery; allergic disease, particularly asthma; hepatic and renal impairment, pregnancy, epilepsy, parkinsonism, psychiatric disturbances, elderly patients.
- Side Effects
- frequently gastro-intestinal disturbances (including diarrhoea), headache, dizziness, and light- headedness; gastro-intestinal ulceration and bleeding
Pregnancy & Lactation
- Pregnancy
- C / D (3rd trimester)
- Lactation
- Drug enters breast milk; use not recommended
INSULINPREPARATIONS:
Antidiabetic Agent
Pregnancy: safeLactation: not in source
INSULINPREPARATIONS:
Antidiabetic Agent
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Unclassified
- Dosage form
- Injection · Suspension · Solution
Dosage Forms
Other
- 1– RAPID - ACTING
- Lispro(100
- 50
- 25%)/protamin(0
- 50
- 75&)
- Aspart
- human novorapid® I.V. & Sub Q: 100 units/ml
- Glulisine
- Apidra® I.V. & Sub Q: 100 units/ml (3 ml pre-
- Filled pen)
- 2-SHORT-ACTING
- Regular
- human: Humulin R® I.V. & Sub Q: 100 units/ml
- 3-INTERMEDIATE-ACTING
- NPH
- human: Humulin N® Sub Q: 100 units/ml (10 ml
- 4-INTERMIDIATE to LONG-ACTING
- Detemir
- human (Levemir®) Sub Q:100 units/ml (1.5 ml
- Cartridge
- 3 ml disposable pen)
- 5-LONG-ACTING
- Glargine
- human (Lantus®) Sub Q:100 units/ml (1.5 ml
- Cartridge
- 3 ml disposable pen
- 6-COMBINATION
- INTERMEDIATE-ACTING
Injection
- -Injection
- (10 ml vial)
- -Injection
- -Injection
- (10 ml vial)
- -Injection
- Vial)
- -Injection
- -Injection
- 10 ml vial)
- - Injection
- Vial)
Solution
- solution
- solution
- solution
- solution
- solution
- solution
- Human insulin solution 30% (Mixtard® 70/30) Sub Q:100 units/ml (10 ml
Suspension
- NPH human insulin suspension 70% and short-acting regular
Dosing & Formulations
- Dose
- *Insulin Regular Type 1 Diabetes Mellitus: Children and Adults: Initial dose: 0.2-0.4 units/ Kg/day in divided doses. Adjustment of dose: Adjust dose to maintain premeal and bedtime glucose of 80-140 mg/dl (children <5 years: 100-200 mg/dl). Usual maintenance range: 0.5-1.2 units/kg/day in divided doses. -Adolescents: May require ≤1.5 units/kg/day during growth spurts -Nonobese: 0.4-0.6 units/kg/day -Obese: 0.8-1.2 units/kg/day -Renal failure: Due to alterations in pharmacokinetics of insulin, may require <0.2 units/kg/day Type 2 Diabetes Mellitus: Augmentation therapy: Insulins other than glargine: Initial dosage of 0.15-0.2 units/kg/day have been Recommended Monotherapy: Initial dose: recommended doses ranging from 6-77 units/day Diabetic ketoacidosis: Children <20 years: I.V.: Regular insulin infused at 0.1 units/kg/hour; continue until acidosis clears Subq, I.M.: If no I.V. infusion access, regular insulin 0.1 units/kg I.M. bolus Followed by 0.1 units/kg/hour subq or I.M.; continue until acidosis clears. Adults: I.V.: Regular insulin 0.15 units/kg initially followed by an infusion of 0.1 units/kg/hour Subq, I.M.: Regular insulin 0.4 units/kg given half as I.V. bolus and half as Subq or I.M., followed by 0.1 units/kg/hour subq or I.M. *Insulin NPH Insulin NPH is usually administered 1-2 times daily. *Insulin Aspart: Refer to Insulin Regular. *Insulin Regular + NPH Fixed ratio insulins are normally administered in 1-2 daily doses. *Insulin detemir Note: when compared to insulin NPH, insulin detemir has a slower, more prolonged absorption; duration is dose– dependant. Insulin detemir may be given once or twice daily when used as the basal insulin component from another insulin to insulin detemir can be done on a unit to– unit basis. Subq: Children ≥6 years and Adults: Basal insulin or basal-bolus (Type 1 or Type 2 diabetes): May be substituted on a unit-per-unit basis. Adjust dose to achieve glycemic targets. Insulin-naive patients (type 2 diabetes only): 0.1-0.2 units/kg once daily in the Evening or 10 units once or twice daily. *Insulin glargine Subq: Children ≥6 years and Adults: Type 1 diabetes: As a basal component of combination insulin regimen, nor- Mally 50% to 75% of daily insulin requirement is administered as a long- acting form. More rapid acting forms are usually used in association with meals. Type 2 diabetes: -Patient not already on insulin: 10 units once daily, adjusted according to patient response (range in clinical study: 2-100 units/day) -Patient already receiving insulin: In clinical studies, when changing to insulin glargine from once-daily NPH, the initial dose was not changed; when chang- ing from twice-daily NPH to once-daily insulin glargine, the total daily dose was reduced by 20% and adjusted according to patient response *Insulin glulisine: Note: Insulin glulisine is equipotent to insulin regular but has a more rapid onset and shorter duration of activity. Subq: Diabetes mellitus (Type 1 & Type 2): Children ≥4 years and Adults: refer to insulin regular
Indications & Contraindications
- Indications
- Treatment of type 1 diabetes mellitus (insulin dependent); type 2 diabetes mellitus (noninsulin dependent) unresponsive to treatment with diet and/or oral hypoglycemics; adjunct to parenteral nutrition (only regular insulin)
Cautions & Side Effects
- Side Effects
- Hypoglycaemia is the most serious side effect of insulin and patients should carefully be directed to avoid it. It could result from an overdose of insulin, missed meal or an unusual physical activity. The early symptoms of hypoglycaemia are; fatigue, dizziness, cold, sweat, headache, hunger, weakness, nervousness, mental lapse and if not treated may lead to convulsion and coma.
Pregnancy & Lactation
- Pregnancy
- B; C (insulin glargine [Lantus®], insulin detemir [Levemir®], insulin glulisine [Apidra®])
IPRATROPIUMBROMIDE,Atrovent®
Anticholinergicagent,Bronchodilator
Pregnancy: safeLactation: caution
IPRATROPIUMBROMIDE,Atrovent®
Anticholinergicagent,Bronchodilator
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection · Inhaler · Nebulizer solution
Dosage Forms
Inhaler
- 20 mcg/puffinhaler
Injection
- 0.025%Nebulizer(poly amp.)
Nebulizer solution
- 0.05%Nebulizer
Dosing & Formulations
- Dose
- By inhalation of nebulized solution, 100-500 mcg up to 4 times daily. Child 1 month-3 years, 62.5-250 meg up to 3 times daily. 3-14 years, 100-500 meg up to 3 times daily.
Indications & Contraindications
- Indications
- An anti-muscarinic bronchodilator used in reversible airways obstruction, particularly in chronic bronchitis. Ipratropium bromide is used intranasally for the treatment of rhinorrhoea in allergic and non-allergic rhinitis. It has also relieved rhinorrhoea and sneezing associated with the common cold.
Cautions & Side Effects
- Cautions
- Glaucoma (standard doses are unlikely to be harmful); prostatic hypertrophy. First inhalation dose should be given under medical supervision.
- Side Effects
- Dry mouth occasionally reported; rarely urinary retention, constipation.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Unknown whether drug is excreted in breast milk
ISOFLURANE,Aerrane®,Forane®
Anesthetic, Volatile liquid
Pregnancy: cautionLactation: caution
ISOFLURANE,Aerrane®,Forane®
Anesthetic, Volatile liquid
- Therapeutic group
- Anaesthesia & Muscle Relaxants
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Solution
Dosage Forms
Solution
- 100 ml solution
Dosing & Formulations
- Dose
- Inhalation: Adults: Anesthesia: Minimum alveolar concentration (MAC), the concentration at which 50% of patients do not respond to surgical incision, is 1.15% (44 years of age) for isoflurane Induction: 1.5% to 3% Maintenance: In nitrous oxide: 1% to 2.5%; in oxygen: 1.5% to 3.5% Elderly: MAC is reduced
Indications & Contraindications
- Indications
- Induction and maintenance of general anesthesia
- Contraindications
- Sensitivity to halogenated compounds.
Cautions & Side Effects
- Side Effects
- Hypotension, myocardial depression, Mood changes
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Use caution
ISONIAZID,Isotamin®
Antitubercular
Pregnancy: cautionLactation: compatible
ISONIAZID,Isotamin®
Antitubercular
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Syrup
Dosage Forms
Tablet
- 100 mg tablet
Syrup
- 50mg/5ml syp
Dosing & Formulations
- Dose
- Adult dose Treatment: (as part of multi-drug regimen) 5–10 mg/kg daily (maximum 300 mg) or 15 mg/kg (maximum 900 mg) 2–3 times a week. Prophylaxis: (latent TB), oral 300 mg daily. Paediatric dose Treatment: (as part of multi-drug regimen) 10–20 mg/kg daily (maximum 300 mg); or 20–40 mg/kg (maximum 900 mg) 2–3 times a week. Prophylaxis: 10 mg/kg (maximum 300 mg) once daily.
Indications & Contraindications
- Indications
- Treatment of susceptibletuberculosis infections; prophylacticallyin thoseindividualsexposedtotuberculosis
Cautions & Side Effects
- Cautions
- Renal and hepatic function, diabetes, epilepsy, pregnancy and breast-feeding.
- Side Effects
- Peripheral neuritis, optic neuritis, nausea and vomiting, impairment of memory, psychosis, allergic reactions, blood disorders.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Distributed into milk but safe for nursing infants
ITRACONAZOLE,Itrazole®
Antifungal
Pregnancy: cautionLactation: see details
ITRACONAZOLE,Itrazole®
Antifungal
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule
Dosage Forms
Capsule
- 100 mgcapsule
Dosing & Formulations
- Dose
- Adult dose 100–400 mg daily. Paediatric dose Oral liquid, 3–5 mg/kg (rounded to the nearest 50 mg) Daily in 1–2 doses. Capsules, 5–7.5 mg/kg (rounded to the nearest 100 mg) Daily in 1–2 doses.
Indications & Contraindications
- Indications
- Treatment of susceptible fungal infections in immunocompromised and im- munocompetent patients including blastomycosis and histoplasmosis; indicated for aspergillosis, and onychomycosis of the toenail; treatment of onychomyco- sis of the fingernail without concomitant toenail infection via a pulse-type dosing regimen; has activity against Aspergillus, Candida, Coccidioides, Cryptococcus,
Cautions & Side Effects
- Cautions
- Liver disease; renal impairment; pregnancy and breastfeeding.
- Side Effects
- Gastrointestinal disturbances, liver disease, peripheral neuropathy.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug enters breast milk; weigh risk against benefit
KETAMINE,ketalar®
Anesthetic,general
Pregnancy: riskLactation: caution
KETAMINE,ketalar®
Anesthetic,general
- Therapeutic group
- Anaesthesia & Muscle Relaxants
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 10mg/ml injection
Dosing & Formulations
- Dose
- Children: Oral; 6-10mg/kgfor1 dose(mixedin0.2-0.3ml/kgof colaorotherbeverages given30 minutes beforetheprocedure Im: 3-7mg/kg IV: range: 0.5-2mg/kg,usesmallerdoses(0.5-1mg/kg)forsedationforminor procedures,usualinduction dosage: 1-2mg/kgcontinuous iv.,infusion:sedation:5-20mcg/kg/minuteadults:im.,: 3-8mg/kg Iv.,range: 1-4.5mg/kg;ususal induction dosage: 1-2mg/kg Childrenandadults:supplementaldosesof 1/3toofinitialdose
Indications & Contraindications
- Indications
- Induction and maintenance of anaesthesia.
- Contraindications
- Hypertension; patients prone to hallucination
Cautions & Side Effects
- Side Effects
- Hypertension,increasedcardiacoutput,paradoxicaldirectmyocardialde-pression,tachycardia,increasedintracranialpressure,visualhallucinations,vividdreams
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Not known if excreted in breast milk; effect on nursing infant unknown
Labetalol,trandate®
Betablockerwithalpha-blockingactivity
Pregnancy: cautionLactation: caution
Labetalol,trandate®
Betablockerwithalpha-blockingactivity
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection
Dosage Forms
Injection
- 5mg/ml(20 ml) injection
Tablet
- 100mgtablet
Dosing & Formulations
- Dose
- By mouth, initially 100 mg (50mg in elderly) twice daily with food, increased at intervals of 14 days to usual dose of 200 mg twice daily; up to 800 mg daily in 2 divided doses (3-4 divided doses if higher); max. 2-4 g daily. By intravenous injection, 50 mg over at least 1 minute, repeated after 5 minutes if necessary; max. Total dose 200mg.
Indications & Contraindications
- Indications
- Hypertension (including hypertension in pregnancy, hypertension with angina, and hypertension following acute myocardial infarction); hypertensive crisis; controlled hypotension in anaesthesia.
- Contraindications
- Asthma; uncontrolled heart failure; prinzmetalss angina; marked bradycardia; hypotension
Cautions & Side Effects
- Side Effects
- Postural hypotension (avoid upright position during and for 3 hours after intravenous administration), tiredness, weakness, headache, rashes, scalp tingling, difficulty in micturition, epigastric pain, nausea, vomiting; liver damage
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Small amounts excreted; use with caution
LACTULOSE,Duphalac®Ezilax®
Osmotic laxatives
Pregnancy: safeLactation: caution
LACTULOSE,Duphalac®Ezilax®
Osmotic laxatives
- Therapeutic group
- Gastrointestinal System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Syrup
Dosage Forms
Syrup
- 10 g/ 15 mlSyrup (300ml)
Dosing & Formulations
- Dose
- Constipation, initially15 ml twice daily, gradually reduced according to patient's needs. Child, less than 1 year, 2.5 ml. Child 1-5 years, 5 ml. 6-12 years, 10 ml twice daily, gradually reduced. Hepatic encephalopathy, 30-50 ml 3 times daily, subsequently adjusted to produce 2-3 soft stools daily.
Indications & Contraindications
- Indications
- treatment of constipation; prevention and treatment of portal-systemic encephalopathy, including stages of hepatic precoma and coma.
- Contraindications
- galactosaemia, intestinal obstruction
Cautions & Side Effects
- Cautions
- lactose intolerance, patients on galactose- free diet. diabetes mellitus.
- Side Effects
- Gaseous distention with flatulence or belching, abdominal discomfort and cramping; diarrhea; nausea; vomiting.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Unknown whether drug is distributed into milk; use with caution
LAMOTRIGINE,Lamictal®
Anticonvulsant
Pregnancy: cautionLactation: caution
LAMOTRIGINE,Lamictal®
Anticonvulsant
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 50&100mg tablet
Dosing & Formulations
- Dose
- Adult dose Monotherapy: Maintenance dose 100–200 mg daily in two doses. Adjunctive therapy With valproate: Maintenance dose 100–200 mg daily in one or two doses. Without valproate: Maintenance dose 200–400 mg daily in two doses (up to 500–700 mg daily in some patients). Paediatric dose Not recommended for paediatric patients as monotherapy when newly diagnosed. With valproate: Initially 0.15 mg/kg once daily, increasing every 2 weeks to maintenance dose of 1–5 mg/kg daily in one or two doses. Maximum 200 mg daily. Without valproate: Initially 0.6 mg/kg daily in two doses, increasing every 2 weeks to maintenance dose of 5–15 mg/kg daily. Maximum daily dose 400 mg.
- Dose in Organ Failure
- Renal impairment Use caution; may consider reduce the dose in significant renal impairment Hepatic impairment Limited data, various recommendations Manufacturer: decrease dose by 25% (moderate-severe without ascites) or by 50% (severe with ascites)
Indications & Contraindications
- Indications
- Monotherapy and adjunctivetreatment of partial seizureand primary and secondary generalizedtonic-clonic seizure.
- Contraindications
- Hepatic impairment
Cautions & Side Effects
- Cautions
- Closely monitor forblood disorder, hepatic and renalfunctions; skin rash, influenza likesymptoms might call for early withdrawal. Avoid abrupt withdrawal;withdraw gradually over 1-2 weeks.
- Side Effects
- Rash, fatigue, dizziness,headache, Steven's johnsonsyndrome, toxic epidermal necrolysis,hypersensitivity reactions.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Distributed into human breast milk; caution advised
LATANOPROST,Xalatan®
Anticholinergic Agent,Ophthalmic
Pregnancy: cautionLactation: caution
LATANOPROST,Xalatan®
Anticholinergic Agent,Ophthalmic
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 50mcg/ml eyedrop
Dosing & Formulations
- Dose
- Adults:Ophthalmic:1drop(1.5mcg)intheaffectedeye(s)oncedailyintheevening; donotexceedtheoncedailydosagebecauseit has beenshown thatmorefrequentadministrationmaydecreasethe IOPloweringeffect
Indications & Contraindications
- Indications
- Glaucoma in patients unresponsive or intolerant to other drugs.
Cautions & Side Effects
- Cautions
- Monitor for changes in eye coloration; brittle or severe asthma; pregnancy and breast-feeding.
- Side Effects
- Darkening of eye coloration, ocular irritation, exacerbation of asthma.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known whether distributed into milk; use with caution
LIDOCAINE,Xylocaine®
Anti-hemorrhoidal
Pregnancy: safeLactation: not in source
LIDOCAINE,Xylocaine®
Anti-hemorrhoidal
- Therapeutic group
- Anaesthesia & Muscle Relaxants
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Ointment · Gel
Dosage Forms
Ointment
- 5%ointment
Gel
- 2%gel
Dosing & Formulations
- Dose
- Apply locally once or twice daily
Indications & Contraindications
- Indications
- Analgesic ointment for painful and various anal conditions.
- Contraindications
- Hypersensitivity
Cautions & Side Effects
- Cautions
- Do not leave on large body areas for > 2 hours.
- Side Effects
- Itching, rash, edema of skin, contact dermatitis.
Pregnancy & Lactation
- Pregnancy
- B
LIDOCAINE+ TRIBENOSIDE,Heamoproct®,Procto-Glyvenol®
Localtreatmentfor hemorrhoids
Pregnancy: cautionLactation: not in source
LIDOCAINE+ TRIBENOSIDE,Heamoproct®,Procto-Glyvenol®
Localtreatmentfor hemorrhoids
- Therapeutic group
- Gastrointestinal System
- Storage
- Unclassified
- Dosage form
- Cream · Suppository
Dosage Forms
Cream
- 5&2 %cream
Suppository
- 400& 40 mgsuppository
Dosing & Formulations
- Dose
- Athinfilmof cream oronesuppositoryshouldbeapplied morning&eveninguntil thereis disappearance ofacutesymptoms.Suppository:1 suppositorybid
Indications & Contraindications
- Indications
- Effectiveintreatingbothexternal&internalhemorrhoids
- Contraindications
- Hypersensitivity
Pregnancy & Lactation
- Pregnancy
- C
LIDOCAINE+PRILOCAINE , Emla®,
Anesthetic, topical
Pregnancy: safeLactation: avoid
LIDOCAINE+PRILOCAINE , Emla®,
Anesthetic, topical
- Therapeutic group
- Anaesthesia & Muscle Relaxants
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Cream
Dosage Forms
Cream
- 5% cream
Dosing & Formulations
- Dose
- Dermal ProceduresMinor dermatological proceduresCream: Apply 2.5 g over 20-25 cm of skin surface area for at least 1 hr Painful dermatological procedures involving large areas (eg, split thickness skin graft harvesting) Cream: Apply 2 g/10 cm of skin and allow to remain in contact with the skin for at least 2 hr Analgesia is achieved in 1 hr, reaches maximum in 2-3 hr, and persists 1-2 hr after removalTopical Anesthetic on Genital Mucous Membranes Superficial minor surgery on male genitalia and as pretreatment for infiltration anesthesia Cream: Apply 1 g/10 cm of skin for 15 min Minor procedures on the female external genitalia (eg, condylomata acuminata) as well as for use as pretreatment for anesthetic infiltration Cream: Apply 5-10 g for 5-10 min
Indications & Contraindications
- Indications
- Dermal Procedures,Topical Anesthetic on Genital Mucous Membranes
- Contraindications
- infants under 1 year.
Cautions & Side Effects
- Cautions
- not for wound, mucous membrane, or atopic dermatitis; avoid use near eyes or middle ear.
- Side Effects
- transient paleness, redness and oedema.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excreted in breast milk; use not recommended
LINAGLIPTINE Tradjenta@
Antidiabetic Agent,Sulfonylurea
Pregnancy: safeLactation: avoid
LINAGLIPTINE Tradjenta@
Antidiabetic Agent,Sulfonylurea
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Unclassified
- Dosage form
- Tablet
Dosage Forms
Tablet
- 5mg tab
Dosing & Formulations
- Dose
- 5 mg orally daily; dose adjustment not required in renal insufficiency or with concomitant drug therapy.
Indications & Contraindications
- Indications
- Type 2 diabetes mellitus
- Contraindications
- Severe hepatic and renal impairment and in porphyria
Cautions & Side Effects
- Cautions
- Do not use with strong inducers of CYP3A4 or p-glycoprotein
- Side Effects
- Gastro-intestinal disturbances such as nausea, vomiting, diarrhoea and Anxiety ,blurred vision ,chills ,cold sweats
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- The use of sulfonylureas in breast- feeding: should be avoided because there is a theoretical possibility of hypoglycaemia in the infant.
LINEZOLID,Zyvomax®
Antibiotic,Oxazolidinone
Pregnancy: cautionLactation: caution
LINEZOLID,Zyvomax®
Antibiotic,Oxazolidinone
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Suspension
Dosage Forms
Tablet
- 600 mgtablet and600 mg injection
Suspension
- 100mg/ml susp
Dosing & Formulations
- Dose
- Adult dose Oral, IV, 400–600 mg twice daily. Paediatric dose Oral, IV, 10 mg/kg 8-hourly.
Indications & Contraindications
- Indications
- Treatment of vancomycin-resistant Enterococcus faecium (VRE) infections, nosocomial pneumonia caused by Staphylococcus aureus including MRSA or Streptococcus pneumoniae (penicillin-susceptible strains only), compli- cated and uncomplicated skin and skin structure infections (including diabetic foot infections without concomitant osteomyelitis), and community-acquired pneumonia caused by susceptible gram-positive organisms.
Cautions & Side Effects
- Cautions
- Pregnancy; breastfeeding; contaminant maois; severe optic neuropathy may occur rarely, particularly if linezolid is used for longer than 28 days.
- Side Effects
- Diarrhoea; eosinophilia; headache; nausea; taste disturbances; vomiting, anaemia; antibiotic associated colitis.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Unknown; use caution
Liquid paraffin
Faecal softeners
Pregnancy: riskLactation: avoid
Liquid paraffin
Faecal softeners
- Therapeutic group
- Gastrointestinal System
- Storage
- Unclassified
- Dosage form
- Solution
Dosage Forms
Solution
- Solution
Other
- 30 ml per bottle
Indications & Contraindications
- Indications
- For the temporary relief of constipation.
- Contraindications
- Use is contraindicated in children under 3 years of age.
Cautions & Side Effects
- Cautions
- Avoid prolonged use
- Side Effects
- Anal seepage of paraffin with consequent anal irritation after prolonged use.
Pregnancy & Lactation
- Pregnancy
- Avoid during early pregnancy
- Lactation
- Avoid
LISINOPRIL,Zinopril®
Angiotensin-convertingenzyme(ace)inhibitor
Pregnancy: cautionLactation: avoid
LISINOPRIL,Zinopril®
Angiotensin-convertingenzyme(ace)inhibitor
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 10 mgtablet
Dosing & Formulations
- Dose
- For hypertension, used alone,initial 10 mg daily. Maintenance,10-20 mg daily. Maximum, 40 mg daily, reduce the dose if used in additionto diuretic. In heart failure as an adjunct therapy,initially 2.5 mg. Maintenance,5-20 mg daily. For prophylaxis after infarction, theb.p. is a determining factor for thedose regimen. Systolic b.p. over120mmhg, 5 mg daily for 3 daysand then 10 mg daily. Systolic b.p. 100-120mmhg, 2.5 mg daily increasedto 5 mg daily.
- Dose in Organ Failure
- Renal impairment Acute myocardial infarction: use caution in renal dysfunction (serum creatinine >2 mg/dl) Hypertension and crcl>30 ml/min: 10 mg po qday initially; not to exceed 40 mg/day Hypertension and crcl 10-30 ml/min: 5 mg po qday initially; not to exceed 40 mg/day Hypertension and crcl<10 ml/min or hemodialysis: 2.5 mg po qday initially; not to exceed 40 mg/day Heart failure and crcl<30 ml/min: 2.5 mg po qday initially; not to exceed 40 mg/day Children with gfr <30 ml/min/1.73 m: not recommended
Indications & Contraindications
- Indications
- Mild to moderate hypertension as an adjunct to thiazide therapy; severe hypertension resistant to other treatment; adjunct treatment in severe congestive heart failure.
- Contraindications
- Hypersensitivity, and in renovascular disease; pregnancy.
Cautions & Side Effects
- Side Effects
- Dry cough, hypersensitivity, pancreatitis, rhinitis, and sore throat, profound hypotension.
Pregnancy & Lactation
- Pregnancy
- C / D (2nd and 3rd trimesters)
- Lactation
- Not known if excreted into breast milk; not recommended
LOPERAMIDE,Imodium®
Antidiarrheal
Pregnancy: safeLactation: caution
LOPERAMIDE,Imodium®
Antidiarrheal
- Therapeutic group
- Gastrointestinal System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule
Dosage Forms
Capsule
- 2mgcapsule
Dosing & Formulations
- Dose
- Acute diarrhoea, 4 mg initially followed by 2 mg after each loose stool for up to 5 days, usual dose 6-8 mg daily, max. 16 mg daily, children under 4 years not recommended, Child, 4-8 years, 1 mg 3- 4 times daily for up to 3 days only, 9-12 years, 2 mg 4 times daily for up to 5 days. Chronic diarrhoea in adults, 4-8 mg daily in divided doses initially and then if necessary adjusted according to response and given twice daily for maintenance. Max. 16 mg daily.
Indications & Contraindications
- Indications
- Symptomatic treatment of acute diarrhea, adjunct to rehydration in acute and chronic diarrhoea in adults and in adults and in acute diarrho4ea in children over 4 years of age.
- Contraindications
- Children below 4 years. Diarrhoea of ulcerative colitis or antibiotic-associated colitis.
Cautions & Side Effects
- Cautions
- liver disease; pregnancy.
- Side Effects
- drowsiness, dizziness, fatigue, sedation, constipation, abdominal pain or discomfort, dry mouth, and nausea, rash, toxic epidermal necrolysis.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Not known if distributed in breast milk; use caution
LORATADINE,Claritin®
Non-sedatingantihistamine
Pregnancy: safeLactation: avoid
LORATADINE,Claritin®
Non-sedatingantihistamine
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Syrup
Dosage Forms
Tablet
- 10mgtablet
Syrup
- 5mg/5ml syrup
Dosing & Formulations
- Dose
- Adult and child over 6 years, 10mg once daily. Child 2-5 years, 5mg daily.
- Dose in Organ Failure
- Renal impairment (GFR <30 ml/min): 10 mg PO every other day Hepatic impairment: 10 mg PO every other day
Indications & Contraindications
- Indications
- Allergic rhinitis; chronic urticaria and other allergic dermatologic disorders. Symptomatic relief of allergy such as hay fever.
- Contraindications
- Sensitivity or idiosyncrasy reactions.
Cautions & Side Effects
- Cautions
- Children under 12 years of age; pregnancy; nursing mothers.
- Side Effects
- Adults: Headache,somnolence,fatigue,xerostomia Children: Nervousness, fatigue,malaise, pain,stomatitis,hyperkinesia,wheezing
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excreted in breast milk; avoid
Lorazepam
Benzodiazepine anticonvulsants
Pregnancy: riskLactation: caution
Lorazepam
Benzodiazepine anticonvulsants
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Powder · Solution
Dosage Forms
Other
- 0.5mg
- 1mg
- oral concentrate
Tablet
- 2mg (oral tablet
Solution
- injectable solution
- intravenous solution
Powder
- compounding powder)
Dosing & Formulations
- Dose
- One to six mg per day, given in divided doses
Indications & Contraindications
- Indications
- used to treatanxietydisorders
- Contraindications
- hypersensitivity to benzodiazepines or to any components of the formulation ,acute narrow-angle glaucoma.
Cautions & Side Effects
- Cautions
- You should not use lorazepam if you have narrow-angle glaucoma or myasthenia gravis, or if you are allergic to Valium or a similar medicine , Do not use lorazepam if you are pregnant, myasthenia gravis .
- Side Effects
- Drowsiness ,relaxed and calm ,sleepines
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Lorazepam has low levels in breastmilk, a short half-life relative to many other benzodiazepines, and is safely administered directly to infants. Evidence from nursing mothers indicates that lorazepam does not cause any adverse effects in breastfed infants with usual maternal dosages. No special precautions are required
LOSARTAN, Sortiva®
Angiotensin II Receptor Antagonist
Pregnancy: riskLactation: avoid
LOSARTAN, Sortiva®
Angiotensin II Receptor Antagonist
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 50mg tablet
Dosing & Formulations
- Dose
- Hypertension 50 mg/day po (25 mg/day in patients with possible intravascular depletion or receiving diuretics) Dosage range: 25-100 mg/day po in 1 or 2 daily doses Pedia: ≥6 years: 0.7 mg/kg/day (up to 50 mg/day) po initially; not to exceed 1.4 mg/kg/day (or 100 mg/day) Diabetes Type 2 diabetes and hypertension: 50-100 mg po qday
Indications & Contraindications
- Indications
- Hypertension; myocardial infarction with left ventricular failure or left ventricular systolic dysfunction.
- Contraindications
- Severe hepatic impairment, cirrhosis, biliary obstruction, breastfeeding.
Cautions & Side Effects
- Side Effects
- Fatigue, rarely diarrhea, headache, epistaxis; thrombocytopenia, arthralgia, myalgia, taste disturbance, neutropenia & rash.
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Unknown if excreted in milk; not recommended
MAGNESIUMSULPHATE
Anticonvulsant,Electrolytesupplement
Pregnancy: safeLactation: compatible
MAGNESIUMSULPHATE
Anticonvulsant,Electrolytesupplement
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Unclassified
- Dosage form
- Injection
Dosage Forms
Injection
- 10% injection
Dosing & Formulations
- Dose
- Hypomagnesemia: Children: I.V., I.O.: 25-50 mg/kg/dose over 10-20 minutes (faster in cardiac arrest); maximum single dose: 2000 mg Adults: -Mild deficiency: I.M.: 1 g every 6 hours for 4 doses, or as indicated by serum magnesium levels -Severe deficiency: I.M.: Up to 250 mg/kg within a 4-hour period I.V.: Severe, nonlife-threatening: 1-2 g/hour for 3-6 hours then 0.5-1 g/hour as needed to correct deficiency -Symptomatic deficiency: I.V.: 1-2 g over 5-60 minutes; maintenance infusion may be required to correct deficiency (0.5-1 g/hour). Arrhythmia, hypomagnesemia-induced (life-threatening): 1-2 g over 5-20 Minutes (torsades with cardiac arrest) or over 5-60 minutes (symptomatic arrhythmias without cardiac arrest) Seizures, hypomagnesemia-induced: I.V.: 2 g over 10 minutes; calcium ad- Ministration may also be appropriate as many patients are also hypocalce- mic. Eclampsia: Adults: I.V.: 4-5 g infusion; followed by a 1-2 g/hour continous infusion; or may follow with I.M. doses of 4-5 g in each buttock every 4 hours. Note: Initial infusion may be given over 3-4 minutes if eclampsia is severe; maximum: 40 g/24 hours Pre-eclampsia (severe): Adults: I.V. 4-5 g infusion; followed by a 1-2 g/hour continous infusion; or may follow with I.M. doses of 4-5 g in each buttock Every 4 hours; maximum: 40 g/24 hour Torsade de pointes: Adults: I.V.: -Pulseless: 1-2 g over 5-20 minutes -With pulse: 1-2 g over 5-60 minutes. Note: Slower administration preferable for stable patients. Parenteral nutrition supplementation: I.V.: Children: <50 kg: 0.3-0.5 meq elemental magnesium/kg/day >50 kg: 10-30 meq elemental magnesium/day Adults: 8-24 meq elemental magnesium/day Soaking aid: Topical: Adults: Dissolve 2 cupfuls of powder per gallon of warm water
- Dose in Organ Failure
- Severe renal impairment: Do not exceed 20 g/48 hr
Indications & Contraindications
- Indications
- Treatment and prevention of hypomagnesemia; seizure prevention in severe pre-eclampsia or eclampsia, pediatric acute nephritis; short-term treatment torsade de pointes; treatment of cardiac arrhythmias (VT/VF) caused by hy- pomagnesemia; short-term treatment of constipation or soaking aid
Cautions & Side Effects
- Side Effects
- Hypotension and asystole may occur with rapid administration Serum magnesium levels >3 mg/dl: depressed CNS, diarrhea, blocked pe- Ripheral neuromuscular transmission leading to anticonvulsant effects Serum magnesium levels >5 mg/dl: Flushing, Somnolence Serum magnesium levels >12.5 mg/dl: Complete heart block, cardiac arrest affected
Pregnancy & Lactation
- Pregnancy
- A / C (manufacturer dependent)
- Lactation
- Safe
MEBENDAZOLE ,antiox®
Anthelmintics
Pregnancy: cautionLactation: caution
MEBENDAZOLE ,antiox®
Anthelmintics
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Suspension
Dosage Forms
Tablet
- 100 mgtablet
Suspension
- 100mg/5mlsuspension
Dosing & Formulations
- Dose
- Children and adults: oral: Pinworms: 100mg as a single dose; may need to repeat after 2 weeks; treat- ment should include any family members in close contact with patient whipworms, roundworms, hookworms: 1 tablet twice daily, morning and evening on 3 consecutive days; if patient is not cured within 3-4 weeks, a second course of treatment may be administered. Capillariasis: 200mg twice daily for 20 days
Indications & Contraindications
- Indications
- Treatment of pinworms (enterobius vermicularis), whipworms (trichuris tri- chiura), roundworms (ascaris lumbricoides), and hookworms.
Cautions & Side Effects
- Cautions
- Pregnancy and breastfeeding, avoid in children under 2 years
- Side Effects
- Very rare due to low systemic bioavailability. Abdominal pain.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excretion in breast milk unknown; use caution
MEBEVERINE, Duspatalin-Retard®
Antispasmodic
Pregnancy: riskLactation: avoid
MEBEVERINE, Duspatalin-Retard®
Antispasmodic
- Therapeutic group
- Gastrointestinal System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 200 mg SR tablet
- 135mg tablet
Dosing & Formulations
- Dose
- ADULT and CHILD over 10 years 135–150 mg 3 times daily preferably 20 minutes before meals.
Indications & Contraindications
- Indications
- Symptomatic treatment of abdominal pain and cramps, bowel disturbances and intestinal discomf or trelated to irritable bowel syndrome.
- Contraindications
- Paralytic ileus
Cautions & Side Effects
- Cautions
- Avoid in paralytic ileus, pregnancy, breast-feeding, porphyria.
- Side Effects
- Allergic reactions (including rash, urticaria, angioedema) reported.
Pregnancy & Lactation
- Pregnancy
- Not known to be harmful (manufacturers advise avoid)
- Lactation
- Manufacturers advise avoid (no information available)
MECLOZINE + VITAMIN B6
Antinauseant & antiemetic
Pregnancy: ---Lactation: caution
MECLOZINE + VITAMIN B6
Antinauseant & antiemetic
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Other
- 25mg
Tablet
- 50mg tablet
Dosing & Formulations
- Dose
- Nausea and vomiting of pregnancy one tablet at bedtime and one tablet in the morning
Indications & Contraindications
- Indications
- Nausea and vomiting of pregnancy, prophylaxis and treatment of Nausea, vomiting and dizziness associated with motion sickness, management of vertigo associated with diseases affecting the vestibular system .
Cautions & Side Effects
- Cautions
- Parkinson diseased patient who are levodopa should consult their doctor, bladder neck obstruction, impaired liver function
- Side Effects
- Drowsiness, blurred vision, dryness of mouth, nose and throat
Pregnancy & Lactation
- Pregnancy
- ---
- Lactation
- Not known whether drug crosses into breast milk
MELOXICAM, Mobic®
NSAIDS
Pregnancy: ---Lactation: see details
MELOXICAM, Mobic®
NSAIDS
- Therapeutic group
- Musculoskeletal & Joint Diseases
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 7.5 / 15 mg tablet
Dosing & Formulations
- Dose
- Initial dose: 7.5 mg orally once a day -Maintenance dose: 15 mg orally once a day in patients requiring additional analgesia -Maximum dose: 15 mg orally once a day
Indications & Contraindications
- Indications
- Meloxicam is used to treat pain or inflammation caused byrheumatoid arthritisandosteoarthritisin adults.Meloxicam is also used to treat juvenile rheumatoid arthritis in children who are at least 2 years old.
- Contraindications
- Acute or severe bronchial asthma ,Hepatic impairment ,Hypercarbia ,Hypersensitivity ,Hypersensitivity to codeine ,Paralytic ileus
Cautions & Side Effects
- Cautions
- caution if renal impairment ,caution if hepatic impairment ,caution if asthma ,caution if recent MI
- Side Effects
- Diarrhea ,Gas ,heartburn, indigestion
Pregnancy & Lactation
- Pregnancy
- ---
- Lactation
- Relevant published information was not found as of the revision date.
MEROPENEM,Meronem®
Antibiotic,Carbapenem
Pregnancy: safeLactation: caution
MEROPENEM,Meronem®
Antibiotic,Carbapenem
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Other
- 500 mg
Injection
- 1ginjection
Dosing & Formulations
- Dose
- Usual dosage range: Neonates:I.V. Postnatal age 0-7 days: 20mg/kg/dose every 12 hours Postnatal age>7 days: -W eight 1200-2000g: 20mg/kg/dose every 12 hours -W eight > 2000g: 20mg/kg/dose every 8 hours Full-term (<3 months ): 20mg/kg/dose every 8 hours (may be increased to 40mg/kg/dose if treating a highly resistant organism such as Pseudomonas aeruginosa) Children >3 months (<50kg): I.V. 60mg/kg/day divided every 8 hours (maximum dose:6g/day) Adults: 1.5-6 g/day divided every 8 hours Elderly: No difference in safety or efficacy have been reported. However, Increased sensitivity may occur in some elderly patients, adjust dose based on renal functions. Indication-Specific dosing: Children >3 months (<50kg): *Intra-abdominal infections: 20mg/kg every 8 hours (maximum dose 1 g every 8 hours) *Meningitis: 40mg/kg every 8 hours (maximum 2g every 8 hours) Children >50kg & Adults: *Cholangitis, Intra-abdominal infections, otitis externa, septic lateral sinus Thrombosis: 1g every 8 hours *Liver abscess: 1g every 8 hours for 2-3 week, then oral therapy for duration of 4-6 weeks. *Meningitis: 2 g every 8 hours
- Dose in Organ Failure
- Renal impairment Crcl>50 ml/min: 0.5-1 g IV q8hr Crcl 26-50 ml/min: 0.5-1 g IV q12hr Crcl 10-25 ml/min: 0.25-0.5 g IV q12hr Crcl<10 ml/min: 0.25-0.5 g IV q24hr
Indications & Contraindications
- Indications
- Intra-abdominal infections; also indicated for bacterial meningitis in pediatric patients >3 months of age caused by S. Pneumoniae, H. Influenzae, and N. Meningitidis; treatment of complicated skin & skin structure infections caused by susceptible organism
- Contraindications
- Hypersensitivity to meropenem; and beta-lactam antibiotics.
Cautions & Side Effects
- Cautions
- Hepatic and renal impairment; pregnancy and breast-feeding.
- Side Effects
- Headache, nausea, vomiting, abdominal pain, diarrhoea; liver function test abnormalities; hypersensitivity reactions.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Unknown whether drug is excreted in breast milk; use with caution
METFORMIN, Glucophage®
Antidiabeticagent,Biguanide
Pregnancy: safeLactation: avoid
METFORMIN, Glucophage®
Antidiabeticagent,Biguanide
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 500 mg tablet
- 750mg XR tablet
Dosing & Formulations
- Dose
- Initially, 500 mg with breakfast for 1 week, then 500 mg with breakfast and dinner for 1 week, then 500 mg three times daily with meals. Maximum 3g daily in divided doses.
- Dose in Organ Failure
- Hepatic impairment: Avoid use; risk of lactic acidosis Renal impairment Males: Contraindicated if serum creatinine ≥1.5 mg/dl Females: Contraindicated if serum creatinine ≥1.4 mg/dl
Indications & Contraindications
- Indications
- Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as monotherapy when hyperglycemia cannot be managed on diet alone. May be used concomitantly with a sulfonylurea or insulin to improve glycemic control.
- Contraindications
- Severe hepatic or renal impairment, ketoacidosis, heart failure.
Cautions & Side Effects
- Side Effects
- Gastro-intestinal disturbances, such as anorexia, nausea, vomiting, diarrhoea, metallic taste, decreased vitamin B12 absorption.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Enters breast milk; not recommended
METHOTREXATE
Antineoplasticagent,Antimetabolite
Pregnancy: riskLactation: avoid
METHOTREXATE
Antineoplasticagent,Antimetabolite
- Therapeutic group
- Malignant Disease & Immunosuppression
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 2.5 mgtablet
Dosing & Formulations
- Dose
- Adult dose Oral/IM/IV, 10 mg three times daily. Maximum dose 0.5 mg/kg daily. Paediatric dose Oral/IM/IV, 0.15 mg/kg three times daily. Maximum dose 0.5 mg/kg daily.
- Dose in Organ Failure
- Renal Impairment Crcl 10-50 ml/min: 50% of dose at normal dosing interval Crcl<10 ml/min: Avoid use Intermittent hemodialysis: 50% of dose at normal dosing interval Continuous renal replacement therapy: 50% of dose at normal dosing interval Hepatic Impairment: Bilirubin 3.1-5.0 mg/dl or AST > 3 times ULN: Give 75% of dose Bilirubin >5.0 mg/dl: Avoid use
Indications & Contraindications
- Indications
- Treatment of trophoblastic neoplasms; leukemias; psoriasis; rheumatoid arthritis, including polyarticular-course juvenile rheumatoid arthritis; breast, head and neck, and lung carcinomas; osteosarcoma; soft-tissue sarcomas; carcinoma of gastroin- testinal tract, esophagus, testes; lymphomas
- Contraindications
- Sever renalimpairment, sever hepatic impairment.
Cautions & Side Effects
- Cautions
- Avoid in pleural effusionor ascites. Administer folinic acidto prevent methotrexate inducedmucositis or myelosuppression.
- Side Effects
- -Vasculitis, acute reaction manifested as severe headache, nuchal rigidity, vomit- ing, and fever -Subacute toxicity: motor paralysis of extremities, cranial nerve palsy, seizures, or coma. -Endocrine: Hyperuricemia, defective oogenesis or spermatogenesis -Gastrointestinal: Ulcerative stomatitis, glossitis, gingivitis, nausea, vomiting, diar- rhea, anorexia, intestinal perforation, mucositis -Renal: Renal failure, azotemia, nephropathy -Respiratory: Pharyngitis
Pregnancy & Lactation
- Pregnancy
- X
- Lactation
- Drug excreted in breast milk; do not nurse
METHYLDOPA, Aldomet®
Central antihypertensive drug
Pregnancy: safeLactation: compatible
METHYLDOPA, Aldomet®
Central antihypertensive drug
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 250 mg tablet
Dosing & Formulations
- Dose
- By mouth, 250 mg 3 times daily gradually increased; max. Dose 3 g daily; in elderly, 125 mg 2 times daily increased to max. Of 2 gm daily.
- Dose in Organ Failure
- Adjust dosage frequency with renal impairment Crcl>50 ml/min: q8hr Crcl 10-50 ml/min: q8-12hr Crcl<10 ml/min: q12-24hr
Indications & Contraindications
- Indications
- Moderate to severe hypertension in conjunction with a diuretic; pregnancy-induced hypertension.
- Contraindications
- History of depression; liver disease, phaeochromocytoma, porphyria
Cautions & Side Effects
- Side Effects
- Gastrointestinal disturbances; dry mouth; stomatitis, sialdenitis, bradycardia, exacerbation of angina, postural hypotension, edema, sedation, depression, dizziness
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Distributed in breast milk but not in clinically significant amounts; compatible w/ breastfeeding
METHYLPREDNISOLONE,Depo-Medrol®, Solu-Medrol®
Corticosteroid,Systemic
Pregnancy: cautionLactation: caution
METHYLPREDNISOLONE,Depo-Medrol®, Solu-Medrol®
Corticosteroid,Systemic
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Other
- 40mg
Injection
- 500 mginjection
Dosing & Formulations
- Dose
- Children: Anti-inflammatory or immunosuppressive: Oral, I.M., I.V. (sodium succinate): 0.5- 1.7 mg/kg/day or 5-25 mg/m2/day in divided doses every 6-12 hours; Pulse ther- apy: 15-30 mg/kg/dose over ≥30 minutes given once daily for 3 days. Acute spinal cord injury: I.V. (sodium succinate): 30 mg/kg over 15 minutes, fol- lowed in 45 minutes by a continuous infusion of 5.4 mg/kg/hour for 23 hours Adults: Acute spinal cord injury: I.V. (sodium succinate): 30 mg/kg over 15 minutes, fol- lowed in 45 minutes by a continuous infusion of 5.4 mg/kg/hour for 23 hours Anti-inflammatory or immunosuppressive: -Oral: 2-60 mg/day in 1-4 divided doses to start, followed by gradual reduction in dosage to the lowest possible level consistent with maintaining an adequate clini- cal response. -I.M. (sodium succinate): 10-80 mg/day once daily -I.M. (acetate): 10-80 mg every 1-2 weeks -I.V. (sodium succinate): 10-40 mg over a period of several minutes and repeated I.V. or I.M. at intervals depending on clinical response; when high dosages are needed, give 30 mg/kg over a period ≥30 minutes and may be repeated every 4-6 hours for 48 hours.
Indications & Contraindications
- Indications
- Suppression of inflammatory and allergic disorders; cerebral oedema associated with malignancy; rheumatic disease.
- Contraindications
- Systemic infection; avoid live virus vaccines in those receiving immunosuppressive doses (serum antibody response diminished).
Cautions & Side Effects
- Cautions
- Pregnancy and breast-feeding. Adrenal suppression and infection, children and adolescents (growth retardation possibly irreversible), elderly (use with supervision particularly on long-term treatment)
- Side Effects
- Gastro-intestinal effects include dyspepsia, peptic ulceration (with perforation), abdominal distension, acute pancreatitis, oesophageal ulceration and candidiasis, Also rapid intravenous administration may cause cardiovascular collapse.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug enters milk; use with caution
METOCLOPRAMIDE, Plasil®,Premosan®
Antiemetic
Pregnancy: safeLactation: compatible
METOCLOPRAMIDE, Plasil®,Premosan®
Antiemetic
- Therapeutic group
- Gastrointestinal System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Syrup
Dosage Forms
Tablet
- 10mg tablet
Syrup
- 5mg/5ml syrup
Injection
- 10mg injection
Dosing & Formulations
- Dose
- Children: Gastroesophageal reflux: Oral:0.1-0.2mg/kg/dose4times/day Post pyloric feeding tube placement: I.V. <6years:0.1mg/kg 6-14years:2.5-5mg >14years: refer to adult dosing Adults: Gastroesophageal reflux: Oral:10-15mg/dose upto 4times/day30 minutes Before meals and at bedtime; single doses of 20mg are occasionally needed for provoking situations. Treatment >12weeks has not been evaluated Post operative nausea and vomiting: I.M., I.V. 10-20mg near end of surgery Post-pyloric feeding tube placement, radiological exam:I.V.:10mg
- Dose in Organ Failure
- Renal impairment crcl<40 ml/min, decrease dose by 50%; crcl<10 ml/min, decrease dose by 75%.
Indications & Contraindications
- Indications
- Nausea and vomiting particularly in gastro intestinal disorders, during treatment with cytotoxic drugs or radiotherapy, and post-operative conditions; migraine.
- Contraindications
- Gastro-intestinal obstruction, perforation or haemorrhage; 3–4 days after gastro- intestinal surgery; phaeochromocytoma; breast-feeding.
Cautions & Side Effects
- Cautions
- Renal impairment, elderly, young adults and children (measure dose accurately); may mask underlying cause such as cerebral irritation; porphyria.
- Side Effects
- Extrapyramidal effects (especially in children and young adults), hyperprolactinaemia, occasionally tardive dyskinesia on prolonged administration; drowsiness, restlessness, diarrhoea, depression, neuroleptic malignant syndrome, rashes, pruritus, oedema
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- May be used short term (up to 10–14 days) in doses up to 45 mg daily. Excreted in breast milk and may accumulate. May be used to promote lactation.
Metoprolol,lopressor®
Betablocker,beta1selective
Pregnancy: cautionLactation: caution
Metoprolol,lopressor®
Betablocker,beta1selective
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 50mgtablet
Dosing & Formulations
- Dose
- By mouth, hypertension, initially 100 mg daily, increased if necessary to 200 mg daily in 1–2 divided doses; max. 400 mg daily (but high doses rarely necessary). Angina, 50–100 mg 2–3 times daily arrhythmias, usually 50 mg 2–3 times daily; up to 300 mg daily in divided doses if necessary. Migraine prophylaxis, 100–200 mg daily in divided doses hyperthyroidism (adjunct), 50 mg 4 times daily.
- Dose in Organ Failure
- Hepatic impairment: reduce oral dose. Renal impairment: manufacturer advises caution—dose reduction may be required.
Indications & Contraindications
- Indications
- Hypertension, prophylaxis of variceal bleeding in portal hypertension, phaeochromocytoma, angina, arrhythmias, hypertrophic cardiomyopathy, anxiety tachycardia, and thyrotoxicosis (adjunct), anxiety with symptoms such as palpitation, sweating, tremor, prophylaxis after myocardial infarction, essential tremor, migraine prophylaxis, arrhythmias and thyrotoxic crisis.
- Contraindications
- Uncontrolled heart failure, prinzmetal's angina, marked bradycardia, hypotension
Cautions & Side Effects
- Cautions
- Avoid abrupt withdrawal especially in ischaemic heart disease; first-degree av block; portal hypertension (risk of deterioration in liver function); diabetes
- Side Effects
- Gastro-intestinal disturbances; bradycardia, heart failure, hypotension, conduction disorders, peripheral vasoconstriction
Pregnancy & Lactation
- Pregnancy
- C (manufacturer); D (2nd and 3rd trimesters, expert analysis)
- Lactation
- Drug is concentrated in breast milk; use with caution
METRONIDAZOLE,Flagyl®
Antibiotic,Miscellaneous
Pregnancy: safeLactation: avoid
METRONIDAZOLE,Flagyl®
Antibiotic,Miscellaneous
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Suspension · Gel
Dosage Forms
Tablet
- 250&500mg tablet
Injection
- 500mginjection
Suspension
- 250mg/5mlsuspension
Gel
- gel 0.75%
Dosing & Formulations
- Dose
- Adult dose Oral, 200–400 mg every 8–12 hours, up to 4 g daily. Rectal, 1 g every 8–12 hours. Severe infections: IV, 500 mg every 8–12 hours. Maximum 4 g daily. Giardiasis: 2 g daily for three days. Paediatric dose Oral/IV, 7.5 mg/kg eight-hourly. Rectal, 1–5 years, 250 mg three times daily. 6–12 years, 500 mg three times daily.
Indications & Contraindications
- Indications
- Treatment of susceptible anaerobic bacterial and protozoal infections in the following conditions: Amebiasis, symptomatic and asymptomatic trichomoni- asis; skin and skin structure infections; CNS infections; intra-abdominal infec- tions (as part of combination regimen); systemic anaerobic infections; treat- ment of antibiotic-associated pseudomembranous colitis (AAPC), bacterial vaginosis; as part of a multidrug regimen for H. Pylori eradication to reduce the risk of duodenal ulcer recurrence.
Cautions & Side Effects
- Cautions
- Hepatic impairment and hepatic encephalopathy, pregnancy and breast-feeding.
- Side Effects
- Nausea and vomiting, unpleasant metallic taste, gastrointestinal disturbances, drowsiness and headache, darkening of urine, pruritus, urticaria.
Pregnancy & Lactation
- Pregnancy
- B (may be contraindicated in 1st trimester)
- Lactation
- Excreted in human milk; not recommended
MICONAZOLE
Antifungalagents
Pregnancy: cautionLactation: avoid
MICONAZOLE
Antifungalagents
- Therapeutic group
- Skin / Dermatological
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Gel
Dosage Forms
Gel
- 2% oral gel
Dosing & Formulations
- Dose
- Adult dose Half a measuring spoon four times a day. 6 months to 2 years: quarter of a measuring spoon four Times a day. >2 years: half a measuring spoon four times a day.
Indications & Contraindications
- Indications
- Treatmentof Oropharyngeal,oral candidosis
- Contraindications
- Substrates known to prolong the QT-interval, Ergot alkaloids, HMG-coa reductase inhibitors such as simvastatin and lovastatin, Triazolam and oral midazolam
Cautions & Side Effects
- Cautions
- Bleeding or bruising, nosebleeds, coughing up blood, blood in the urine, black tarry stools or coffee ground vomit, to stop treatment with miconazole and seek medical advice.
- Side Effects
- Rash or urticaria, severe irritation, reddening or blistering of your skin.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excretion in milk unknown; avoid use because of potential tumorigenicity
MICONAZOLE,Dermazole®, Daktarin®
Antifungal,Topical&Vaginal
Pregnancy: cautionLactation: caution
MICONAZOLE,Dermazole®, Daktarin®
Antifungal,Topical&Vaginal
- Therapeutic group
- Skin / Dermatological
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Cream · Gel · Suppository · Powder · Solution
Dosage Forms
Suppository
- Vaginalsuppositories 200 mg
Gel
- oral gel
Powder
- 2% powder
Solution
- 2% solution
Cream
- Miconazol 2%+ hydrocortison 1% cream
Dosing & Formulations
- Dose
- Topical: Children and Adults: Note: Not for OTC use in children <2 years: Tinea pedis and tinea corporis: Apply twice daily for 4 weeks Tinea cruris: Apply twice daily for 2 weeks Vaginal: Adults: Vulvovaginal candidiasis: Cream, 2%: Insert 1 applicatorful at bedtime for 7 days Cream, 4%: Insert 1 applicatorful at bedtime for 3 days Suppository, 100 mg: Insert 1 suppository at bedtime for 7 days Suppository, 200 mg: Insert 1 suppository at bedtime for 3 days Suppository, 1200 mg: Insert 1 suppository at bedtime (a one-time dose)
Indications & Contraindications
- Indications
- Treatmentofvulvovaginalcandidiasisandavarietyofskin andmucousmembranefungalinfections
Cautions & Side Effects
- Side Effects
- Topical: Allergic contact dermatitis, burning, maceration Vaginal: Abdominal cramps, burning, irritation, itching
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known whether distributed into milk; use caution
MICONAZOLE,Dermazole®, Daktarin®
Antifungal , Topical & Vaginal
Pregnancy: cautionLactation: caution
MICONAZOLE,Dermazole®, Daktarin®
Antifungal , Topical & Vaginal
- Therapeutic group
- Skin / Dermatological
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Cream · Gel · Suppository · Powder · Solution
Dosage Forms
Suppository
- Vaginal suppositories 200 mg
Gel
- oral gel
Powder
- 2% powder
Solution
- 2% solution
Cream
- Miconazol 2%+ hydrocortison 1% cream
Dosing & Formulations
- Dose
- Topical: Children and Adults: Note: Not for OTC use in children <2 years: Tinea pedis and tinea corporis: Apply twice daily for 4 weeks Tinea cruris: Apply twice daily for 2 weeks Vaginal: Adults: Vulvovaginal candidiasis: Cream, 2%: Insert 1 applicatorful at bedtime for 7 days Cream, 4%: Insert 1 applicatorful at bedtime for 3 days Suppository, 100 mg: Insert 1 suppository at bedtime for 7 days Suppository, 200 mg: Insert 1 suppository at bedtime for 3 days Suppository, 1200 mg: Insert 1 suppository at bedtime (a one-time dose)
Indications & Contraindications
- Indications
- Treatment of vulvovaginal candidiasis and a variety of skin and mucous mem- brane fungal infections
Cautions & Side Effects
- Cautions
- pregnancy and breast feeding
- Side Effects
- Topical: Allergic contact dermatitis, burning, maceration Vaginal: Abdominal cramps, burning, irritation, itching
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- not known whether distributed into milk; use caution
MIDAZOLAM,Dormicum®
Anxiolytic-sedative– hypnotic,Benzodiazepine
Pregnancy: riskLactation: caution
MIDAZOLAM,Dormicum®
Anxiolytic-sedative– hypnotic,Benzodiazepine
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 15 mg/3mlinjection
Dosing & Formulations
- Dose
- Sedation, by slow intravenous injection, 70-100 mcg/kg 30-60 minutes before surgery. Usual dose 5 mg (2.5 mg in elderly patients) Induction, by slow intravenous injection, 200-300 mcg/kg (elderly patients 100-200 mcg/kg).
Indications & Contraindications
- Indications
- Sedation with amnesia; sedation in intensive care; premedication, induction of anaesthesia; status epilepticus.
- Contraindications
- Marked neuromuscular respiratory weakness including unstable myasthenia gravis; severe respiratory depression; acute pulmonary insufficiency
Cautions & Side Effects
- Cautions
- Cardiac disease; respiratory disease; myasthenia gravis; children (particularly if cardiovascular impairment)
- Side Effects
- Gastro-intestinal disturbances, increased appetite, jaundice; hypotension, cardiac arrest, heart rate changes, anaphylaxis, thrombosis; laryngospasm, bronchospasm, respiratory depression and respiratory arrest.
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Distributed in breast milk, use caution
MIRTAZAPINE, Remeron®
Atypical antipsychotics
Pregnancy: cautionLactation: caution
MIRTAZAPINE, Remeron®
Atypical antipsychotics
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- Applies to the following strengths: 15 mg
- 30 mg
- 45 mg
- 7.5 mg
Dosing & Formulations
- Dose
- Initial dose: 15 mg orally once a day at bedtime Maintenance dose: 15 to 45 mg orally once a day Maximum dose: 45 mg/day
Indications & Contraindications
- Indications
- Used to treatmajor depressive disorder
- Contraindications
- Hypersensitivity, Monoamine Oxidase Inhibitors
Cautions & Side Effects
- Cautions
- Discontinuation Symptoms, Akathisia/Psychomotor Restlessness,Hyponatremia, Dizziness
- Side Effects
- Constipation, Dizziness, drowsiness, drymouth ,increased appetite ,weight gain
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Limited information indicates that maternal doses of up to 120 mg daily produce low levels in milk and would not be expected to cause any adverse effects in breastfed infants, especially if the infant is older than 2 months
MISOPROSTOL , Cytotic®
Prostaglandin
Pregnancy: riskLactation: caution
MISOPROSTOL , Cytotic®
Prostaglandin
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Room Temperature (15–25°C)
- Dosage form
- Tablet
Dosage Forms
Tablet
- 200mg tab
Dosing & Formulations
- Dose
- NSAID Induce ulcer Prophylaxis 200 mcg PO q6hr with food; may be decreased to 100 mcg q6hr if higher dose is not tolerated; last dose to be administered at bedtime Should take therapy for duration of therapy Pregnancy termination Administer 400 mcg PO once if abortion has not occur 3 days following mifepristone administration; refer to mifepristone monograph for complete therapy protocol
- Dose in Organ Failure
- Renal impairment: Use with caution; peak plasma concentration, half-life, andbioavailability may be increased, but it is not clear whether these increases are of clinical relevance
Indications & Contraindications
- Indications
- To induce medicalabortion, cervical ripening procedure,management of post partumhaemorrhage, prophylaxis fornsaid-induced gastric ulcer.
- Contraindications
- Pregnancy, severeasthma requiring corticosteroids,hepatic failure, adrenalfailure,bleeding disorders of concurrentanticoagulation therapy, allergy tomisoprostol
Cautions & Side Effects
- Cautions
- Conditions where hypotensionmight precipitate severecomplications (e.g. Cerebrovasculardisease, cardiovascular disease)
- Side Effects
- Abdominal pain, diarrhoea,indigestion, nausea, cardiacdysrhythmia, anaemia, vaginalbleeding, chills and fever.
Pregnancy & Lactation
- Pregnancy
- X
- Lactation
- Drug is rapidly metabolized in mother to misoprostol acid, which is biologically active and is excreted in breast milk; although no published reports of adverse effects of misoprostol in breast-feeding infants exist, caution should be exercised when misoprostol is administered to breastfeeding women
MOMETASONE , Gamavate®
Corticosteroid
Pregnancy: cautionLactation: caution
MOMETASONE , Gamavate®
Corticosteroid
- Therapeutic group
- Skin / Dermatological
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Cream · Ointment
Dosage Forms
Cream
- Ointment& cream
Dosing & Formulations
- Dose
- Topical: ≤12 years: Use is not recommended. ≥13 years: Apply once or twice daily Adults: Foam: Apply to the scalp twice daily, once in the morning and once at night Cream/ointment: Apply once or twice daily
Indications & Contraindications
- Indications
- Severe inflammatory skin disorderseczema,psoriasis,allergies, andrash.
- Contraindications
- Untreated bacterial, fungal or viral skin infections, acne vulgaris, rosacea.
Cautions & Side Effects
- Cautions
- Avoid prolonged use especially in children and infants; avoid prolonged use on the face
- Side Effects
- Burning,itching, or stinging
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known whether topical corticosteroid use could result in sufficient systemic absorption to produce detectable quantities in human milk; use with caution.
MONTELUKAST Singulair
LEUKOTRIENE RECEPTOR ANTAGONISTS
Pregnancy: riskLactation: avoid
MONTELUKAST Singulair
LEUKOTRIENE RECEPTOR ANTAGONISTS
- Therapeutic group
- Respiratory System
- Storage
- Unclassified
- Dosage form
- Tablet
Dosage Forms
Other
- 5 mg
Tablet
- 10 mg Tablet
Dosing & Formulations
- Dose
- Rophylaxis of asthma, ADULT and CHILD over 15 years, 10mg once daily in the evening; CHILD 6 months–6 years 4mg once daily in the evening, 6–15 years 5mg once daily in the evening. Seasonal allergic rhinitis, ADULT and CHILD over 15 years, 10mg once daily in the evening.
Indications & Contraindications
- Indications
- Prophylaxis of asthma, see notes above and Management of Chronic Asthma table, p. 180; symptomatic relief of seasonal allergic rhinitis in patients with asthma.
Cautions & Side Effects
- Cautions
- Pregnancy, breast-feeding.
- Side Effects
- Abdominal pain, thirst; hyperkinesia (in young children), headache, dry mouth, diarrhoea, dyspepsia, nausea, vomiting, hepatic disorders, palpitation.
Pregnancy & Lactation
- Pregnancy
- Manufacturer advises avoid unless essential,
- Lactation
- Manufacturer advises avoid unless essential.
MOXIFLOXACIN,Vigamox®, Avalox®
Antibiotic,Ophthalmic
Pregnancy: cautionLactation: avoid
MOXIFLOXACIN,Vigamox®, Avalox®
Antibiotic,Ophthalmic
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Solution
Dosage Forms
Solution
- 0.5%(3mL)ophthalmicsolution
Tablet
- 400mg inj& tablet
Dosing & Formulations
- Dose
- Ophthalmic:Children>1yearandAdults:Instill1dropintoaffectedeye(s)3 times/dayfor7days
Indications & Contraindications
- Indications
- Treatmentofbacterialconjunctivitis (ophthalmic formulation)
Cautions & Side Effects
- Cautions
- Not recommended forneonates
- Side Effects
- Dryeye,oculardiscomfort,ocular hyperemia,ocularpain,ocularpruritus,subconjunctivalhemorrhage,tearing,visualacuitydecreased
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Unknown if excreted in milk; discontinue drug, or do not nurse
MULTIVITAMIN,Mixavit®
Vitamins and Minerals
Pregnancy: safeLactation: compatible
MULTIVITAMIN,Mixavit®
Vitamins and Minerals
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Syrup
Dosage Forms
Tablet
- -Tablet (each film-coated tablet contains: Thiamine mononitrate 2mg
Other
- Riboflavine 1mg
- Ascorbic acid 20 mg
- Nicotinamide 15 mg
- Vitamin A (Palmitate) 3000 unit & Vitamin D3
- 300 unit)
- Vitamin D3
- 500 unit
- Vitamin B1 5 mg
- Vitamin B2 2 mg
- Vitamin B6 6 mg
- Nicotinamide 20 mg &
- Vitamin C 50 mg)
- Retinol (Vitamin A) 3500 IU
- Cholecalciferol (Vitamin D3) 200 IU
- DL a-tocopherol
- 10.2 mg
- corresponding to a-tocopherol (Vitamin E) 11.2 IU
- Ascorbic Acid
- (Vitamin C) 125 mg
- Nicotinamide (Vitamin B3) 46 mg
- Dexpanthenol 16.15 mg
- corresponding to pantothenic acid (Vitamin B 5) 17.25 mg
- Pyridoxine hydrochloride
- 5.5 mg
- corresponding to pyridoxine (Vitamin B6) 4.53 mg
- Riboflavin sodium phos-
- Phate 5.67 mg
- corresponding to riboflavin (Vitamin B2) 4.14 mg
- Cocarboxylase tetrahydrate 5.8 mg
- corresponding to thiamine (Vitamin B1) 3.51 mg
- Folic Acid
- 414 mcg
- D-Biotin 60 mcg
- Cyanocobalamin (Vitamin B12) 5.5 mcg
- Glycine 250 mg
- Glycocholic acid140 mg & Soybean lecithin112.5 mg)
Syrup
- -100 ml Syrup for pediatric & adult (each 5 ml contain: Vitamin A 4250 unit
Injection
- -Vial for adult & children over 11 years of age (each vial contain: corresponding to
Dosing & Formulations
- Dose
- -Tablet: one tablet three times daily -Syrup: Adult: 5 ml twice daily, Children: 2-4 years of age: 2.5 ml once daily, >4 years of age: 5 ml once daily -Injection: one vial/ day (5ml).
Indications & Contraindications
- Indications
- Deficiency states; neurological disorders influenced by B-complex vitamin deficiency.
Pregnancy & Lactation
- Pregnancy
- B(Syrup& tablet),C (Injection)
- Lactation
- Safe
MUPIROCIN,Bacteroban®
Antibacterial ,topical
Pregnancy: safeLactation: see details
MUPIROCIN,Bacteroban®
Antibacterial ,topical
- Therapeutic group
- Skin / Dermatological
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 2% nasal oint
Dosing & Formulations
- Dose
- Impetigo Apply 2% ointment to affected area q8hr If no response in 3-5 days, reevaluate Secondary Skin Infection Apply cream to affected area q8hr x10 days If no response in 3-5 days, reevaluate Elimination of MRSA Colonization Intranasal: Apply 1/2 tube in nostril q12hr x5 days
Indications & Contraindications
- Indications
- Impetigo ,Secondary Skin Infection, Elimination of MRSA Colonization.
Cautions & Side Effects
- Side Effects
- Headache, Nausea, Burning, Stinging, Pain, Pruritus, Rash, Cellulitis, Dry skin, Erythema,Incr exudate, Pain or bleeding secondary to eczema, Secondary wound infection, Swelling, Tenderness, Urticaria
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Not known if distributed into milk; recommended that nursing be temporarily discontinued during therapy
NALOXONE, Narcan®
Antidote
Pregnancy: cautionLactation: caution
NALOXONE, Narcan®
Antidote
- Therapeutic group
- Antidotes & Toxicology
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Other
- 0.02 mg/mL
Injection
- 0.4mg/mLinjection
Dosing & Formulations
- Dose
- Opiateintoxication: Birth(includingprematureinfants)to5yearsor<20kg:0.1mg/kg;repeatevery2- 3minutesifneeded;mayneedtorepeatdosesevery20-60minutes >5yearsor≥20kg:2 mg/dose;ifnoresponse,repeatevery 2-3 minutes; mayneed torepeatdosesevery20-60minutes Childrenand Adults: Continuousinfusion:I.V.: Ifcontinuousinfusion isrequired,calculatedosage/hourbasedoneffectiveintermittentdose usedand durationof adequateresponse seen, titratedose0.04-0.16 mg/kg/hourfor 2-5 daysin chil- dren,adultdosetypically0.25-6.25 mg/hour(short-terminfusionsashigh as2.4mg/kg/hour havebeentoleratedinadultsduringtreatment forsepticshock);alter-natively,continuousinfusion utilizes2 /3oftheinitialnaloxonebolusonanhourlybasis;add 10 timesthisdoseto eachliterofD5Wandinfuse atarateof 100mL/hour;1 /2 oftheinitialbolusdoseshouldbereadministered15 minutesafterinitia- tionofthecontinuousinfusion topreventadropinnaloxone levels;increaseinfu- sion rateasneededto assure adequate ventilation Narcoticoverdose:Adults:I.V.:0.4-2 mgevery 2-3 minutesasneeded;mayneedtorepeatdosesevery20-60 minutes,ifnoresponseisobservedafter10mg.
Indications & Contraindications
- Indications
- Complete or partialreversalofopioiddepression,includingrespiratorydepression,inducedbynaturalandsynthetic opioids,includingpropoxyphene,methadone, andcertain mixedagonist-antagonist analgesics:nalbuphine, pentazocine, and butorphanol,adjunctiveagenttoincreasebloodpressureinthemanagementofsepticshock
Cautions & Side Effects
- Cautions
- opioid physical dependence, cardiac disease.
- Side Effects
- precipitation of withdrawal syndrome.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known if distributed in milk; use caution
NAPHAZOLINE + CHLORPHENIRAMINE, Riazolin®
Eye allergy
Pregnancy: cautionLactation: see details
NAPHAZOLINE + CHLORPHENIRAMINE, Riazolin®
Eye allergy
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Unclassified
- Dosage form
- Unclassified
Dosage Forms
Other
- 0.056mg + 0.01mg
Dosing & Formulations
- Dose
- ------
Indications & Contraindications
- Indications
- Naphazoline Is Used In Eye Preparations To Relieve Redness, Puffiness, And Itchy/Watering Eyes Due To Colds, Allergies, Or Eye Irritations.
- Contraindications
- Narrow-Angle Glaucoma
Cautions & Side Effects
- Cautions
- Pregnancy and Lactation. Not Recommended In Infants And Young Children. Chronic Asthma, Hypertension, Heart Failure, Coronary Artery Disease, Cerebral Arteriosclerosis, DM, Hyperthyroidism, Local Infection or Injury, Benign Prostatic Hyperplasia. Rebound Hyperaemia May Occur on Prolonged Use (Ophthalmic)
- Side Effects
- Hyperglycaemia; Nausea; Nasal Mucosa Irritation, Dryness, Rebound Congestion; Weakness; Blurred Vision, Discomfort, Increased Intraocular Pressure, Irritation, Lacrimation, Mydriasis, Punctuate Keratitis, Redness; Sneezing; Diaphoresis
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- ------
NAPROXENNopain
NSAID
Pregnancy: not in sourceLactation: not in source
NAPROXENNopain
NSAID
- Therapeutic group
- Musculoskeletal & Joint Diseases
- Storage
- Unclassified
- Dosage form
- Tablet
Dosage Forms
Tablet
- 250mg tablet
Dosing & Formulations
- Dose
- by mouth, 0.5-1 g daily in 2 divided doses; Child (over 5 years), Still's disease, 10mg/kg daily in 2 divided doses. Acute musculoskeletal disorders and dysmenorrhoea, 500mg initially, then 250mg every 6-8 hours as required. Acute gout, 750mg initially, then 250mg every 8 hours until attack has passed.
Indications & Contraindications
- Indications
- pain and inflammation in rheumatic disease (including Still's disease) and other musculoskeletal disorders; acute gout; dysmenorrhoea.
- Contraindications
- patient with hypersensitivity to Aspirin or other NSAIDs, pregnancy, breast feeding and patients with coagulase defects, severe heart failure.
Cautions & Side Effects
- Cautions
- n patients with renal, cardiac, or hepatic impairment caution is required since NSAIDs may impair renal function.
- Side Effects
- Gastro-intestinal discomfort, nausea, diarrhoea, and occasionally bleeding and ulceration occur; hypersensitivity reactions (particularly rashes, angioedema, and bronchospasm
NEOSTIGMINE,Prostigmine®
AcetylcholinesteraseInhibitor
Pregnancy: cautionLactation: caution
NEOSTIGMINE,Prostigmine®
AcetylcholinesteraseInhibitor
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 0.5mg/mlinjection
Dosing & Formulations
- Dose
- Myasthenia gravis: Diagnosis: IM.: Children: 0.04mg/kg as a single dose Adults: 0.02 mg/kg as a single dose Myasthenia gravis: treatment: Children: Oral: 2 mg/kg/day divided every 3-4 hours IM., IV., SubQ.,: 0.01-0.04 mg/kg every 2-4 hours Adults: Oral: 15mg/dose every 3-4 hours up to 375mg/day maximum IM., IV.,SubQ.,: 0.5-2.5 mg every 1-3 hours up to 10mg/24 hours maximum Reversal of nondepolarizing neuromuscular blockade after surgery in con- junction with Atropine. IV.: Infants: 0.025-0.1 mg/kg/dose Children: 0.025-0.08 mg/kg/dose Adults: 0.5-2.5mg; total dose not to exceed 5mg Bladder atony: Adults: IM., SubQ., -Prevention: 0.25mg every 4-6 hours for 2-3 days -Treatment: 0.5-1 mg every 3 hours for 5 doses after bladder has emptied.
Indications & Contraindications
- Indications
- Diagnosis and treatment of myasthenia gravis; prevention and treatment of postoperative bladder distention and urinary retention; reversal of the effects of nondepolarizing neuromuscular-blocking agents after surgery
- Contraindications
- intestinal orurinary obstruction.
Cautions & Side Effects
- Cautions
- asthma, bradycardia, hypotension,epilepsy, peptic ulceration,pregnancy and breast feeding.
- Side Effects
- muscarinic effectssuch as excessive salivation, gastrointestinaldiscomfort, bronchial secretion,miosis.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Unknown if distributed in human breast milk; use caution
NITROFURANTOIN,Macrodantin®
Antibiotic,Miscellaneous
Pregnancy: safeLactation: avoid
NITROFURANTOIN,Macrodantin®
Antibiotic,Miscellaneous
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 100mgtablet
Dosing & Formulations
- Dose
- Oral: Children >1 month: 5-7 mg/kg/day in divided doses every 6 hours; maxi- mum: 400 mg/day UTI prophylaxis (Chronic): 1-2 mg/kg/day in divided doses every 12-24 hours; Maximum dose: 100 mg/day Adults: 50-100 mg/dose every 6 hours for 7 days Macrocrystal/monohydrate: 100 mg twice daily UTI prophylaxis (Chronic): 50-100 mg/dose at bedtime
Indications & Contraindications
- Indications
- Prevention and treatment of urinary tract infections caused by susceptible gram - negative and some gram-positive organisms; Pseudomonas, Serratia, and most species of Proteus are generally resistant to nitrofurantoin
- Contraindications
- Impaired renalfunction; infants less than 3months of age.
Cautions & Side Effects
- Cautions
- Anaemia, diabetes mellitus,pulmonary disease, hepatic impairment.
- Side Effects
- Gastrointestinal disturbances;pulmonary reactions, peripheralneuropathy, blood disorders,skin reactions.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Enters breast milk; discontinue drug or do not nurse
NORETHISTERONE,PrimulotN®
Progestin
Pregnancy: riskLactation: not in source
NORETHISTERONE,PrimulotN®
Progestin
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 5mg tablet
Dosing & Formulations
- Dose
- Endometriosis, 10 mg daily starting on 5th day of cycle (increased if spotting occurs to 25 mg daily in divided doses to prevent breakthrough bleeding) for at least 6 months. Dysfunctional uterine bleeding, menorrhagia, 5 mg 3 times daily for 10 days to arrest bleeding; to prevent bleeding, 5 mg twice daily from 19th to 26th day of cycle. Dysmenorrhea, 5 mg 3 times daily from 5th to 25th day for 3-4 cycles. Premenstrual syndrome, 5 mg 2-3 times daily from 19th to 26th day for several cycles (not recommended since there is no physiologic basis for such treatment). Postponement of menstruation, 5 mg 3 times daily starting 3 days before anticipated onset (menstruation occurs 2-3 days after stopping).
Indications & Contraindications
- Indications
- Endometriosis, premenstrual syndrome, dysmenorrhoea, dysfunctional uterine bleeding, postponement of menstruation, contraception, HRT, malignant diseases.
- Contraindications
- History of liver tumours; severe liver impairment; genital or breast cancer; severe arterial disease; undiagnosed vaginal bleeding & porphyria; history of idiopathic jaundice, severe pruritis, pemphinoid gestations.
Cautions & Side Effects
- Cautions
- Conditions that may worsen with fluid retention e.g. Epilepsy, hypertension, migraine, asthma, cardiac or renal dysfunction, and in those susceptible to thromboembolism.
- Side Effects
- Menstrual disturbances; premenstrual like syndrome (including bloating, fluid retention, breast tenderness); weight gain, nausea, headache, dizziness, insomnia, drowsiness, depression, skin reactions.
Pregnancy & Lactation
- Pregnancy
- X
NYSTATIN,Mycostatin®
Antifungal,Topical,Oral nonabsorbed&Vaginal
Pregnancy: safeLactation: caution
NYSTATIN,Mycostatin®
Antifungal,Topical,Oral nonabsorbed&Vaginal
- Therapeutic group
- Skin / Dermatological
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Suspension · Cream · Ointment
Dosage Forms
Cream
- Ointment&cream 100
Other
- 000 units/g
- 000 units
- 000/ml
Tablet
- vaginaltablet 100
Suspension
- oral suspension100
Dosing & Formulations
- Dose
- Adult dose Oropharyngeal candidiasis: 100,000 units four Times daily. Intestinal candidiasis: 500,000 to 1 million units three Times daily. Paediatric dose 100,000 units four times daily.
Indications & Contraindications
- Indications
- Treatmentofsusceptiblecutaneous,mucocutaneous,andoral cavityfungalinfection
Cautions & Side Effects
- Side Effects
- Nausea and vomiting, diarrhoea; oral burning sensation
Pregnancy & Lactation
- Pregnancy
- B/C(oral)
- Lactation
- Not known if excreted in breast milk; use caution
OCTREOTIDE,Sandostatin®
Somatostatinanalog
Pregnancy: safeLactation: avoid
OCTREOTIDE,Sandostatin®
Somatostatinanalog
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 0.1 mg/mlinjection
Dosing & Formulations
- Dose
- Adults: Carcinoid tumors: -subq, I.V.: Initial 2 weeks: 100-600 mcg/day in 2-4 divided doses; usual range 50 -750 mcg/day (some patients may require up to 1500 mcg/day) -I.M. depot injection: Patients must be stabilized on subcutaneous octreotide for at least 2 weeks before switching to the long-acting depot. Upon switch: 20 mg I.M. intragluteally every 4 weeks for 2 months, then the dose may be modified based upon response. Vipomas: -subq, I.V.: Initial 2 weeks: 200-300 mcg/day in 2-4 divided doses; titrate dose based on response/tolerance. Range: 150-750 mcg/day (doses >450 mcg/day are rarely required) -I.M. depot injection: Patients must be stabilized on subcutaneous octreotide for at least 2 weeks before switching to the long-acting depot. Upon switch: 20 mg I.M. intragluteally every 4 weeks for 2 months, then the dose may be modified based upon response. Acromegaly: -subq, I.V.: Initial: 50 mcg 3 times/day; titrate to achieve growth hormone levels <5 ng/ml or IGF-I (somatomedin C) levels <1.9 units/ml in males and <2.2 units/ ml in females. Usual effective dose 100-200 mcg 3 times/day; range 300-1500 mcg/day. -I.M. depot injection: Patients must be stabilized on subcutaneous oc- treotide for at least 2 weeks before switching to the long-acting depot. Upon switch: 20 mg I.M. intragluteally every 4 weeks for 3 months, then the dose may be modified based upon response.
- Dose in Organ Failure
- Hepatic impairment: Cirrhosis, 10 mg IM every 4 weeks initially, then titrate to effect Renal impairment: Without dialysis, dose adjustment not necessary; with dialysis, 10 mg IM every 4 weeks initially, then titrate to effect
Indications & Contraindications
- Indications
- Control of symptoms in patients with metastatic carcinoid and vasoactive intestinal peptide-secreting tumors (vipomas); acromegaly
Cautions & Side Effects
- Cautions
- Do regular ultrasound examination of gallbladder; monitor glucose tolerance; check on growth hormone abnormal secretion.
- Side Effects
- Sinus bradycardia, conduction abnormalities, arrhythmias; diarrhoea; hypo/hyperglycaemia; gallbladder abnormalities.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Whether octreotide crosses into breast milk is not known; avoid giving tolactating women
OFLOXACIN,Oflox®
Antibiotic,Quinolones(ophthalmic)
Pregnancy: cautionLactation: avoid
OFLOXACIN,Oflox®
Antibiotic,Quinolones(ophthalmic)
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Other
- 0.3%eye drop
Tablet
- 200mg tablet
Dosing & Formulations
- Dose
- Ophthalmic: Children >1 year and Adults: Conjunctivitis: Instill 1-2 drops in affected eye(s) every 2-4 hours for the first 2 days, then use 4 times/day for an additional 5 days Corneal ulcer: Instill 1-2 drops every 30 minutes while awake and every 4-6 Hours after retiring for the first 2 days; beginning on day 3, instill 1-2 drops every hour while awake for 4-6 additional days; thereafter, 1-2 drops 4 times/ day until clinical cure.
Indications & Contraindications
- Indications
- Ophthalmic:Treatmentofsuperficialocularinfectionsinvolvingtheconjunctivaorcorneaduetostrainsofsusceptibleorganisms
Cautions & Side Effects
- Cautions
- Pregnancy; not to beused for more than 10 days
- Side Effects
- Nausea,Headache,Insomnia,Dizziness,Vaginitis,Diarrhea,Vomiting,Appetite decreased,Abdominal cramps,Abnormal taste,Chest pain,External genital pruritis in women,Fatigue,Flatulence,GI distress,Nervousness,Pharyngitis Pyrexia ,Rash/pruritis,Sleep disorders,Visual disturbances,Xerostomia,
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excreted in breast milk, discontinue drug or do not nurse
OLANZAPINE, Zyprexa®
Atypical antipsychotics
Pregnancy: cautionLactation: see details
OLANZAPINE, Zyprexa®
Atypical antipsychotics
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Powder
Dosage Forms
Tablet
- (oral tablet
- oral tablet
Other
- disintegrating
- extended release)
Injection
- intramuscular powder for injection
- intramuscular powder for injection
Dosing & Formulations
- Dose
- Monotherapy: -Initial dose: 10 or 15 mg orally once a day -Dose adjustments: If indicated, dose adjustments should occur at intervals of at least 24 hours in 5 mg increments/decrements. -Maintenance dose: 5 to 20 mg orally once a day -Maximum dose: 20 mg/day
Indications & Contraindications
- Indications
- used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression) in adults and children who are at least 13 years old
- Contraindications
- None with olanzapine monotherapy
Cautions & Side Effects
- Cautions
- Elderly Patients with Dementia-Related Psychosis , Suicide , Neuroleptic Malignant Syndrome(NMS) , Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)
- Side Effects
- weight gain , headache, dizziness, drowsiness, feeling tired or restless ,problems with speech or memory ,tremors or shaking, numbness or tingly feeling ,changes in personality ,dry mouth, or increased salivation
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Maternal doses of olanzapine up to 20 mg daily produce low levels in milk and undetectable levels in the serum of breastfed infants. In most cases, short-term side effects have not been reported, but sedation has occurred
OMEPRAZOLE, Losec®
Proton Pump Inhibitor
Pregnancy: cautionLactation: caution
OMEPRAZOLE, Losec®
Proton Pump Inhibitor
- Therapeutic group
- Gastrointestinal System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection
Dosage Forms
Tablet
- 20 mg tablet
Injection
- 40 mg injection
Dosing & Formulations
- Dose
- Adult dose: 20–80 mg daily. Paediatric dose >12 years: 20–40 mg daily.
- Dose in Organ Failure
- Hepatic impairment: Not studied; expert analysis recommends a reduction in dose, especially for maintenance of healing of erosive esophagitis Renal impairment: Dose adjustments not necessary
Indications & Contraindications
- Indications
- Benign gastric, duodenal and NSAID induced ulcer, oesophageal reflux disease, ulcer associated with H. pylori infection, Zollinger- Ellison syndrome, gastric acid reduction during anaesthesia, acid- related dyspepsia and severe ulcerating reflux oesophagitis.
Cautions & Side Effects
- Cautions
- To be used with caution in presence of liver diseases (dos e not more than 20 mg daily should be needed, reduced dose, not more than 8 mg daily in severe cases), gastric malignancy should be excluded before initiation of treatment.
- Side Effects
- Flatulence; abdominal pain, dyspepsia, nausea; vomiting, diarrhoea, dry mouth; constipation; Headache
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Distributes into human breast milk; use caution
ORAL REHYDRATING SALTS, ORS®
electrolytes
Pregnancy: No dataLactation: see details
ORAL REHYDRATING SALTS, ORS®
electrolytes
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Unclassified
- Dosage form
- Unclassified
Dosage Forms
Other
- Combined sachet
Dosing & Formulations
- Dose
- 200-400 ml after loose motions
Indications & Contraindications
- Indications
- oral replacement ofwater and electrolyte in acute diarrhoea.
Cautions & Side Effects
- Cautions
- ORS should be used with caution in patients with heart failure, hypertensionand diabetes.
- Side Effects
- rarely hypernatraemia, which is very brief andclinically not very important
Pregnancy & Lactation
- Pregnancy
- No data
- Lactation
- unkown
OSELTAMIVIR
Antiviral agent
Pregnancy: cautionLactation: see details
OSELTAMIVIR
Antiviral agent
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 200mg tablet
Dosing & Formulations
- Dose
- 30mg ,45mg ,75mg
Indications & Contraindications
- Indications
- Treatment ofInfluenza
- Contraindications
- serious hypersensitivity to oseltamivir or any component of the product. Severe allergic reactions have includedanaphylaxisand serious skin reactions including toxicepidermalnecrolysis,Stevens-Johnson Syndrome, anderythema multiforme
Cautions & Side Effects
- Cautions
- renal impairment ,hereditary fructose intolerance
- Side Effects
- Diarrhea, nausea ,vomiting Phlegm-producing cough wheezing
Pregnancy & Lactation
- Pregnancy
- c
- Lactation
- poorly excreted into breastmilk
OXYMETAZOLINE,Nasivin®
Adrenergic Agonist Agent, Vasoconstrictor
Pregnancy: cautionLactation: see details
OXYMETAZOLINE,Nasivin®
Adrenergic Agonist Agent, Vasoconstrictor
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Drops
Dosage Forms
Drops
- 0.25% nasal drops
Dosing & Formulations
- Dose
- Intranasal (therapy should not exceed 3-5 days): Children 2-5 years: 0.025% solution: Instill 2-3 drops in each nostril twice daily Children >6 years and Adults: 0.05% solution: Instill 2-3 drops or 2-3 sprays into each nostril twice daily
Indications & Contraindications
- Indications
- Adjunctive therapy of middle ear infections, associated with acute or chronic rhinitis, the common cold, sinusitis, hay fever, or other allergies
Cautions & Side Effects
- Cautions
- avoid excessive use.
- Side Effects
- local irritation, headache; tolerance with prolonged use; rebound congestion.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known if excreted in breast milk
OXYTOCIN, Syntocinon®
Uterinestimulant, oxytocicagent
Pregnancy: riskLactation: caution
OXYTOCIN, Syntocinon®
Uterinestimulant, oxytocicagent
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 5internationalunitinjection
Dosing & Formulations
- Dose
- I.v. administration requires the use of an infusion pump. Adults: Induction of labor: i.v.: 0.5-1 milliunits/minute; gradually increase dose in incre- ments of 1-2 milliunits/minute until desired contraction pattern is established; dose may be decreased after desired frequency of contractions is reached and labor has progressed to 5-6 cm dilation. Infusion rates of 6 milliunits/minute provide oxytocin levels similar to those at spontaneous labor; rates >9-10 milliunits/minute are rarely required.-postpartum bleeding:I.m.: total dose of 10 units after delivery I.v.: 10-40 units by i.v. infusion in 1000 ml of intravenous fluid at a rate sufficient to control uterine atonyAdjunctive treatment of abortion: i.v.: 10-20 milliunits/minute; maximum total dose:30 units/12 hours
Indications & Contraindications
- Indications
- Induction and augmentation of labor; management of missed or incomplete abortion; post- partum haemorrhage.
- Contraindications
- Hypertonic uterine contractions, fetal distress; any condition where spontaneous labour or vaginal delivery inadvisable; avoid prolonged administration in oxytocin-resistant uterine inertia, severe pre-eclamptic toxaemia or severe cardiovascular disease.
Cautions & Side Effects
- Cautions
- Hypertension, pressor drugs, multiple pregnancy, high parity, previous caesarean section. Particular caution needed when given for induction or enhancement of labour in presence of borderline cephalopelvic disproportion,
- Side Effects
- Uterine spasm (may occur at low doses), uterine hyperstimulation (usually with excessive doses— may cause fetal distress, asphyxia and death, or may lead to hypertonicity, tetanic contractions, soft-tissue damage or uterine rupture).
Pregnancy & Lactation
- Pregnancy
- X
- Lactation
- May be distributed milk; commencement of nursing should be delayed for at least 1 day when discontinued; use caution
PARACETAMOL ,Adol®,Fevadol plus®,Panadol®
Analgesic&Antipyretic
Pregnancy: safeLactation: compatible
PARACETAMOL ,Adol®,Fevadol plus®,Panadol®
Analgesic&Antipyretic
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Syrup · Drops · Suppository
Dosage Forms
Tablet
- 500mg tablet
Other
- 125mg
- Paracetamol+caffeine+codeine(500mg+30mg+8mg) fevadol plus®
Suppository
- 500mgsuppository
Injection
- 1ginjection
Syrup
- 120mg/5mlsyrup
Drops
- 100mg/ml drops
Dosing & Formulations
- Dose
- Children<12years:15-20mg/kg/doseevery4-6hoursasneeded; donotexceed (2 g)in24 hour Adults: 500-1000mg every6hours,donotexceed4g/day
Indications & Contraindications
- Indications
- Treatmentofmildtomoderatepainandfever (antipyretic/analgesic);doesnothaveantirheumaticoranti-inflammatoryeffects
Cautions & Side Effects
- Cautions
- Liver damage in prolonged use or overdosage; renal impairment
- Side Effects
- Mayincreasechloride,uricacid,glucose;maydecrease sodium,bicarbonate,calcium, bilirubinincreased,alkalinephosphataseincrease.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excreted in breast milk; compatible with breastfeeding
PENICILLING BENZATHINE,Retarpen®
Antibiotic,Penicillin
Pregnancy: safeLactation: caution
PENICILLING BENZATHINE,Retarpen®
Antibiotic,Penicillin
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Unclassified
- Dosage form
- Unclassified
Dosage Forms
Other
- 1
- 200
- 000internationalunit
Dosing & Formulations
- Dose
- Adult dose IM, 0.9–1.8 g deep IM, single dose, or may be Repeated at weekly intervals (e.g. For syphilis, Three successive weeks). Paediatric dose Prophylaxis, rheumatic fever: IM, 900 mg every 3–4 weeks.
- Dose in Organ Failure
- Renal Impairment Crcl 10-50 ml/min: Decrease dose by 25% Crcl<10 ml/min: Decrease dose by 50-70% Hemodialysis: Removed by hemodialysis; administer after dialysis
Indications & Contraindications
- Indications
- Activeagainstsomegram-positiveorganisms,fewgram-negativeorganismssuchas Neisseria gonorrhoeae,andsomeanaerobesandspirochetes;used inthetreatmentofsyphilis;usedonlyforthetreatmentofmildtomoderately severeinfectionscausedbyorganismssusceptible tolowconcentrationsof penicillin orforprophylaxisofinfectionscausedbythese organisms
- Contraindications
- Penicillin hypersensitivity.
Cautions & Side Effects
- Cautions
- Renal impairment necessitates dose reduction; history of sensitivity.
- Side Effects
- Hypersensitivity reactions, including urticaria, rash, fever, joint pain, anaphylaxis, haemolyticanaemia and interstitial nephritis; cardiac disorders; blood disorders; CNS toxicity with very high dose.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excreted into breast milk, caution advised
Pethidine,meperidine,demerol®
Analgesic,narcotic
Pregnancy: cautionLactation: see details
Pethidine,meperidine,demerol®
Analgesic,narcotic
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 50mg&100 mginjection
Dosing & Formulations
- Dose
- Adult dose SC/IM, 25–100 mg 4-hourly. IV, 25–50 mg 4-hourly. Paediatric dose IM/IV/SC, 0.5–2 mg/kg (up to 100 mg) 3–4 hourly; maximum 10 mg/kg daily. Caution in infants <12 months.
- Dose in Organ Failure
- Renal impairment: avoid use Hepatic impairment: consider lower initial dose intially; increased opioid effect possible in cirrhosis
Indications & Contraindications
- Indications
- Moderate to severe pain, obstetric analgesia, perioperative analgesia.
- Contraindications
- Avoid in acute respiratory depression, acute alcoholism and where risk of paralytic ileus; avoid injection in pheochromocytoma; severe renal impairment
Cautions & Side Effects
- Cautions
- Head injuries, severe hepatic or renal impairment, biliary tract disorders, hypothyroidism; patients exhibiting acute alcoholism, raised intracranial pressure, convulsive disorders. Not suitable for severe continuing pain;
- Side Effects
- Nausea and vomiting (particularly in initial stages), constipation, and drowsiness; larger doses produce respiratory depression, hypotension, and muscle rigidity.
Pregnancy & Lactation
- Pregnancy
- C / D (prolonged use or high doses at term)
- Lactation
- Drug excreted in breast milk
PHENYLEPHRINE, Mydfrin®
-Alpha/betaagonist
-ophthalmicagent,Antiglaucoma
-ophthalmicagent,Mydriatic
Pregnancy: cautionLactation: compatible
PHENYLEPHRINE, Mydfrin®
-Alpha/betaagonist -ophthalmicagent,Antiglaucoma -ophthalmicagent,Mydriatic
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 10 mg/ mlinjection
Other
- 2.5%eyedrop
Dosing & Formulations
- Dose
- Hypotension/shock: Children: -IV bolus; 5-20mcg/kg/dose every 10-15 minutes as needed -IV infusion: 0.1-0.5 mcg/kg/minute Adult: -IV bolus; 0.1-0.5 mg/dose every 10-15 minutes as needed (initial dose should not exceed 0.5mg) -IV infusion: initial dose: 100-180mcg/minute, when blood pressure is stabi- lized, maintenance rate: 40-60mcg/minute; rates up to 360 mcg/minute have been reported. -Dosing range: 0.4-9.1mcg/kg/minute Pyroxysmal supraventricular tachycardia: IV., Children: 5-10mcg/kg/dose over 20-30 seconds Adult: 0.25-0.5mg/dose over 20-30 seconds
Indications & Contraindications
- Indications
- -Treatment of hypotension, vascular failure in shock; as a vasoconstrictor in regional analgesia; as a mydriatic in ophthalmic procedures and treatment of wide angle glaucoma superventricularr tachycardia -For OTC use as symptomatic relief of nasal and nasopharyngeal mucosal Congestion, treatment of hemorrhoids, relief of redness of the eye
- Contraindications
- Angle-closureglaucoma.
Cautions & Side Effects
- Cautions
- Use low strength in childrenand elderly; caution in presenceof cardiovascular disease
- Side Effects
- Reflex bradycardia, excitability, restlessness, hypertension, severe peripheral and visceral vasoconstriction, decreased cardiac output , tremor, paresthesia, restlessness, metabolic acidosis
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Safe
PHENYTOIN,Epanutin®
Anticonvulsant,Antiarrhythmic Agent,Class Ib
Pregnancy: riskLactation: avoid
PHENYTOIN,Epanutin®
Anticonvulsant,Antiarrhythmic Agent,Class Ib
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule · Injection
Dosage Forms
Capsule
- 100mgcapsule
Injection
- 250mg/5mlinjection
Dosing & Formulations
- Dose
- Adult dose Anticonvulsant: Oral, initially 4–5 mg/kg daily in two or three doses. Adjust dosage according to plasma levels; usual maintenance dose 200–500 mg daily. Maximum daily dose 600 mg. Status epilepticus: IV, 15–20 mg/kg. Paediatric dose Anticonvulsant: Oral, initially 5 mg/kg/day in two or three divided doses (maximum 300 mg daily). Adjust dosage according to plasma levels; usual maintenance dose 4–8 mg/kg daily. Status epilepticus: IV, 10–20 mg/kg.
Indications & Contraindications
- Indications
- All forms of epilepsyexcept absence seizure.
Cautions & Side Effects
- Cautions
- Hepatic impairment;pregnancy and breast feeding;avoid sudden withdrawal; bloodcount to be carried out regularly.
- Side Effects
- Nausea and vomiting,mental confusion, headache, insomnia,and tremor occur commonly.Skin rash, coarse facies,acne and hirsutism.
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Excreted in breast milk; not recommended
PILOCARPINE,Selagen®,Pilotina®
Anticholinergicagent,ophthalmic
Pregnancy: cautionLactation: caution
PILOCARPINE,Selagen®,Pilotina®
Anticholinergicagent,ophthalmic
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 2%eyedrop
Dosing & Formulations
- Dose
- Glaucoma: Solution: Instill 1-2 drops up to 6 times/day; adjust the concentration and frequency as required to control elevated intraocular pressure
Indications & Contraindications
- Indications
- Managementofchronicsimple glaucoma, chronicandacute angle-closureglaucoma.
- Contraindications
- Acute iritis, uveitis, acute inflammatory disease of the anterior segment.
Cautions & Side Effects
- Cautions
- Asthma, hypertension and other cardiac disease, peptic ulceration; darkly pigmented iris may require higher concentration or more frequent administration to achieve therapeutic effects, avoid overdosage.
- Side Effects
- Headache and browache, local irritation, blurred vision, conjunctival vascular congestion.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excretion in breast milk unknown; use with caution
PIPRACILLIN+ TAZOBACTAM,Tazocin®
Antibiotic,Penicillin
Pregnancy: safeLactation: caution
PIPRACILLIN+ TAZOBACTAM,Tazocin®
Antibiotic,Penicillin
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Unclassified
- Dosage form
- Injection
Dosage Forms
Injection
- 2.25&4.5ginjection
Dosing & Formulations
- Dose
- Usual dose range: Note: Not FDA approved for use in children <12years of age Infants 2-8 months: 80 mg /kg every 8 hours. Infants and Children > 6months: IV. 240mg of piperacillin component/kg/day In divided doses every 8 hours, for sever infection: maximum: pipracillin 18g/ Day Adults: I.V.: 2.25-4.5 g every 6-8 hours, maximum: pipracillin 18g/day Indication– Specific dosing: I.V. Children: Note: dosing based on Piperacillin component: 2-9 month: 80mg/kg every 8 hours >9 months &< 40 kg: 100mg/kg every 8 hours >40 kg: refer to dosing Adults Adults: Diverticulitis, intra-abdominal abscess, peritonitis:IV., Piperacillin/ Tazobactam 4.5g every 8 hours or 3.375g every 6 hours *Moderate infections: IM., Piperacillin/tazobactam 2/25g every 6-8 hours ; Treatment should be continued for >7-10 days depending on severity of dis- ease ( I.M. route not FDA approved) *Nosocomial pneumonia: IV., Piperacillin/tazobactam 4.5g every 6 hours for 7-14 days (when used empirically, combination with an aminoglycoside is recommended; consider discontinuation of aminoglycoside if P. Aeruginosa is not isolated) *Severe infections: IV., Piperacillin/tazobactam 4.5g every 8 hours or 3.375g Every 6 hours for 7-10 days
- Dose in Organ Failure
- Renal impairment Crcl>40 ml/min: Dose adjustment not necessary Crcl 20-40 ml/min: 2.25 g IV q6hr, OR 3 g/0.375 g IV q6hr (for nosocomial pneumonia), OR extended infusion of 3.375 g IV over 4 hr q12hr (off-label) Crcl<20 ml/min: 2.25 g IV q8hr, OR 2.25 g IV q6hr (for nosocomial pneumonia)
Indications & Contraindications
- Indications
- Treatment of infections caused by susceptible organisms, including infections of the lower respiratory tract (community-acquired pneumonia, nosocomial pneumonia);urinary tract; skin and skin structures; gynecologic (endometritis, pelvic inflammatory disease); bone and joint infections; intra-abdominal infec- tions and septicemia.Tazobactam expands activity of piperacillin to include beta-lactamase producing strains of S. Aureus, H. Influenzae, Bacteroides, and other gram-negative bacteria.
- Contraindications
- Penicillin hypersensitivity.
Cautions & Side Effects
- Cautions
- Renal impairment, Hepatic impairment, history of allergy, skin rash, viral infections.
- Side Effects
- Hypersensitivity reactions, including urticaria, rash, fever, joint pain, anaphylaxis, haemolyticanaemia and interstitial nephritis; cardiac disorders; blood disorders; CNS toxicity with very high dose.
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Low concentrations of piperacillin excreted in breast milk; tazobactam unknown; use caution
PLASMA PROTEIN FRACTION
Pregnancy: not in sourceLactation: not in source
PLASMA PROTEIN FRACTION
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 5 mg/ml
Dosing & Formulations
- Dose
- Hypovolaemia: 12.5-25g (250-500 ml) IV, repeat as needed
Indications & Contraindications
- Indications
- Hypovolaemia due toburns, severe infections, and as proteinreplacement in hypoproteinaemia.
- Contraindications
- Hypersensitivityto albumin; severe anaemia,cardiac or circulatory disease.
Cautions & Side Effects
- Cautions
- Avoid rapid infusion; renalinsufficiency.
- Side Effects
- Hypersensitivity reactions.
POTASSIUMCHLORIDE,Slow-K®
Electrolytesupplement,Oral,Parenteral
Pregnancy: cautionLactation: not in source
POTASSIUMCHLORIDE,Slow-K®
Electrolytesupplement,Oral,Parenteral
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 600mg tablet
Other
- 20mmol/10(15%)IVpolyamp
Dosing & Formulations
- Dose
- Treatment of hypokalemia: Children: -I.V. intermittent infusion: 0.5-1 meq/kg/dose (maximum dose: 40 meq). If Infusion exceeds 0.5 meq/kg/hour, physician should be at bedside and pa- Tient should have continuous ECG monitoring; repeat as needed based on frequently obtained lab values. Adults: -Oral: Asymptomatic, mild hypokalemia: Usual dosage range: 40-100 meq/day divided in 2-5 doses; generally recommended to limit doses to 20-25 meq/dose to avoid GI discomfort. Mild-to-moderate hypokalemia: Some clinicians may administer up to 120-240 meq/day divided in 3-4 doses; limit doses to 40-60 meq/dose. If deficits are severe or ongoing losses are great, I.V. route should be considered. -I.V. intermittent infusion: Peripheral or central line: ≤10 meq/hour; repeat as needed based on frequently obtained lab values; central line infusion and continu- ous ECG monitoring highly recommended for infusions >10 meq/hour. Potassium dosage/rate of infusion general guidelines: Serum potassium >2.5 meq/L: Maximum infusion rate: 10 meq/hour; maximum concentration: 40 meq/L; maximum 24-hour dose: 200 meq Serum potassium <2 meq/L and symptomatic (excluding emergency treatment of cardiac arrest): Maximum infusion rate (central line only): 40 meq/hour in presence of continuous ECG monitoring and frequent lab monitoring; In selected situations, patients may require up to 400 meq/24 hours.
Indications & Contraindications
- Indications
- Potassium depletion.
- Contraindications
- Severe renal impairment.
Cautions & Side Effects
- Cautions
- Elderly, mild to moderate renal impairment, history of peptic ulceration, hiatus hernia; avoid with drugs that raise plasma potassium level such as potassium sparing diuretics or ACE inhibitors
- Side Effects
- Nausea and vomiting, oesophageal or small bowel ulceration.
Pregnancy & Lactation
- Pregnancy
- C
POTASSIUMPHOSPHATE
Electrolytesupplement,Parenteral
Pregnancy: cautionLactation: caution
POTASSIUMPHOSPHATE
Electrolytesupplement,Parenteral
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 3 mmol/ml(5 ml)Injection
Dosing & Formulations
- Dose
- General replacement guidelines for Adult: -Low dose: 0.08 mmol/kg over 6 hours; use if losses are recent and uncomplicated -Intermediate dose: 0.16-0.24 mmol/kg over 4-6 hours; use if serum phosphorus level 0.5-1 mg/dl (0.16-0.32 mmoles/L) Patients receiving TPN; supplemental dose -Low dose: 0.16 mmol/kg over 4-6 hours; use if serum phosphorus level 2.3-3 mg/ Dl (0.73-0.96 mmoles/L) -Intermediate dose: 0.32 mmol/kg over 4-6 hours; use if serum phosphorus level 1.6-2.2 mg/dl (0.51-0.72 mmoles/L) -High dose: 0.64 mmol/kg over 8-12 hours; use if serum phosphorus <1.5 mg/dl (<0.5 mmoles/L) Critically-ill adult trauma patients receiving TPN: -Low dose: 0.32 mmol/kg over 4-6 hours; use if serum phosphorus level 2.3-3 mg/ Dl (0.73-0.96 mmoles/L) -Intermediate dose: 0.64 mmol/kg over 4-6 hours; use if serum phosphorus level 1.6-2.2 mg/dl (0.51-0.72 mmoles/L) -High dose: 1 mmol/kg over 8-12 hours; use if serum phosphorus <1.5 mg/dl (<0.5 mmoles/L) Maintenance: I.V. solutions: Doses may be incorporated into the patient's mainte- nance I.V. fluids. Children: 0.5-1.5 mmol/kg/24 hours I.V. or 2-3 mmol/kg/24 hours orally in divided doses Adults: 15-30 mmol/24 hours I.V. or 50-150 mmol/24 hours orally in divided doses
Indications & Contraindications
- Indications
- Treatmentandpreventionofhypophosphatemia or hypokalemia
Cautions & Side Effects
- Cautions
- Hyperkalaemia, renal impairment.
- Side Effects
- Diarrhoea; magnesiumdeficiency.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Unknown whether distributed in breast milk
PrednisoLONE,Prednisone,Gupisone®,Deltasone®, Predforte®,
Corticosteroid
Pregnancy: cautionLactation: avoid
PrednisoLONE,Prednisone,Gupisone®,Deltasone®, Predforte®,
Corticosteroid
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 5mg& 20mg tablet
Other
- 1%eyedrop
Dosing & Formulations
- Dose
- Children: Oral: Acute asthma: 1-2 mg/kg/day in divided doses 1-2 times/day for 3-5 days Anti-inflammatory or immunosuppressive dose: 0.1-2 mg/kg/day in divided Doses 1-4 times/day Nephrotic syndrome: -Initial (first 3 episodes): 2 mg/kg/day or 60 mg/m2 /day (maximum: 80 mg/ day) in divided doses 3-4 times/day until urine is protein free for 3 consecu- tive days (maximum: 28 days); followed by 1-1.5 mg/kg/dose or 40 mg/m2 / dose given every other day for 4 weeks -Maintenance (long-term maintenance dose for frequent relapses): 0.5-1 mg/ Kg/dose given every other day for 3-6 months Adults: Oral: Usual range: 5-60 mg/day Multiple sclerosis: 200 mg/day for 1 week followed by 80 mg every other day for 1 month Rheumatoid arthritis: Initial: 5-7.5 mg/day; adjust dose as necessary *Ophthalmic suspension/solution: Conjunctivitis, corneal injury: Children and Adults: Instill 1-2 drops into con- junctival sac every hour during day, every 2 hours at night until favorable Response is obtained, then use 1 drop every 4 hours.
Indications & Contraindications
- Indications
- Suppression of inflammatory and allergic disorders; inflammatory bowel disease; asthma; immunosuppression; rheumatic disease.
- Contraindications
- Systemic infection (unless specific antimicrobial therapy given); avoid live virus vaccines in those receiving immunosuppressive doses (serum antibody response diminished).
Cautions & Side Effects
- Cautions
- Adrenal suppression and infection, children and adolescents (growth retardation possibly irreversible), elderly (close supervision required particularly on long- term treatment);
- Side Effects
- Minimised by using lowest effective dose for minimum period possible; gastro-intestinal effects include dyspepsia, peptic ulceration (with perforation), abdominal distension, acute pancreatitis, oesophageal ulceration and candidiasis.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Of maternal serum metabolites, 5-25% are found in breast milk; not recommended, or, if benefit outweighs risk, use lowest dose
PROCAINAMIDE , Pronestyl®
Antiarrhythmicagent
Pregnancy: cautionLactation: avoid
PROCAINAMIDE , Pronestyl®
Antiarrhythmicagent
- Therapeutic group
- Cardiovascular System
- Storage
- Unclassified
- Dosage form
- Injection
Dosage Forms
Other
- 100mg/ml
Injection
- 250mg/ml inj
Dosing & Formulations
- Dose
- Im administration 0.5-1 g im q4-8hr Iv administration Loading dose: 100-200 mg/dose or 15-18 mg/kg; infuse slowly over 25-30 min; may repeat q5min prn not to exceed 1 g
- Dose in Organ Failure
- Renal impairment: Reduce loading dose to 12 mg/kg Maintenance: 1-4 mg/min by continuous IV infusion Renal impairment: Reduce infusion to one third in moderate renal or cardiac impairment and two thirds in severe renal or cardiac impairment
Indications & Contraindications
- Indications
- Arrhythmia
- Contraindications
- Heart failure; history of myocardial infarction; long standing atrial fibrillation.
Cautions & Side Effects
- Side Effects
- Arrhythmia, dizziness, visual disturbances, dyspnoea, headache
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Crosses into breast milk, discontinue drug or do not nurse
PROMETHAZINE, Phenergan®
Antihistamine,Antiemetic
Pregnancy: cautionLactation: avoid
PROMETHAZINE, Phenergan®
Antihistamine,Antiemetic
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Syrup
Dosage Forms
Other
- 10mg
Tablet
- 25 mgtablet
Injection
- 50 mginjection
Syrup
- 5mg/5mlsyrup
Dosing & Formulations
- Dose
- By mouth, 25mg at night, may be increased to 50- 75mg at night if necessary. Child below 2 years, not recommended. 2-5 years, 5-15mg daily. 5-10 years, 10-25mg daily. By IM injection, adult, 25-50mg. Child 5-10 years, half oral dose i.e 6.25-12.5mg. By slow IV injection after dilution with water for injection to 2.5mg/ml, 25-50mg. Max. Parenteral dose, 100mg.
Indications & Contraindications
- Indications
- Symptomatic relief of allergy such as hay fever, urticaria, emergency treatment of anaphylactic reactions; premedication in anesthesia; sedation; motion sickness.
- Contraindications
- Porphyria.
Cautions & Side Effects
- Cautions
- Intramuscular injection may be painful.
- Side Effects
- Headache, psychomotor impairment, and antimuscarinic effects such as urinary retention, dry mouth, blurred vision, and gastro-intestinal disturbances. Cardiovascular adverse effects more commonly seen after injection
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known whether drug crosses into breast milk; discontinue drug, or do not nurse
PROPOFOL , Diprivan®
Anesthetic,general
Pregnancy: safeLactation: see details
PROPOFOL , Diprivan®
Anesthetic,general
- Therapeutic group
- Anaesthesia & Muscle Relaxants
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 200 mg injection
Dosing & Formulations
- Dose
- Induction of anaesthesia using 0.5%or 1%injection by slow intravenous injection, or by intravenous Infusion adult 18–54 years: usual dose 1.5–2.5 mg/kg, to be Administered at a rate of 20–40 mg every 10 seconds Until response, for debilitated patients use dose for 55 years and over adult 55 years and over: usual dose 1–1.5 mg/kg, to be Administered at a rate of 20 mg every 10 seconds until Response Induction of anaesthesia using 2%injection by intravenous infusion adult 18–54 years: usual dose 1.5–2.5 mg/kg, to be Administered at a rate of 20–40 mg every 10 seconds Until response. For debilitated patients use dose for 55 years and over adult 55 years and over: usual dose 1–1.5 mg/kg, to be Administered at a rate of 20 mg every 10 seconds until Response Maintenance of anaesthesia using 1%injection initially by intravenous infusion adult: usual dose 4–12 mg/kg/hour, alternatively (by Slow intravenous injection) 25–50 mg, dose may be Repeated according to response, for debilitated patients Use dose for elderly elderly: usual dose 3–6 mg/kg/hour, alternatively (by Slow intravenous injection) 25–50 mg, dose may be Repeated according to response Maintenance of anaesthesia using 2%injection by intravenous infusion adult: usual dose 4–12 mg/kg/hour, for debilitated Patients use dose for elderly elderly: usual dose 3–6 mg/kg/hour Sedation of ventilated patients in intensive care using 1%or 2%injection by continuous intravenous infusion adult: usual dose 0.3–4 mg/kg/hour, adjusted According to response Induction of sedation for surgical and diagnostic Procedures using 0.5%or 1%injection by slow intravenous injection adult: initially 0.5–1 mg/kg, to be administered over 1–5 minutes, dose and rate of administration adjusted According to desired level of sedation and response Maintenance of sedation for surgical and diagnostic Procedures using 0.5%injection initially by intravenous infusion adult: initially 1.5–4.5 mg/kg/hour, dose and rate of Administration adjusted according to desired level of Sedation and response, followed by continued Bnf 73 general anaesthesia 1175 Anaesthesia 15 (by slow intravenous injection) 10–20 mg, (if rapid Increase in sedation required), patients over 55 years or Debilitated may require lower initial dose and rate of Administration Maintenance of sedation for surgical and diagnostic Procedures using 1%injection initially by intravenous infusion adult: initially 1.5–4.5 mg/kg/hour, dose and rate of Administration adjusted according to desired level of Sedation and response, followed by (by slow Intravenous injection) 10–20 mg, (if rapid increase in Sedation required), patients over 55 years or debilitated May require lower initial dose and rate of Administration Maintenance of sedation for surgical and diagnostic Procedures using 2%injection initially by intravenous infusion adult: initially 1.5–4.5 mg/kg/hour, dose and rate of Administration adjusted according to desired level of Sedation and response, followed by (by slow Intravenous injection) 10–20 mg, using 0.5%or 1% Injection (if rapid increase in sedation required), Patients over 55 years or debilitated may require lower Initial dose and rate of administration
Indications & Contraindications
- Indications
- Inductionof anesthesia
Cautions & Side Effects
- Side Effects
- Hypotension, movement, injection site burning, stinging, or pain, apnea
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excreted in breast milk; effect on nursing infant not known
Propranolol,inderal®
Antiarrhythmic agent,class ii, nonselectivebblocker
Pregnancy: cautionLactation: see details
Propranolol,inderal®
Antiarrhythmic agent,class ii, nonselectivebblocker
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection
Dosage Forms
Tablet
- 10&40 mgtablet
Injection
- 1mg injection
Dosing & Formulations
- Dose
- By mouth, hypertension, initially 80 mg twice daily. Maintenance, 160-320 mg daily. Angina, initially 40 mg 2-3 times daily. Maintenance, 120-240 mg daily. Arrhythmias and thyrotoxicosis, 10-40 mg 3-4 times daily. Prophylaxis after infarction, 40 mg 4 times daily for 2-3 days, then 80 mg twice daily, beginning 5-21 days after infarction. Migraine prophylaxis and essential tremor, initially 40 mg 2-3 times daily. Maintenance, 80-160 mg daily. By iv injection, arrhythmias and thyrotoxic crisis, 1 mg over 1minute, preceded by atropine sulphate 1-2 mg in divided doses. If necessary, repeat at 2 minute intervals; max. Dose 10 mg (5 mg in anaesthesia).
Indications & Contraindications
- Indications
- Hypertension, angina, arrhythmias, thyrotoxicosis, secondary prevention after acute myocardial infarction, migraine, and in phaeochromocytoma along with an alpha blocker.
- Contraindications
- Asthma; uncontrolled heart failure; prinzmetalss angina; marked bradycardia; hypotension.
Cautions & Side Effects
- Cautions
- First degree av block; portal hypertension and chronic obstructive pulmonary disease; late pregnancy; breast feeding
- Side Effects
- Gastro intestinal disturbances; bradycardia, heart failure, hypotension, conduction disorders, bronchospasm, peripheral vasoconstriction
Pregnancy & Lactation
- Pregnancy
- C (manufacturer); D (2nd and 3rd trimesters, expert analysis)
- Lactation
- Use is controversial; an insignificant amount is excreted in breast milk
PROPYLTHIOURACIL, Propylthyracil®
Antithyroidagent
Pregnancy: riskLactation: avoid
PROPYLTHIOURACIL, Propylthyracil®
Antithyroidagent
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 50 mgtablet
Dosing & Formulations
- Dose
- 100-200mg 3 times daily. Maintenance dose, 50-150 mg daily. Propylthiouracil is given in a dose of 200 to 400 mg daily in adults and this dose is maintained until the patient becomes euthyroid; the dose may then be gradually reduced to a maintenance dose of 50 to 150 mg daily.
Indications & Contraindications
- Indications
- Hyperthyroidism; thyrotoxicosis.
Cautions & Side Effects
- Cautions
- Pregnancy, breast-feeding; tracheal obstruction; large goiter, hepatic and renal impairment.
- Side Effects
- Nausea, mild gastro-intestinal disturbances, headache, rashes and pruritus, arthralgia.
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Distributed in breast milk, contraindicated by some sources
PYRAZINAMIDE,Tebrazid®
Antitubercular
Pregnancy: cautionLactation: see details
PYRAZINAMIDE,Tebrazid®
Antitubercular
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 500 mg tablet
Dosing & Formulations
- Dose
- Adult dose 20–35 mg/kg (maximum 1.5 g) daily or 50 mg/kg (maximum 3 g) three times a week. Paediatric dose 15–30 mg/kg (maximum 1.5 g) daily or 50 mg/kg (maximum 2 g) three times a week.
Indications & Contraindications
- Indications
- Adjunctive treatmentoftuberculosisincombinationwithotherantituberculosisagents
- Contraindications
- liver disease.
Cautions & Side Effects
- Cautions
- pregnancy, hepatic impairment, gout, diabetes.
- Side Effects
- hepatotoxicity, urticaria, arthralgia, rash, nausea and vomiting.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- enters breast milk
PYRIDOXINE
Vitamin,watersoluble
Pregnancy: safeLactation: compatible
PYRIDOXINE
Vitamin,watersoluble
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 40mgtablet
Dosing & Formulations
- Dose
- Pyridoxine-dependent Infants: -Oral: 2-100 mg/day Dietary deficiency: Oral: Children: 5-25 mg/24 hours for 3 weeks, then 1.5-2.5 Then 1.5-2.5 mg/day in multiple vitamin product Adults: 10-20 mg/day for 3 weeks Drug-induced neuritis (eg, isoniazid, hydralazine, penicillamine, cycloserine): Children: -Treatment: 10-50 mg/24 hours -Prophylaxis: 1-2 mg/kg/24 hours Adults: -Treatment: 100-200 mg/24 hours -Prophylaxis: 25-100 mg/24 hours
Indications & Contraindications
- Indications
- Pyridoxine deficiency, including inadequate diet, drug-induced causes (e.g. Isoniazid, hydralazine, oral contraceptives) or inborn errors of metabolism; Idiopathic sideroblastic anaemia; parenteral use is indicated when oral therapy is not feasible.
Pregnancy & Lactation
- Pregnancy
- A / C (dose exceeding RDA recommendation)
- Lactation
- Safe
RIFAMPICIN,Rifampin®
Antitubercular
Pregnancy: cautionLactation: see details
RIFAMPICIN,Rifampin®
Antitubercular
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 150&300mgtablet
Dosing & Formulations
- Dose
- Adult dose Oral/IV, 450–600 mg once daily or 15 mg/kg (maximum 600 mg) three times weekly. Paediatric dose Oral/IV, 10–20 mg/kg (maximum 600 mg) daily in 1–2 doses, or 5 mg/kg (maximum 600 mg) 3 times weekly.
Indications & Contraindications
- Indications
- Management of active tuberculosis in combination with other agents; elimi- nate meningococci from asymptomatic carriers; prophylaxis of Haemophilus influenzae type b infection; used in combination with other anti-infectives in the treatment of staphylococcal infections; Legionella pneumonia
- Contraindications
- Sensitivity to rifampicin, jaundice.
Cautions & Side Effects
- Cautions
- Hepatic impairment; renal impairment; pregnancy and breast-feeding; porphyria.
- Side Effects
- Gastrointestinal disturbances, headache, drowsiness, dizziness, visual disturbances, confusion
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug enters breast milk
RISPERIDONE, Resperidal®
Atypical antipsychotics
Pregnancy: cautionLactation: caution
RISPERIDONE, Resperidal®
Atypical antipsychotics
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Injection · Powder
Dosage Forms
Tablet
- (oral tablet
- oral tablet
Other
- disintegrating
- extended release)
Injection
- intramuscular powder for injection
- intramuscular powder for injection
Dosing & Formulations
- Dose
- The initial dose range is 2 mg to 3 mg per day. The dose may be adjusted at intervals of 24 hours or greater, in increments of 1 mg per day. The effective dose range is 1 mg to 6 mg per day, as studied in the short-term, placebo-controlled trials. In these trials, short-term (3 week) anti-manic efficacy was demonstrated in a flexible dosage range of 1 mg to 6 mg per day
Indications & Contraindications
- Indications
- used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar disorder (manic depression) in adults and children who are at least 10 years old
- Contraindications
- Risperidoneis contraindicated in patients with a known hypersensitivity to either Risperidone or paliperidone, or to any of the excipients in the Risperidone formulation. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with Risperidone and in patients treated with paliperidone. Paliperidone is a metabolite of Risperidone.
Cautions & Side Effects
- Cautions
- Elderly Patients with Dementia-Related Psychosis , Neuroleptic Malignant Syndrome(NMS) , Tardive Dyskinesia
- Side Effects
- Aggressive behavior ,Agitation ,anxiety ,changes in vision, including blurred vision ,difficulty concentrating ,difficulty speaking or swallowing ,inability to move the eyes ,increase in amount of urine
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Limited information indicates that maternal risperidone doses of up to 6 mg daily produce low levels in milk
SALBUTAMOL, Ventolin®
Beta2-Adrenergic Agonist,Bronchodilator
Pregnancy: cautionLactation: avoid
SALBUTAMOL, Ventolin®
Beta2-Adrenergic Agonist,Bronchodilator
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Syrup · Inhaler · Solution
Dosage Forms
Tablet
- 2&4mg tablet
Syrup
- 2mg/5mlsyrup
Inhaler
- 100mcg/puffinhaler
Solution
- 0.5%solution
Dosing & Formulations
- Dose
- By mouth, 4mg (elderly and sensitive patients initially 2mg) 3-4 times daily, max. 8mg (but unlikely to be tolerated); Child under 2 years, 100 mcg/kg 4 times daily (not licensed). Child 2-6 years, 1-2mg 3 -4 times daily. 6-12 years, 2mg 3-4 times daily. By SC or IM injection, 500 mcg repeated every 4 hours if necessary. By slow IV injection, 250 mcg repeated if necessary. By continuous IV infusion, initially 5 mcg/minute, adjusted according to response and heart-rate usually in the range of 3-20 mcg/minute or more if necessary. By aerosol inhalation, acute and intermittent episodes of wheezing and asthma, 100-200 mcg repeated after 4 hours if necessary; Child, 100 mcg. Prophylaxis in exercise-induced bronchospasm, 200 mcg. Child, 100 mcg. Chronic maintenance therapy, 200 mcg 3-4 times daily, or in severe bronchospasm every 4 hours. Child, 100 mcg 3-4 times daily increased to 200 mcg if necessary. By inhalation of nebulized solution, chronic bronchospasm unresponsive to conventional therapy and severe acute asthma, 2.5mg (2.5ml of a solution containing 1mg/ml), repeated up to times daily; increased to 5mg if necessary. In refractory patients with severe acute asthma 10mg can be used if side effects permit. Child 2.5mg, increased to 5mg if required.
Indications & Contraindications
- Indications
- A selective beta 2-adrenceptor agonist used in reversible airway obstruction, status asthmaticus, severe acute asthma and premature labour.
Cautions & Side Effects
- Cautions
- Hyperthyroidism, ischaemic heart disease, hypertension, pregnancy, elderly patients (reduce dose); intravenous administration to diabetics (blood sugar estimates required).
- Side Effects
- Fine tremor (usually hands), nervous tension, headache, peripheral vasodilatation, tachycardia (seldom troublesome when by aerosol inhalation); hypokalaemia after high doses, slight pain on intramuscular injection.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excretion in breast milk unknown; not recommended
Senna concentrateLaxal®
Stimulant laxatives
Pregnancy: No known adverse effects durinLactation: see details
Senna concentrateLaxal®
Stimulant laxatives
- Therapeutic group
- Gastrointestinal System
- Storage
- Unclassified
- Dosage form
- Tablet
Dosage Forms
Tablet
- Tablet
Dosing & Formulations
- Dose
- 2 tablets orally at bedtime, not to exceed 4 tablets twice a day
Indications & Contraindications
- Indications
- Relief of occasional constipation
- Contraindications
- intestinal obstruction, bleeding or persistent abdominal symptoms are present.
Cautions & Side Effects
- Cautions
- Senna should be used with caution shortly after bowel surgery.
- Side Effects
- Temporary mild griping may occur.
Pregnancy & Lactation
- Pregnancy
- No known adverse effects during pregnancy.
- Lactation
- Clinical studies have shown that the breast fed infants mothers taking a senna laxative did not show any side effects to the drug
SEVOFLURANE,Sevorane®AF
GeneralAnesthetic,Inhalation
Pregnancy: safeLactation: see details
SEVOFLURANE,Sevorane®AF
GeneralAnesthetic,Inhalation
- Therapeutic group
- Anaesthesia & Muscle Relaxants
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- Liquidforinhalation100%
Dosing & Formulations
- Dose
- Minimum alveolar concentrations (MAC) values for surgical levels of anesthe- sia: 0 to 1 month old full-term neonates: Sevoflurane in oxygen: 3.3% 1 to <6 months: Sevoflurane in oxygen: 3% 6 months to <3 years: Sevoflurane in oxygen: 2.8% Sevoflurane in 60% N20/40% oxygen: 2% 3-12 years: Sevoflurane in oxygen: 2.5% 25 years: Sevoflurane in oxygen: 2.6% Sevoflurane in 65% N20/35% oxygen: 1.4% 40 years: Sevoflurane in oxygen: 2.1% Sevoflurane in 65% N20/35% oxygen: 1.1% 60 years: Sevoflurane in oxygen: 1.7% Sevoflurane in 65% N20/35% oxygen: 0.9% 80 years: Sevoflurane in oxygen: 1.4% Sevoflurane in 65% N20/35% oxygen: 0.7%
Indications & Contraindications
- Indications
- Induction and maintenance of general anesthesia
- Contraindications
- Sensitivity to halogenated compounds.
Cautions & Side Effects
- Side Effects
- Hypotension (4% to 11% dose dependent), agitation (7% to 15%), nausea (25%), vomiting (18%), cough increased (5% to 11%), salivation (2% to 4%)
Pregnancy & Lactation
- Pregnancy
- B
- Lactation
- Excreted in breast milk; no adverse effect on nursing infant
SODIUM BICARBONATE
Alkalinizingagent,antacid,electrolytesupplement
Pregnancy: cautionLactation: see details
SODIUM BICARBONATE
Alkalinizingagent,antacid,electrolytesupplement
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule · Injection · Powder
Dosage Forms
Capsule
- 325mgcapsule
Injection
- 8.4%50ml injection
- 5%250ml injection
Powder
- powder
Dosing & Formulations
- Dose
- Cardiacarrest: Infantsandchildren: I.V.:0.5-1meq/kg/doserepeatedevery10minutesorasindicatedby arterialbloodgases;rateof infusionshouldnotexceed 10 meq/minute; neonatesand children<2yearsofageshouldreceive4.2%(0.5meq/ml)solution Adults:I.V.:initial:1meq/kg/dose onetime; maintenance:0.5meq/kg/dose every10minutesorasindicatedbyarterialbloodgases Metabolic acidosis:infants,children,andadults:dosageshouldbebasedon Thefollowingformulaif bloodgasesandphmeasurementsareavailable Hco3 -(meq)=0.3x weight(kg)x basedeficit(meq/l) Administer1/2doseinitially,thenremaining1/2doseoverthenext24hours; Monitorph,serumhco3 -,andclinicalstatus Note:ifacid-basestatusisnotavailable:dosefor olderchildrenandadults:2-5meq/ KgI.V.infusionover4-8hours;subsequentdosesshouldbe basedonpatient'sacid- basestatus Chronic renalfailure:oral:initiatewhenplasmahco3 -<15meq/l Children:1-3meq/kg/day Adults:startwith20-36meq/dayindivided doses,titratetobicarbonatelevel Of18-20meq/l Hyperkalemia:adults:I.V.:1 meq/kgover5 minutes Renaltubularacidosis: oral:-distal: Children:2-3meq/kg/day Adults:0.5-2meq/kg/dayin4-5divided doses Urine alkalinization: oral: Children: 1-10 meq (84-840 mg)/kg/day in divided doses every 4-6 hours; Dose should be titrated to desired urinary ph Adults: initial: 48 meq (4 g), then 12-24 meq (1-2 g) every 4 hours; dose Should be titrated to desired urinary ph; doses up to 16 g/day (200 meq) in patients <60 years and 8 g (100 meq) in patients >60 years Antacid: adults: oral: 325 mg to 2 g 1-4 times/day Proximal: children and adults: initial: 5-10 meq/kg/day; maintenance: in- crease as required to maintain serum bicarbonate in the normal range
Indications & Contraindications
- Indications
- Managementofmetabolicacidosis;gastrichyperacidity;asanalkalinizationagentfortheurine;treatmentofhyperkalemia; managementofoverdoseofcertaindrugs,includingtricyclicantidepressantsandaspirin
Cautions & Side Effects
- Side Effects
- Hypocalcemia,hypokalemia,hypernatremia
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known if excreted in breast milk
SODIUM CHLORIDE / HYPROMELLOSE, Oculac®
Sterile eye drops
Pregnancy: ----Lactation: caution
SODIUM CHLORIDE / HYPROMELLOSE, Oculac®
Sterile eye drops
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 10ml
Dosing & Formulations
- Dose
- 1-2 drops instilled in each eye evry 3-4 times daily or as reqired
Indications & Contraindications
- Indications
- Dry eyes, Inflammation of the cornea of the eye,Protect the eye from injury and infection ,Burning in the eye ,Itching in the eye
- Contraindications
- Hypersensitivity to active substance
Cautions & Side Effects
- Cautions
- May cause transient mild stinging or temporary blurred vision. If irritation persists or worsens, or headache, eye pain, vision changes or continued redness occur
- Side Effects
- nausea, vomiting, diarrhea, muscular twitching, inflammation of the gastrointestinal tract, and congestion.
Pregnancy & Lactation
- Pregnancy
- ----
- Lactation
- It is unknown whether topical hypromellose/metabolites are excreted in human milk
SODIUM HYALURONATE, Provisc®
Ophthalmic surgical agents
Pregnancy: Sodium hyaluronate has not beeLactation: caution
SODIUM HYALURONATE, Provisc®
Ophthalmic surgical agents
- Therapeutic group
- Musculoskeletal & Joint Diseases
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- Eye inj
Dosing & Formulations
- Dose
- Adult: Apply as required
Indications & Contraindications
- Indications
- Dry eye conditions
- Contraindications
- Sodium hyaluronate is contraindicated in people who are sensitive tohyaluronatepreparations, or when there are infections or skin disease at the injection site
Cautions & Side Effects
- Cautions
- --
- Side Effects
- Change in eyesight, eye pain, or very bad eye irritation
Pregnancy & Lactation
- Pregnancy
- Sodium hyaluronate has not been formally assigned to a pregnancy category by the FDA
- Lactation
- There are no data on the excretion of sodium hyaluronate ophthalmic into human milk
SODIUMCHLORIDE
Electrolytesupplement,Parenteral,genitourinaryirrigant,Irrigant
Pregnancy: cautionLactation: not in source
SODIUMCHLORIDE
Electrolytesupplement,Parenteral,genitourinaryirrigant,Irrigant
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection · Ointment · Spray
Dosage Forms
Other
- 0
- 0.9%prefilled syring (3
- 5
- 10 ml)
Injection
- 9%500 mlinjection
- 3% (10ml)injection
Ointment
- 5% eye ointment
Spray
- 0.9%15-30ml nasal spray
Dosing & Formulations
- Dose
- Children: I.V.: Hypertonic solutions (>0.9%) should only be used for the initial treatment of acute serious symptomatic hyponatremia; maintenance: 3-4 meq/kg/day; maximum: 100-150 meq/day; dosage varies widely depending on clinical condition -Replacement: Determined by laboratory determinations meq Sodium deficiency (meq/kg) = [% dehydration (L/kg)/100 x 70 (meq/L)] + [0.6 (L/kg) x (140 - serum sodium) (meq/L)] Children ≥2 years and Adults: -Intranasal: 2-3 sprays in each nostril as needed -Irrigation: Spray affected area Children and Adults: Inhalation: Bronchodilator diluent: 1-3 sprays (1-3 ml) to dilute bronchodilator solution in nebulizer prior to administration Adults: GU irrigant: 1-3 L/day by intermittent irrigation -Replacement I.V.: Determined by laboratory determinations meq Sodium deficiency (meq/kg) = [% dehydration (L/kg)/100 x 70 (meq/L)] + [0.6 (L/kg) x (140 - serum sodium) (meq/L)] To correct acute, serious hyponatremia: meq sodium = [desired sodium (meq/L) - actual sodium (meq/L)] x [0.6 x wt (kg)]; for acute correction use 125 meq/L as the desired serum sodium; acutely correct serum sodium in 5 meq/L/dose increments; more gradual correction in increments of 10 meq/L/ day is indicated in the asymptomatic patient Chloride maintenance electrolyte requirement in parenteral nutrition: 2- 4 meq/kg/24 hours or 25-40 meq/1000 kcals/24 hours; maximum: 100-150 meq/24 hours Sodium maintenance electrolyte requirement in parenteral nutrition: 3-4 meq/kg/24 hours or 25-40 meq/1000 kcals/24 hours; maximum: 100-150 meq/24 hours.
Indications & Contraindications
- Indications
- -Parenteral: Restores sodium ion in patients with restricted oral intake (especially hyponatremia states or low salt syndrome). In general, parenteral saline uses: -Concentrated sodium chloride: Additive for parenteral fluid therapy -Hypertonic sodium chloride: For severe hyponatremia and hypochloremia -Hypotonic sodium chloride: Hydrating solution -Normal saline: Restores water/sodium losses -Ophthalmic: Reduces corneal edema -Intranasal: Restores moisture to nasal membranes -Irrigation: W ound cleansing, irrigation, and flushing
- Contraindications
- Hyperhydration, hypernatremia, hypokalaemia, acidotic situations, hypertension.
Cautions & Side Effects
- Cautions
- Restrict intake in patients with renal failure, hypertension, cardiac failure, oedema, toxaemia of pregnancy.
- Side Effects
- Large dose may cause sodium accumulation and oedema.
Pregnancy & Lactation
- Pregnancy
- C
SODIUMPHOSPHATE+BIPHOSPHATESODIUM,Fleetenema®
Osmotic laxatives
Pregnancy: cautionLactation: caution
SODIUMPHOSPHATE+BIPHOSPHATESODIUM,Fleetenema®
Osmotic laxatives
- Therapeutic group
- Gastrointestinal System
- Storage
- Unclassified
- Dosage form
- Unclassified
Dosage Forms
Other
- 118 mlreadytouseenema
Dosing & Formulations
- Dose
- Children2-5years:One-halfcontentsofone2.25ozpediatricenema Children5-12years:Contentsofone2.25ozpediatricenema, mayrepeat Children≥12yearsandAdults:Contentsofone 4.5ozenemaasasingledose,mayrepeat
Indications & Contraindications
- Indications
- constipation; bowel evacuation before surgery or endoscopy.
- Contraindications
- acute GI conditions; renal failure, congestiveheart failure
Cautions & Side Effects
- Side Effects
- local irritation, oedema, hypotension.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Unknown whether distributed in breast milk; caution because of risk for electrolyte disturbances or dehydration
SODIUMSTIBOGLUCONATE,Pentostam®
Leishmanicides
Pregnancy: cautionLactation: caution
SODIUMSTIBOGLUCONATE,Pentostam®
Leishmanicides
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 100 mg injection
Dosing & Formulations
- Dose
- Adults: Note: Relapse: Duration of treatment should be twice that of initial treatment Cutaneous Leishmaniasis not cause by L. Aethiopica: Intralesional : Single non-inflamed nodular lesions not due to L.braziliensis: 100-300 mg pentavalent antimony (thoroughly blanching the base of the lesion): may be repeated once or twice if necessary every 1-2 days. IM., IV., treatment Should occur for several days after the lesion has healed -IM., IV., (slowly over 5 minutes): 10-20 mg (mucocutaneous confirmed by parasite: 20 mg): pentavalent antimony/kg/day for a minimum of 20 days *Maximum dose: 850 mg Continue for several days after parasitological and clinical cure; re-examination for relapse should occur at 2-6 months Visceral leishmaniasis: IM., IV., : 10-20 mg pentavalent entimony/kg/day for a minimum of 20days *Maximum does: 850 mg; re-examination for relapse should occur ay 2-6months
Indications & Contraindications
- Indications
- Antiprotozoal
- Contraindications
- Severe renal impairment; breast-feeding.
Cautions & Side Effects
- Cautions
- Avoid rapid intravenous administration; heart disease, hepatic impairment.
- Side Effects
- Pain at site of intramuscular injection, gastrointestinal disturbances, stiffness of joints, delayed muscle pain; ECG changes may precede arrhythmias.
Pregnancy & Lactation
- Pregnancy
- Unknown
- Lactation
- Unknown
SODIUMVALPROATE,Depakine®
Anticonvulsant
Pregnancy: - d for seizures or manic episLactation: caution
SODIUMVALPROATE,Depakine®
Anticonvulsant
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet · Syrup
Dosage Forms
Syrup
- 200mg/3.5 mlsyrup
Tablet
- 200mgtablet
Dosing & Formulations
- Dose
- Adult dose Epilepsy and bipolar disorder: Initially, oral, 600 mg daily in one or two doses, increasing by 200 mg daily every 3 days according to response. Maintenance, oral/IV, 20–30 mg/kg daily in one or two doses. Maximum daily dose 2.5 g. Prevention of migraine: Oral, 200–400 mg twice daily. Paediatric dose Epilepsy: Initially, oral, 15 mg/kg daily in two or three doses, increasing according to response. Maintenance, oral/IV, 20–30 mg/kg daily in two doses.
- Dose in Organ Failure
- Renal impairment No adjustment necessary; protein binding is reduced and may cause measurement of total valproate concentrations to be inaccurate Hepatic impairment Administer lower doses Contraindicated in severe impairment
Indications & Contraindications
- Indications
- All forms of epilepsy.
- Contraindications
- Active liverdisease, porphyria.
Cautions & Side Effects
- Cautions
- Monitor liver function;renal impairment; check for bleedingtendencies.
- Side Effects
- Nausea, gastric irritation,reversible hair loss; oedema, inhibition of platelet aggregation; weight gain and increased appetite
Pregnancy & Lactation
- Pregnancy
- - d for seizures or manic episodes associated with bipolar disorder that are unresponsive to other treatments - x for migraine headache prevention
- Lactation
- Excreted in milk; use caution
SPIRONOLACTONE,Aldactone®
Diuretic,potassium-sparing
Pregnancy: cautionLactation: avoid
SPIRONOLACTONE,Aldactone®
Diuretic,potassium-sparing
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 25 mgtablet
Dosing & Formulations
- Dose
- Adult: 100-200 mg daily increased to 400 mg if required, Child, 3 mg/kg daily in divided doses. Elderly:initial:25-50mg/dayin1-2divided doses,increasingby25-50mg Every5 daysas needed.
- Dose in Organ Failure
- Crcl ≥50 ml/min/1.73 m: 12.5-25 mg qday; use maintenance dose of 25 mg qday or q12hr after 4 weeks of treatment with potassium ≤5 meq/L Crcl 30-49 ml/min/1.73 m: 12.5 mg qday or every other day; use maintenance dose of 12.5-25 mg qday after 4 weeks of treatment with potassium ≤5 meq/L Crcl<30 ml/min/1.73 m: Avoid use
Indications & Contraindications
- Indications
- Oedema and ascitis in cirrhosis of the liver, nephrotic syndrome, congestive heart failure; primary hyper aldosteronism; malignant ascitis.
- Contraindications
- Hyperkalemia; hypernatremia; Addisons disease.
Cautions & Side Effects
- Cautions
- Breast feeding; pregnancy; hepatic and renal impairment.
- Side Effects
- Gastrointestinal disturbances, gynecomastia, menstrual irregularity, impotence; lethargy; headache; confusion; rashes; hepatotoxicity; ostoemalacia.
Pregnancy & Lactation
- Pregnancy
- C / D in pregnancy-induced hypertension (per expert analysis)
- Lactation
- Metabolite excreted into breast milk; discontinue breastfeeding or do not use drug
STREPTOMYCIN,Trobicin®
Antibiotic,Aminoglycoside,antitubercularagent
Pregnancy: riskLactation: compatible
STREPTOMYCIN,Trobicin®
Antibiotic,Aminoglycoside,antitubercularagent
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Unclassified
- Dosage form
- Injection
Dosage Forms
Injection
- 1ginjection
Dosing & Formulations
- Dose
- Usual dosage range: For I.M. administer, I.V. not recommended Children: 20-40 mg/kg/day (maximum 1g) Adult: 15-30 mg/kg/day or 1-2 g/day Indication-Specific dosing: Children:Tuberculosis I.M.: Daily therapy: 20-40 mg/kg/day (maximum: 1 g/day) Directly observed therapy: Twice weekly: 25-30 mg/kg (maximum: 1.5 g) DOT: 3 times/week: 25-30 mg/kg (maximum: 1.5 g) Adults: *Brucellosis: 1g/dday for 14-21 days (with doxycycline: 100mg twice daily for 6 weeks) *Tuberculosis: Daily therapy: 15 mg/kg/day (maximum: 1 g) Directly observed therapy: Twice weekly: 25-30 mg/kg (maximum: 1.5 g) DOT: 3 times/week: 25-30 mg/kg (maximum: 1.5 g) *Enterococcal endocarditis: 1 g every 12 hours for 2 weeks, 500 mg every 12 Hours for 4 weeks in combination with penicillin *Streptococcal endocarditis: 1 g every 12 hours for 1 week, 500 mg every 12 hours for 1 week *Tularemia: 1-2 g/day in divided doses for 7-10 days or until patient is afebrile for 5-7 days *Plague: 15 mg/kg or 1gm every 12 hours until the patient is afebrile for at Least 3 days
- Dose in Organ Failure
- Renal Impairment Load: 1 g IM, THEN Crcl: 50-80 ml/min: 7.5 mg/kg IM q24hr Crcl: 10-50 ml/min: 7.5 mg/kg IM q24-72hr Crcl<10 ml/min: 7.5 mg/kg IM q72-96hr Hemodialysis: 50-75% of initial loading dose at end of dialysis period
Indications & Contraindications
- Indications
- Part of combination therapy of active tuberculosis; used in combination with other agents for treatment of streptococcal or enterococcal endocarditis, mycobacterial infections, plague, tularemia, and brucellosis
- Contraindications
- Myastheniagravis.
Cautions & Side Effects
- Cautions
- Pregnancy; renal impairment, infants and elderly (adjust dose and frequency); avoid prolong therapy.
- Side Effects
- Ototoxic and nephrotoxic effects, neuromuscular blocking effect, allergic reactions.
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Enters breast milk (AAP Committee states compatible w/ nursing)
SULFAMETHOXAZOLE+TRIMETHHOPRIM(CO-TRIMOXAZOLE), Sep-trin®
Antibiotic,Sulfonamides
Pregnancy: cautionLactation: avoid
SULFAMETHOXAZOLE+TRIMETHHOPRIM(CO-TRIMOXAZOLE), Sep-trin®
Antibiotic,Sulfonamides
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Unclassified
- Dosage form
- Tablet · Injection · Suspension
Dosage Forms
Tablet
- 800/160mgtablet
Suspension
- 200/400in5mlsuspension
Injection
- 400+80injection
Dosing & Formulations
- Dose
- Adult dose Doses are expressed as trimethoprim/sulfamethoxazole. Mild–moderate infections: oral, 80/400–160/800 mg Every 12 hours. Severe infections: IV, 160/800–320/1,600 mg every 12 hours. Maximum: Oral/IV, 20/100 mg/kg daily in divided doses (in P. Jirovecii pneumonia). Paediatric dose Mild–moderate infections: oral, 4/20 mg/kg every 12 hours. Severe infections: IV, 5/25 mg/kg every 12 hours.
Indications & Contraindications
- Indications
- Oral treatment of urinary tract infections due to E. Coli, Klebsiella and Entero- bacter sp, M. Morganii, P. Mirabilis and P. Vulgaris; acute otitis media in chil- dren and acute exacerbations of chronic bronchitis in adults due to suscepti- ble strains of H. Influenzae or S.Pneumoniae; prophylaxis of Pneumocystis carinii pneumonitis (PCP), traveler's diarrhea due to enterotoxigenic E. Coli or Cyclospora I.V. treatment or severe or complicated infections when oral therapy is not Feasible, for documented PCP, empiric treatment of PCP in immune compro- mised patients; treatment of documented or suspected shigellosis, typhoid fever, Nocardia asteroides infection, or other infections caused by suscepti- ble bacteria
- Contraindications
- Porphyria; sensitivity to sulphonamides.
Cautions & Side Effects
- Cautions
- Hepatic and renal impairment; blood disorders; predisposition to folate deficiency; asthma; G6PD deficiency.
- Side Effects
- Nausea, vomiting, skin reactions, blood disorders, hypoglycaemia, diarrhoea and antibiotic- associated colitis.
Pregnancy & Lactation
- Pregnancy
- C/D(atterm-expertanalysis)
- Lactation
- Excreted in breast milk; use caution; contraindicated by some sources
SUMATRIPTAN,Imigran®
Antimigraine,Serotonin5-HT1DReceptorAgonist
Pregnancy: cautionLactation: avoid
SUMATRIPTAN,Imigran®
Antimigraine,Serotonin5-HT1DReceptorAgonist
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 100mg tablet
Dosing & Formulations
- Dose
- Adults:Oral: Asingledose of25 mg,50 mg,or100 mg (takenwithfluids).
Indications & Contraindications
- Indications
- Acutetreatmentof migraine withorwithoutaura
- Contraindications
- Ischaemic heart disease, uncontrolled hypertension.
Cautions & Side Effects
- Cautions
- Should not be used for prophylaxis; hepatic impairment; pregnancy and breast-feeding; not to be used with other migraine therapy.
- Side Effects
- Dizziness,warm/hotsensation,Chestpain. Tightness, heaviness.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excreted in breast milk at very low levels (NLM TOXNET); minimize infant to potential exposure by avoiding breastfeeding for 8-12 hours after administration
SUXAMETHONIUM
Musclerelaxant,neuromuscularblocker Agent
Pregnancy: cautionLactation: not in source
SUXAMETHONIUM
Musclerelaxant,neuromuscularblocker Agent
- Therapeutic group
- Anaesthesia & Muscle Relaxants
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 100mg/2 ml
Dosing & Formulations
- Dose
- Neuromuscular blockade (short duration) during surgery And intubation by intravenous injection adult: 1–1.5 mg/kg
Indications & Contraindications
- Indications
- Adjuncttogeneralanesthesiatofacilitatebothrapidsequenceandroutineendotrachealintubationandtorelaxskeletalmusclesduringsurgery;tore-ducetheintensityofmusclecontractionsofpharmacologically-orelectrically- inducedconvulsions;does notrelievepainorproducesedation
- Contraindications
- History of malignant hyperthermia; deficiency of plasma cholinesterase; severe liver disease.
Cautions & Side Effects
- Side Effects
- Ocular: Increasedintraocular pressure,Postoperativestiffness
Pregnancy & Lactation
- Pregnancy
- C
TAMSULOSIN,Omnic®
Alpha1 blocker
Pregnancy: safeLactation: not in source
TAMSULOSIN,Omnic®
Alpha1 blocker
- Therapeutic group
- Obstetrics, Gynaecology & Urinary
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 0.4mgtablet
Dosing & Formulations
- Dose
- 400 micrograms daily as asingle dose.
Indications & Contraindications
- Indications
- Hypertension, benignprostatic hyperplasia
- Contraindications
- Hypersensitivityto the drug
Cautions & Side Effects
- Cautions
- First dose may cause collapse due to hypotension; reduce initial dose in renal failure. Avoid abrupt withdrawal in heart failure.
- Side Effects
- Postural hypotension, drowsiness, weakness, dizziness, headache, lack of energy; nausea, palpitation, urinary frequency; incontinence & priapism reported.
Pregnancy & Lactation
- Pregnancy
- B
TELMISARTAN, Micardis
Angiotensin II Receptor Antagonist
Pregnancy: riskLactation: see details
TELMISARTAN, Micardis
Angiotensin II Receptor Antagonist
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Other
- 20 mg
- 40 mg
Tablet
- 80mg tablet
Dosing & Formulations
- Dose
- Initially 20–40 mg once daily for at least 4 weeks, increased if necessary up to 80 mg once daily
Indications & Contraindications
- Indications
- Hypertension, Prevention of cardiovascular events in patients with established atherosclerotic cardiovascular disease, or type 2 diabetes mellitus with target-organ damage
Cautions & Side Effects
- Side Effects
- Arthralgia. back pain. chest pain. eczema. gastro-intestinal disturbances. influenza-likesymptoms. leg cramps. myalgia. pharyngitis. sinusitis. urinary-tract infection
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Relevant published information was not found as of the revision date.
TERIPARATIDE, Forteo ®
Parathyroid hormone
Pregnancy: cautionLactation: caution
TERIPARATIDE, Forteo ®
Parathyroid hormone
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 20mg inj
Dosing & Formulations
- Dose
- Applies to the following strength(s): 600 mcg/2.4 ml ; 750 mcg/3 ml
Indications & Contraindications
- Indications
- Postmenopausal women with osteoporosis at a high risk for fracture or with a history of osteoporotic fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy
- Contraindications
- Teriparatide should not be prescribed for people who are at increased risks for osteosarcoma. This includes those withPaget's Diseaseof bone or unexplained elevations of serum alkaline phosphate, openepiphysis, or prior radiation therapy involving the skeleton.
Cautions & Side Effects
- Cautions
- Use should be avoided. Excreted into human milk: Unknown
- Side Effects
- Osteosarcoma
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known if distributed in breast milk; use caution
TETRACYCLINE,Teramycin®
Antibiotic,tetracycline
Pregnancy: riskLactation: avoid
TETRACYCLINE,Teramycin®
Antibiotic,tetracycline
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Ointment
Dosage Forms
Other
- 250mgcapsulre
Ointment
- 1%eyeointment
Dosing & Formulations
- Dose
- Oral: Children >8 years: 25-50mg/kg/day in divided doses every 6 hours Adults: 250-500mg/dose every 6 hourshelicobacter pylori eradication: 500mg 2-4 times/day depending on regimen; requires combination therapy with at least one other antibiotic and an acid-suppressing agent (proton pump inhibi- tor or H2 blocker)
- Dose in Organ Failure
- Renal impairment Crcl 50-80 ml/min: dose q8-12hr Crcl 10-50 ml/min: dose q12-24hr Crcl<10 ml/min: dose q24hr
Indications & Contraindications
- Indications
- Local treatment of infection including trachoma.
- Contraindications
- Sensitivity to tetracycline.
Cautions & Side Effects
- Side Effects
- Pericarditis,Discolorationofteethandenamelhypoplasia(youngchildren),Hepatotoxicity,Photosensitivity,Intracranialpressureincreased
Pregnancy & Lactation
- Pregnancy
- D
- Lactation
- Enters breast milk; some manufacturers say do not nurse;
THIAMINE,Benerva®
Vitamin,watersoluble
Pregnancy: safeLactation: compatible
THIAMINE,Benerva®
Vitamin,watersoluble
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 100 mg/ml injection
Dosing & Formulations
- Dose
- Parenteral nutrition supplementation: Infants: 1.2 mg/day Adults: 6 mg/day; may be increased to 25-50 mg/day with history of alcohol abuse Thiamine deficiency (beriberi): Children: 10-25 mg/dose I.M. or I.V. daily (if critically ill), or 10-50 mg/dose Orally every day for 2 weeks, then 5-10 mg/dose orally daily for 1 month Adults: 5-30 mg/dose I.M. or I.V. 3 times/day (if critically ill); then orally 5-30 mg/day in single or divided doses 3 times/day for 1 month Alcohol withdrawal syndrome: Adults: 100 mg/day I.M. or I.V. for several days, followed by 50-100 mg/day orally Wernicke's encephalopathy: Adults: Treatment: Initial: 100 mg I.V., then 50 -100 mg/day I.M. or I.V. until consuming a regular, balanced diet.
Indications & Contraindications
- Indications
- Deficiency of vitamin(B1).
Cautions & Side Effects
- Cautions
- Anaphylaxis may followinjection
- Side Effects
- Frequency not defined: Cyanosis, Restlessness, Hemorrharge into GI tract, nausea, tightness of the throat.
Pregnancy & Lactation
- Pregnancy
- A / C (dose exceeding RDA recommendation)
- Lactation
- Safe
THIOPENTAL
General Anesthetics
Pregnancy: cautionLactation: not in source
THIOPENTAL
General Anesthetics
- Therapeutic group
- Anaesthesia & Muscle Relaxants
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 500mg injection
Dosing & Formulations
- Dose
- Anesthesia Slow Induction: 2-6 mg/kg IV x1 dose OR 50-75 mg slow IV Rapid Induction: 3-4 mg/kg IV (210-280 mg) divided in 2-4 doses Maint: 25-100 mg IV PRN Regional: 50-75 mg slow IV Neurosurgical Patients with Increased Intracranial Pressure 1.5-3.5 mg/kg IV with proper ventilatory support Convulsive States 75-125 mg IV
Indications & Contraindications
- Indications
- Anesthesia, Neurosurgical Patients with Increased Intracranial Pressure Convulsive States
- Contraindications
- porphyria; airway obstruction.
Cautions & Side Effects
- Side Effects
- Shivering,Allergic reactions, Cardiac arrhythmias, Circulatory depression, Cough, Dyspnea, Hiccups.
Pregnancy & Lactation
- Pregnancy
- C
THYROXINE(Levothyroxine), Eltroxin®
Thyroidproduct
Pregnancy: safeLactation: caution
THYROXINE(Levothyroxine), Eltroxin®
Thyroidproduct
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Other
- 25
- 50
Tablet
- 100mcg tablet
Dosing & Formulations
- Dose
- Initially 50-100 mcg increasing by 25-50 mcg at 3-4 weeks intervals; Maintenance dose, 100-200 mcg or more daily; Infants, 10 mcg/kg daily to a max. Of 50 mcg daily. Up to 5 years, 100 mcg daily; Up to 12 years, adult dose.
Indications & Contraindications
- Indications
- Hypothyroidism including myxoedema.
- Contraindications
- Thyrotoxicosis, uncorrected adrenal insufficiency.
Cautions & Side Effects
- Cautions
- Angina, cardiovascular disorders, hypertension, adrenal insufficiency, thyrotoxicosis; diabetes insipidus, diabetes mellitus.
- Side Effects
- Hyperthyroidism due to therapeutic overdose, headache, anxiety, irritability, emotional liability, insomnia, tremors,
Pregnancy & Lactation
- Pregnancy
- A
- Lactation
- Enters breast milk; use caution
TIMOLOL,ocumol®,betimol®
Nonselectivebblocker, glaucoma.
Pregnancy: cautionLactation: avoid
TIMOLOL,ocumol®,betimol®
Nonselectivebblocker, glaucoma.
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 0.5%eye drop
Dosing & Formulations
- Dose
- Children and Adult: Ophthalmic: Solution: initial: Instill 1 drop (0.25% solution) into affected eye(s) twice daily. Increase to 0.5% solution if response not adequate, decrease one drop/day if controlled, do not exceed one drops twice daily of 0.5% solution.
Indications & Contraindications
- Indications
- Ophthalmic dosage form used in treatment of elevated intraocular pressure such as glaucoma or ocular hypertension; oral dosage form used for treat- ment of hypertension and angina, to reduce mortality following myocardial infarction, and for prophylaxis of migraine
Cautions & Side Effects
- Cautions
- Cardiac disease, angle closure glaucoma.
- Side Effects
- Local irritation, pain, dry eyes, erythema.
Pregnancy & Lactation
- Pregnancy
- C (manufacturer); D (2nd and 3rd trimesters, expert analysis)
- Lactation
- Excreted in milk; Mfr's recommends avoid nursing
TIOTROPIUM,Spiriva®
AnticholinergicAgent,Bronchodilator
Pregnancy: not in sourceLactation: not in source
TIOTROPIUM,Spiriva®
AnticholinergicAgent,Bronchodilator
- Therapeutic group
- Respiratory System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule
Dosage Forms
Capsule
- 18mcg/capsule for inhalation
Dosing & Formulations
- Dose
- PO inhalations of 1 capsule (18 mcg) qDay via HandiHaler inhalation device
Indications & Contraindications
- Indications
- Chronic Obstructive Pulmonary Disease,Asthma
Cautions & Side Effects
- Side Effects
- upper respiratory tract infection,drymouth,sinusitis,abdominalpain,allergicreaction,anginapectoris,cataract,chestpain,constipation,depression, dyspepsia,dysphonia,edema,epistaxis,gastroesophageal reflux.
TOBRAMYCIN + DEXAMETHASONE, Topradex®
Antibioticandsteroidcombination for topical ophthalmic use.
Pregnancy: cautionLactation: caution
TOBRAMYCIN + DEXAMETHASONE, Topradex®
Antibioticandsteroidcombination for topical ophthalmic use.
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 0.3%
- 0.1% eye oint
Dosing & Formulations
- Dose
- One or two drops instilled into theconjunctivalsac(s) every four to six hours. During the initial 24 to 48 hours ,
Indications & Contraindications
- Indications
- Used to treat or preventonly bacterialeyeinfections
- Contraindications
- Tuberculosis of the Eye, herpes zoster ophthalmicus ,herpes simplex dendritic keratitis .
Cautions & Side Effects
- Cautions
- Glaucoma, allergic to either drug; or to other aminoglycosideantibiotics(e.g.,gentamicin)
- Side Effects
- Eyeredness,eyediscomfort, and eyeliditching/swelling may occur
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- NOT distributed in breast milk; use caution
TOPIRAMATE,Topamax®
Anticonvulsant
Pregnancy: cautionLactation: not in source
TOPIRAMATE,Topamax®
Anticonvulsant
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Other
- 15
Tablet
- 25&100mg tablet
Dosing & Formulations
- Dose
- Adult dose Initially 25–50 mg once daily; maintenance dose 25–200 mg twice daily. Maximum daily dose 1 g. Paediatric dose >2 years, initially 0.5–1 mg/kg once daily; increase by 1–3 mg/kg daily; maintenance dose 3–9 mg/kg daily. Usual maximum is 10 mg daily.
- Dose in Organ Failure
- Renal impairment CrCl<70 mL/min: Reduce dose by 50% Hemodialysis: Cleared by hemodialysis at rate 4-6 times greater than normal; prolonged period of dialysis may decrease topiramate serum concentrations Hepatic impairment Clearance may decrease; monitor
Indications & Contraindications
- Indications
- partial and generalizedtonic-clonic seizures; adjunctivetreatment of seizures in Lennox–Gastaut syndrome; preventionof migraine in adults.
- Contraindications
- breast-feeding
Cautions & Side Effects
- Cautions
- history of psychiatricdisorders, ensure adequate hydration(especially if history of nephrolithiasisand hypercalciuria), renalimpairment and hepatic impairment.
- Side Effects
- headache, confusion,amnesia, impaired concentration,depression, nervousness, agitation.
Pregnancy & Lactation
- Pregnancy
- C
TRAMADOL,Tramal®
Analgesic,Non-narcotic
Pregnancy: cautionLactation: not in source
TRAMADOL,Tramal®
Analgesic,Non-narcotic
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule · Injection
Dosage Forms
Capsule
- 50 mgcapsule
Injection
- 100 mginjection
Dosing & Formulations
- Dose
- Adults:Moderatetoseverechronicpain:50-100mgevery 4-6 hours,not to exceed400 mg/day Forpatientsnotrequiringrapidonsetofeffect, tolerabilitymaybeimproved bystartingdoseat25 mg/dayandtitratingdose by25 mgevery3 days,untilreaching 25 mg4 times/day.Dosemaythenbeincreased by50 mgevery3 daysastolerated,toreachdose of 50 mg4times/day. Elderly:>75years: 50-100mgevery4-6 hours(notto exceed300mg/day)
- Dose in Organ Failure
- Severe renal impairment (CrCl<30 mL/min): Immediate release, 50-100 mg PO q12hr; extended release not recommended Severe hepatic impairment: Immediate release, 50 mg PO q12hr; extended release not recommended
Indications & Contraindications
- Indications
- Moderate to severe pain.
Cautions & Side Effects
- Side Effects
- Dizziness,headache, somnolence, vertigo,constipation,nausea
Pregnancy & Lactation
- Pregnancy
- C
TRIAMCINOLONE ACETONIDE , Kenacort-A®,Kenalogorabase®
Corticosteroid
Pregnancy: cautionLactation: caution
TRIAMCINOLONE ACETONIDE , Kenacort-A®,Kenalogorabase®
Corticosteroid
- Therapeutic group
- Endocrine System & Diabetes
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 40mg vial
Dosing & Formulations
- Dose
- 60 mg IM every 6 weeks; may be supplemented by additional 20-100 mg IM PRN Intralesional injection (10 mg/ml suspension): 1 mg per injection site 1 or more times weekly; not to exceed 30 mg/day Intra-articular/intrasynovial/soft-tissue injection: Large joints, 15-40 mg; small joints/tendon sheath inflammation, 2.5-10 mg Topical:Inflammatory Dermatoses BID - TID. Oral Inflammatory or Ulcerative Lesionsqhs; may increase to BID/TID PC if lesions are severe
Indications & Contraindications
- Indications
- For alleviating the joint pain, swelling and stiffness associated with rheumatoid arthritis and osteoarthrosis; also for bursitis, epicondylitis, tenosynovitis, lichen simplex chronicus (neuro dermatitis), granuloma annulare, lichen planus, keloids, alopecia areata and hypertrophic scars.
Cautions & Side Effects
- Cautions
- Should not be injected into unstable joints. Avoid given over a long period of time, recent intestinal anastomoses, diverticulitis, thrombophlebitis, existing or previous history of severe affective disorders.
- Side Effects
- Minimised by using lowest effective dose for minimum period possible; gastro-intestinal effects include dyspepsia, peptic ulceration (with perforation), abdominal distension, acute pancreatitis, oesophageal ulceration and candidiasis.
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Excreted in breast milk; use caution
TROPICAMIDE,Mydriacyl®
Ophthalmic Agent,Mydriatic
Pregnancy: cautionLactation: see details
TROPICAMIDE,Mydriacyl®
Ophthalmic Agent,Mydriatic
- Therapeutic group
- Eye / Ophthalmic
- Storage
- Room Temperature (15–25°C)
- Dosage form
- Unclassified
Dosage Forms
Other
- 1%eyedrop
Dosing & Formulations
- Dose
- Children and Adults (individuals with heavily pigmented eyes may require larger doses): Cycloplegia: Instill 1-2 drops (1%); may repeat in 5 minutes Exam must be performed within 30 minutes after the repeat dose; if the pa- tient is not examined within 20-30 minutes, instill an additional drop Mydriasis: Instill 1-2 drops (0.5%) 15-20 minutes before exam; may repeat every 30 minutes as needed
Indications & Contraindications
- Indications
- Short-acting mydriatic used in diagnostic procedures; as well as preopera- tively and postoperatively; treatment of some cases of acute iritis, iridocyclitis, and keratitis
Cautions & Side Effects
- Side Effects
- Blurredvision,photophobia withorwithoutcornealstaining
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Not known if distributed in milk
VALSARTAN,Diovan®
Angiotensin II Receptor Antagonist
Pregnancy: cautionLactation: caution
VALSARTAN,Diovan®
Angiotensin II Receptor Antagonist
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Other
- 80 mg
Tablet
- 160mgtablet
Dosing & Formulations
- Dose
- Hypertension, usually 80 mg once daily; in elderly over 75 years, mild to moderate hepatic impairment, moderate to severe renal impairment, intravascular volume depletion, initially 40 mg once daily; if necessary increased after at least 4 weeks to 160 mg daily. Myocardial infarction, initially 20 mg twice daily increased over several weeks to 160 mg twice daily if tolerated; consider lower dose in mild to moderate hepatic impairment.
Indications & Contraindications
- Indications
- Hypertension; myocardial infarction with left ventricular failure or left ventricular systolic dysfunction.
- Contraindications
- Severe hepatic impairment, cirrhosis, biliary obstruction, breastfeeding.
Cautions & Side Effects
- Side Effects
- Fatigue, rarely diarrhea, headache, epistaxis; thrombocytopenia, arthralgia, myalgia, taste disturbance, neutropenia & rash.
Pregnancy & Lactation
- Pregnancy
- C / D (2nd and 3rd trimesters)
- Lactation
- No human data; use with caution
VANCOMYCIN,Vancocin®
Antibiotic,Miscellaneous
Pregnancy: cautionLactation: avoid
VANCOMYCIN,Vancocin®
Antibiotic,Miscellaneous
- Therapeutic group
- Infections & Antimicrobials
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Injection
Dosage Forms
Injection
- 500 mg injection
Dosing & Formulations
- Dose
- Adult dose IV, 500 mg six-hourly or 1 g 12-hourly. Pseudomembranous colitis: oral, 250–500 mg six-hourly. Paediatric dose IV, 10-15 mg/kg six-hourly. Pseudomembranous colitis: oral, 5–10 mg/kg six-hourly.
- Dose in Organ Failure
- Renal impairment: 15 mg/kg initially; further doses are based on renal function, serumdrug level, and institutional protocol; dosing intervals range from q24hr to q96hr, depending on severity of impairment
Indications & Contraindications
- Indications
- Treatment of patients with infections caused by staphylococcal species and streptococcal species; used orally for staphylococcal enterocolitis or for anti- biotic-associated pseudomembranous colitis produced by C. Difficile
Cautions & Side Effects
- Cautions
- Avoid rapid infusion; renal impairment; avoid in elderly with a history of deafness; blood count
- Side Effects
- Nephrotoxicity, ototoxicity, blood disorders; anaphylaxis reactions; red-man syndrome (flushing of the upper body); nausea and vomiting
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Drug enters breast milk; not recommended
VITAMIN C ( ASCORBIC ACID), Vita-C®
Vitamin water soluble
Pregnancy: safeLactation: not in source
VITAMIN C ( ASCORBIC ACID), Vita-C®
Vitamin water soluble
- Therapeutic group
- Central Nervous System & Analgesics
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Tablet
Dosage Forms
Tablet
- 500mg tab
Dosing & Formulations
- Dose
- RDA Males: 90 mg/day Females: 75 mg/day Pregnant: 85 mg/day; not to exceed 2000 mg/day (80 mg if <18 years; not to exceed 1800 mg/day) Nursing: 120 mg/day; not to exceed 2000 mg/day (115 mg if <18 years old; not to exceed 1800 mg/day) Urinary Acidification 4-12 g/day PO/IV divided three or four times daily
Indications & Contraindications
- Indications
- Urinary Acidification, RDA
Cautions & Side Effects
- Side Effects
- Flushing,Flank pain,Faintness, headache,Diarrhea, dyspepsia, nausea, vomiting,Hyperoxaluria (large doses)
Pregnancy & Lactation
- Pregnancy
- A (dose within RDA); C (dose exceeding RDA recommendation)
VITAMINA,ItaminA®,Afaxin®
Vitamin,fatsoluble
Pregnancy: riskLactation: compatible
VITAMINA,ItaminA®,Afaxin®
Vitamin,fatsoluble
- Therapeutic group
- Nutrition, Blood & Fluids
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Capsule
Dosage Forms
Capsule
- Softgelatincapsule50000 unit
Dosing & Formulations
- Dose
- 1-2capsulestobetaken duringoraftermealsthreetimes daily
Indications & Contraindications
- Indications
- TreatmentandpreventionofvitaminA deficiency.
Cautions & Side Effects
- Side Effects
- Fever,headache,irritability, lethargy, malaise,vertigo,dryingorcrackingofskin,hypercalcemia,weightloss,visualchanges,hypervitaminosisA
Pregnancy & Lactation
- Pregnancy
- X
- Lactation
- Distributed into milk; safe at RDA levels
ZINCOXIDE
Topical Skin Product
Pregnancy: cautionLactation: caution
ZINCOXIDE
Topical Skin Product
- Therapeutic group
- Cardiovascular System
- Storage
- Controlled / Narcotics Safe
- Dosage form
- Unclassified
Dosage Forms
Other
- 100 g container
Dosing & Formulations
- Dose
- Infants, Children, and Adults: Topical: Apply as required for affected areas several times daily
Indications & Contraindications
- Indications
- Protective coating for mild skin irritations and abrasions; soothing and protec- tive ointment to promote healing of chapped skin, diaper rash
Pregnancy & Lactation
- Pregnancy
- C
- Lactation
- Unknown
